WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Monday, November 08, 2004

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ		
☐	L11	L10 AND antibody	25
☐	L10	L9 AND AScr	29
☐	L9	prion	4636
☐	L8	L6 AND AScr	0
☐	L7	L6 AND prion disorder	1
☐	L6	424/130.1,135.1,141.1,142.1,178.1.CCLS.	2866
☐	L5	Schenk.IN.	2953
☐	L4	Schenk-D-B.IN.	18
☐	L3	Schenk-D.IN.	10
☐	L2	Schenk-Dale.IN.	3
☐	L1	(Schenk-Dale-B.IN.)	46

END OF SEARCH HISTORY

h e b b cg b chh e h ge f c e c ch

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 46 of 46 returned.

☐ 1. Document ID: US 20040219146 A1

Using default format because multiple data bases are involved.

L1: Entry 1 of 46 File: PGPB Nov 4, 2004

PGPUB-DOCUMENT-NUMBER: 20040219146
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040219146 A1

TITLE: Prevention and treatment of amyloidogenic disease

PUBLICATION-DATE: November 4, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schenk, Dale B.	Burlingame	CA	US	

US-CL-CURRENT: 424/141.1; 424/145.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 2. Document ID: US 20040175394 A1

L1: Entry 2 of 46 File: PGPB Sep 9, 2004

PGPUB-DOCUMENT-NUMBER: 20040175394
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040175394 A1

TITLE: PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE

PUBLICATION-DATE: September 9, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schenk, Dale B.	Burlingame	CA	US	

US-CL-CURRENT: 424/185.1

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

h e b b g e e e f e h ge ef b e

☐ 3. Document ID: US 20040171816 A1

L1: Entry 3 of 46 File: PGPB Sep 2, 2004

PGPUB-DOCUMENT-NUMBER: 20040171816
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040171816 A1

TITLE: Humanized antibodies that recognize beta amyloid peptide

PUBLICATION-DATE: September 2, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schenk, Dale B.	Burlingame	CA	US	
Basi, Guriq	Palo Alto	CA	US	

US-CL-CURRENT: 530/388.15

ABSTRACT:

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A.beta. in the brain of a patient. Preferred agents include humanized antibodies.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 4. Document ID: US 20040171815 A1

L1: Entry 4 of 46 File: PGPB Sep 2, 2004

PGPUB-DOCUMENT-NUMBER: 20040171815
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040171815 A1

TITLE: Humanized antibodies that recognize beta amyloid peptide

PUBLICATION-DATE: September 2, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schenk, Dale B.	Burlingame	CA	US	
Yednock, Ted	Forest Knolls	CA	US	
Basi, Guriq	Palo Alto	CA	US	

US-CL-CURRENT: 530/388.15

ABSTRACT:

The invention provides improved agents and methods for treatment of diseases

h e b b g e e e f e h ge ef b e

associated with amyloid deposits of A.beta. in the brain of a patient. Preferred agents include humanized antibodies.

☐ 5. Document ID: US 20040170641 A1

L1: Entry 5 of 46 File: PGPB Sep 2, 2004

PGPUB-DOCUMENT-NUMBER: 20040170641
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040170641 A1

TITLE: PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE

PUBLICATION-DATE: September 2, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schenk, Dale B.	Burlingame	CA	US	

US-CL-CURRENT: 424/184.1

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

☐ 6. Document ID: US 20040166119 A1

L1: Entry 6 of 46 File: PGPB Aug 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040166119
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040166119 A1

TITLE: Prevention and treatment of amyloidogenic disease

PUBLICATION-DATE: August 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schenk, Dale B.	Burlingame	CA	US	

US-CL-CURRENT: 424/185.1

ABSTRACT:

h e b b g e e e f e h ge ef b e

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 7. Document ID: US 20040157779 A1

L1: Entry 7 of 46 File: PGPB Aug 12, 2004

PGPUB-DOCUMENT-NUMBER: 20040157779
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040157779 A1

TITLE: Prevention and treatment of amyloidogenic disease

PUBLICATION-DATE: August 12, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schenk, Dale B.	Burlingame	CA	US	

US-CL-CURRENT: 514/12

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 8. Document ID: US 20040146521 A1

L1: Entry 8 of 46 File: PGPB Jul 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040146521
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040146521 A1

TITLE: Prevention and treatment of synucleinopathic disease

PUBLICATION-DATE: July 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schenk, Dale B.	Burlingame	CA	US	
Masliah, Eliezer	San Diego	CA	US	

h e b b g e e e f e h ge ef b e

US-CL-CURRENT: 424/185.1

ABSTRACT:

The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

---

☐ 9. Document ID: US 20040136993 A1

L1: Entry 9 of 46 File: PGPB Jul 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040136993
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040136993 A1

TITLE: Prevention and treatment of synucleinopathic disease

PUBLICATION-DATE: July 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schenk, Dale B.	Burlingame	CA	US	
Masliah, Eliezer	San Diego	CA	US	

US-CL-CURRENT: 424/145.1

ABSTRACT:

The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

---

☐ 10. Document ID: US 20040081657 A1

L1: Entry 10 of 46 File: PGPB Apr 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040081657
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040081657 A1

TITLE: Prevention and treatment of amyloidogenic disease

PUBLICATION-DATE: April 29, 2004

INVENTOR-INFORMATION:

h e b b g e e e f e h ge ef b e

NAME	CITY	STATE	COUNTRY	RULE-47
Schenk, Dale B.	Burlingame	CA	US	

US-CL-CURRENT: 424/185.1; 424/486, 514/54

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

---

☐ 11. Document ID: US 20030148392 A1

L1: Entry 11 of 46 File: PGPB Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030148392
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030148392 A1

TITLE: Screening compounds for the ability to alter the production of amyloid-beta peptide (x-41)

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Citron, Martin	Thousand Oaks	CA	US	
Selkoe, Dennis J.	Jamaica Plain	MA	US	
Seubert, Peter A.	San Francisco	CA	US	
Schenk, Dale B.	Burlingame	CA	US	

US-CL-CURRENT: 435/7.2; 435/7.93

ABSTRACT:

This invention provides methods of screening compounds for their ability to alter the production of A.beta.(x.gtoreq.41) alone or in combination with A.beta.(x.ltoreq.40). The methods involve administering compounds to cells, specifically measuring the amounts of A.beta.(x.ltoreq.40) and A.beta.(x.gtoreq.41) produced by the cells, and comparing these amounts to that produced by the cells without administration of the compounds.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

---

☐ 12. Document ID: US 6808712 B2

L1: Entry 12 of 46 File: USPT Oct 26, 2004

US-PAT-NO: 6808712

h e b b g e e e f e h ge ef b e

DOCUMENT-IDENTIFIER: US 6808712 B2

TITLE: Prevention and treatment of amyloidogenic disease

DATE-ISSUED: October 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 424/193.1; 424/185.1, 514/2, 514/4, 530/300, 530/327, 530/329, 530/330, 530/350, 530/391.7, 530/403

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response an amyloid deposit in the patient. The methods are particularly useful for prophylatic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

29 Claims, 20 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

13. Document ID: US 6787637 B1

L1: Entry 13 of 46 File: USPT Sep 7, 2004

US-PAT-NO: 6787637
DOCUMENT-IDENTIFIER: US 6787637 B1

TITLE: N-Terminal amyloid-.beta. antibodies

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 530/387.1; 424/130.1, 530/300, 530/350

ABSTRACT:

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A.beta. in the brain of a patient Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred including N-terminal fragments of A.beta. and antibodies binding to the same.

7 Claims, 25 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 18

h e b b g e e e f e h ge ef b e

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des

☐ 14. Document ID: US 6787523 B1

L1: Entry 14 of 46 File: USPT Sep 7, 2004

US-PAT-NO: 6787523
DOCUMENT-IDENTIFIER: US 6787523 B1

TITLE: Prevention and treatment of amyloidogenic disease

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 514/21; 424/1.57, 424/185.1, 424/9.1, 424/9.2, 436/15, 436/507, 436/86, 514/12, 514/2, 530/324

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto,

24 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des

☐ 15. Document ID: US 6787144 B1

L1: Entry 15 of 46 File: USPT Sep 7, 2004

US-PAT-NO: 6787144
DOCUMENT-IDENTIFIER: US 6787144 B1

TITLE: Prevention and treatment of amyloidogenic disease

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 424/197.11; 424/1.57, 424/185.1, 424/193.1, 424/236.1, 424/9.2, 436/86, 514/2, 514/21, 530/324

h e b b g e e e f e h ge ef b e

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

24 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

☐ 16. Document ID: US 6787143 B1

L1: Entry 16 of 46 File: USPT Sep 7, 2004

US-PAT-NO: 6787143
DOCUMENT-IDENTIFIER: US 6787143 B1

TITLE: Prevention and treatment of amyloidogenic disease

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 424/193.1; 424/1.57, 424/185.1, 424/197.11, 424/236.1, 424/9.2, 436/86, 514/12, 514/2, 530/324

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

24 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

☐ 17. Document ID: US 6787140 B1

L1: Entry 17 of 46 File: USPT Sep 7, 2004

US-PAT-NO: 6787140
DOCUMENT-IDENTIFIER: US 6787140 B1

TITLE: Prevention and treatment of amyloidogenic disease

h e b b g e e e f e h ge ef b e

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 424/185.1; 424/1.57, 424/9.1, 424/9.2, 436/15, 436/507, 436/86, 514/12, 514/2, 514/21, 530/324

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

43 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

☐ 18. Document ID: US 6787139 B1

L1: Entry 18 of 46 File: USPT Sep 7, 2004

US-PAT-NO: 6787139
DOCUMENT-IDENTIFIER: US 6787139 B1

TITLE: Prevention and treatment of amyloidogenic disease

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 424/185.1; 424/1.57, 424/9.2, 436/86, 514/2, 514/21

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

70 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

h e b b g e e e f e h ge ef b e

☐ 19. Document ID: US 6787138 B1

L1: Entry 19 of 46 File: USPT Sep 7, 2004

US-PAT-NO: 6787138
DOCUMENT-IDENTIFIER: US 6787138 B1

TITLE: Prevention and treatment of amyloidogenic disease

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 424/185.1; 424/1.57, 424/9.1, 424/9.2, 436/15, 436/507, 436/86, 514/12, 514/2, 514/21, 530/324

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide or an antibody thereto.

36 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

☐ 20. Document ID: US 6761888 B1

L1: Entry 20 of 46 File: USPT Jul 13, 2004

US-PAT-NO: 6761888
DOCUMENT-IDENTIFIER: US 6761888 B1

TITLE: Passive immunization treatment of Alzheimer's disease

DATE-ISSUED: July 13, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 424/130.1; 530/300, 530/350, 530/387.1

ABSTRACT:

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A.beta. in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A.beta. and

h e b b g e e e f e h ge ef b e

antibodies binding to the same.

36 Claims, 25 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 18

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des

---

21. Document ID: US 6750324 B1

L1: Entry 21 of 46 File: USPT Jun 15, 2004

US-PAT-NO: 6750324
DOCUMENT-IDENTIFIER: US 6750324 B1

TITLE: Humanized and chimeric N-terminal amyloid beta-antibodies

DATE-ISSUED: June 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		
Bard; Frederique	Pacifica	CA		
Yednock; Theodore	Forest Knolls	CA		

US-CL-CURRENT: 530/387.1; 424/130.1, 530/300, 530/350

ABSTRACT:

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A.beta. in the brain of a patient Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A.beta. and antibodies binding to the same.

12 Claims, 25 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 18

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des

---

22. Document ID: US 6743427 B1

L1: Entry 22 of 46 File: USPT Jun 1, 2004

US-PAT-NO: 6743427
DOCUMENT-IDENTIFIER: US 6743427 B1

TITLE: Prevention and treatment of amyloidogenic disease

DATE-ISSUED: June 1, 2004

INVENTOR-INFORMATION:

h e b b g e e e f e h ge ef b e

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 424/130.1; 530/300, 530/350, 530/387.1

ABSTRACT:

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A.beta. in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A.beta. and antibodies binding to the same.

19 Claims, 0 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 18

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

☐ 23. Document ID: US 6710226 B1

L1: Entry 23 of 46 File: USPT Mar 23, 2004

US-PAT-NO: 6710226
DOCUMENT-IDENTIFIER: US 6710226 B1

TITLE: Transgenic mouse assay to determine the effect of A.beta. antibodies and A.beta. Fragments on alzheimer's disease characteristics

DATE-ISSUED: March 23, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 800/12; 800/18, 800/3

ABSTRACT:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A.beta. peptide, active fragments thereof or an antibody thereto.

32 Claims, 22 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 16

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

h e b b g e e e f e h ge ef b e

☐ 24. Document ID: US 6287793 B1

L1: Entry 24 of 46 File: USPT Sep 11, 2001

US-PAT-NO: 6287793
DOCUMENT-IDENTIFIER: US 6287793 B1

TITLE: Diagnostic methods for alzheimer's disease

DATE-ISSUED: September 11, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Redwood City	CA		
Barbour; Robin M.	Newark	CA		
Johnson; Kelly L.	Santa Cruz	CA		

US-CL-CURRENT: 435/7.95; 252/301.6F, 252/301.6R, 435/70.21, 436/548, 436/811, 530/388.25

ABSTRACT:

Methods are disclosed for the identification of key diagnostic antibodies and antigens characteristic of a disease state of interest. Key diagnostic antibodies and antigens, diagnostic kits, and methods for diagnosis, are disclosed for Alzheimer's disease.

29 Claims, 6 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

☐ 25. Document ID: US 6284221 B1

L1: Entry 25 of 46 File: USPT Sep 4, 2001

US-PAT-NO: 6284221
DOCUMENT-IDENTIFIER: US 6284221 B1

TITLE: Method for identifying .beta.-amyloid peptide production inhibitors

DATE-ISSUED: September 4, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Pacifica	CA		
Schlossmacher; Michael G.	Vienna			AU
Selkoe; Dennis J.	Jamaica Plain	MA		
Seubert; Peter A.	South San Francisco	CA		
Vigo-Pelfrey; Carmen	Mountain View	CA		

US-CL-CURRENT: 424/9.2; 424/9.1, 435/7.1, 800/18

ABSTRACT:

h e b b g e e e f e h ge ef b e

A method for identifying inhibitors of the production of .beta.-amyloid peptides by administration of a compound to a mammalian host is provided.

9 Claims, 9 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

☐ 26. Document ID: US 6114133 A

L1: Entry 26 of 46 File: USPT Sep 5, 2000

US-PAT-NO: 6114133
DOCUMENT-IDENTIFIER: US 6114133 A
**** See image for Certificate of Correction ****

TITLE: Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-.beta. peptide (x-.gtoreq.41)

DATE-ISSUED: September 5, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Seubert; Peter A.	South San Francisco	CA		
Vigo-Pelfrey; Carmen	Mountain View	CA		
Schenk; Dale B.	Pacifica	CA		
Barbour; Robin	Newark	CA		

US-CL-CURRENT: 435/7.94; 435/7.1, 435/7.92, 436/518, 436/811

ABSTRACT:

This invention provides methods useful in aiding in the diagnosis of Alzheimer's disease. The methods involve measuring the amount of amyloid-.beta. peptide (x-.gtoreq.41) in the cerebrospinal fluid of a patient. High levels of the peptide generally are inconsistent with a diagnosis of Alzheimer's. Low levels of the peptide are consistent with the disease and, with other tests, can provide a positive diagnosis.

20 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

☐ 27. Document ID: US 6018024 A

L1: Entry 27 of 46 File: USPT Jan 25, 2000

US-PAT-NO: 6018024
DOCUMENT-IDENTIFIER: US 6018024 A

h e b b g e e e f e h ge ef b e

TITLE: Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein

DATE-ISSUED: January 25, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Seubert; Peter A.	South San Francisco	CA		
Schenk; Dale B.	Pacifica	CA		
Fritz; Lawrence C.	San Francisco	CA		

US-CL-CURRENT: 530/350

ABSTRACT:

Processing of .beta.-amyloid precursor protein (.beta.APP) is monitored by detecting the secretion of a soluble .beta.APP fragment resulting from cleavage of .beta.APP at the amino-terminus of .beta.-amyloid peptide. In vivo monitoring of secretion of the .beta.APP fragment may be monitored for diagnosis and prognosis of Alzheimer's disease and other .beta.-amyloid-related diseases, while in vitro monitoring of such secretion from cultured cells may be monitored to identify inhibitors of .beta.-amyloid production. The .beta.APP fragment may be detected using antibodies and other specific binding substances which recognize a carboxy-terminal residue on the fragment.

3 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

☐ 28. Document ID: US 5837672 A

L1: Entry 28 of 46 File: USPT Nov 17, 1998

US-PAT-NO: 5837672
DOCUMENT-IDENTIFIER: US 5837672 A

TITLE: Methods and compositions for the detection of soluble .beta.-amyloid peptide

DATE-ISSUED: November 17, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Pacifica	CA		
Schlossmacher; Michael G.	Vienna			AT
Selkoe; Dennis J.	Jamaica Plain	MA		
Seubert; Peter A.	South San Francisco	CA		
Vigo-Pelfrey; Carmen	Mountain View	CA		

US-CL-CURRENT: 514/2; 424/520, 435/7.2, 435/7.9, 436/518, 436/811, 514/169, 514/222.2, 514/42

ABSTRACT:

h e b b g e e e f e h ge ef b e

Soluble .beta.-amyloid peptide (.beta.AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of .beta.AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compounds are administered to the animals or exposed to the cultured cells and the accumulation of .beta.AP in the animal or culture medium observed. It has been found that elevated levels of .beta.AP in body fluids, such as blood and cerebrospinal fluid, is associated with the presence of a .beta.AP-related condition in a patient, such as Alzheimer's Disease. Methods for diagnosing and monitoring .beta.AP-related conditions comprise measuring the levels of .beta.AP in such body fluids from a patient.

14 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8

☐ 29. Document ID: US 5721130 A

L1: Entry 29 of 46 File: USPT Feb 24, 1998

US-PAT-NO: 5721130
DOCUMENT-IDENTIFIER: US 5721130 A

TITLE: Antibodies and fragments thereof which bind the carboxyl-terminus of an amino-terminal fragment of .beta.APP

DATE-ISSUED: February 24, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Seubert; Peter A.	South San Francisco	CA		
Schenk; Dale B.	Pacifica	CA		
Fritz; Lawrence C.	San Francisco	CA		

US-CL-CURRENT: 435/332; 435/326, 435/331, 435/70.21, 530/387.1, 530/387.9, 530/388.1, 530/389.1, 530/391.1, 530/391.3

ABSTRACT:

Processing of .beta.-amyloid precursor protein (.beta.APP) is monitored by detecting the secretion of a soluble .beta.APP fragment resulting from cleavage of .beta.APP at the amino-terminus of .beta.-amyloid peptide. In vivo monitoring of secretion of the .beta.APP fragment may be monitored for diagnosis and prognosis of Alzheimer's disease and other .beta.-amyloid-related diseases, while in vitro monitoring of such secretion from cultured cells may be monitored to identify inhibitors of .beta.-amyloid production. The .beta.APP fragment may be detected using antibodies and other specific binding substances which recognize a carboxy-terminal residue on the fragment.

14 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Drawi Desc

h e b b g e e e f e h ge ef b e

☐ 30. Document ID: US 5605811 A

L1: Entry 30 of 46 File: USPT Feb 25, 1997

US-PAT-NO: 5605811
DOCUMENT-IDENTIFIER: US 5605811 A

TITLE: Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein

DATE-ISSUED: February 25, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Seubert; Peter A.	South San Francisco	CA		
Schenk; Dale B.	Pacifica	CA		
Fritz; Lawrence C.	San Francisco	CA		

US-CL-CURRENT: 435/29; 424/9.2, 435/23, 435/69.2

ABSTRACT:

The present invention provides methods for identifying beta amyloid production inhibitors, wherein cells are cultured under conditions which result in secretion of a soluble fragment of beta amyloid precursor protein. The amino acid sequence of the fragment extends from the amino terminus of beta APP to the amino terminus of the beta amyloid peptide. The cultured cells are exposed to test compounds which cause a change in the secreted amount of the soluble fragment of beta APP which is determined.

7 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

☐ 31. Document ID: US 5604102 A

L1: Entry 31 of 46 File: USPT Feb 18, 1997

US-PAT-NO: 5604102
DOCUMENT-IDENTIFIER: US 5604102 A

TITLE: Methods of screening for .beta.-amyloid peptide production inhibitors

DATE-ISSUED: February 18, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
McConlogue; Lisa C.	San Francisco	CA		
Schenk; Dale B.	Pacifica	CA		
Seubert; Peter A.	South San Francisco	CA		
Sinha; Sukanto	San Francisco	CA		
Zhao; Jun	La Jolla	CA		

h e b b g e e e f e h ge ef b e

US-CL-CURRENT: 435/7.1; 424/9.2, 435/7.21, 530/350

ABSTRACT:

Processing of .beta.-amyloid precursor protein (.beta.APP) is monitored by detecting the secretion of a soluble amino-terminal fragment or .beta.APP (ATF-.beta.APP) resulting from cleavage of .beta.APP at the amino-terminus of .beta.-amyloid peptide. Secretion of ATF-.beta.APP in animal models may be monitored to identify inhibitors of .beta.-amyloid production. The ATF-.beta.APP may be detected using antibodies and other specific binding substances which recognize a carboxy terminal residue on the fragment. Animals expressing the Swedish mutation of .beta.APP are described which produce abundant amounts of ATF-.beta.APP.

19 Claims, 13 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8

32. Document ID: US 5593846 A

L1: Entry 32 of 46 File: USPT Jan 14, 1997

US-PAT-NO: 5593846
DOCUMENT-IDENTIFIER: US 5593846 A

TITLE: Methods for the detection of soluble .beta.-amyloid peptide

DATE-ISSUED: January 14, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Pacifica	CA		
Seubert; Peter A.	South San Francisco	CA		
Vigo-Pelfrey; Carmen	Mountain View	CA		

US-CL-CURRENT: 435/7.9; 435/7.92, 435/7.94, 436/518, 436/528, 436/811

ABSTRACT:

Soluble .beta.-amyloid peptide (.beta.AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of .beta.AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compounds are administered to the animals or exposed to the cultured cells and the accumulation of .beta.AP in the animal or culture medium observed. It has been found that elevated levels of .beta.AP in body fluids, such as blood and cerebrospinal fluid, is associated with the presence of a .beta.AP-related condition in a patient, such as Alzheimer's Disease. Methods for diagnosing and monitoring .beta.AP-related conditions comprise measuring the levels of .beta.AP in such body fluids from a patient.

16 Claims, 9 Drawing figures
Exemplary Claim Number: 12
Number of Drawing Sheets: 8

h e b b g e e e f e h ge ef b e

33. Document ID: US 5512455 A

L1: Entry 33 of 46 File: USPT Apr 30, 1996

US-PAT-NO: 5512455
DOCUMENT-IDENTIFIER: US 5512455 A

TITLE: Atrial natriuretic peptide receptor protein

DATE-ISSUED: April 30, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Campbell	CA		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/252.33, 435/320.1, 435/325, 536/23.5, 930/50

ABSTRACT:

Purified native Atrial Naturetic Peptide (ANP) receptor protein is provided, as well as synthetic ANP receptor and methods of making and using ANP receptor protein and antibodies.

10 Claims, 14 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 14

34. Document ID: US 5441870 A

L1: Entry 34 of 46 File: USPT Aug 15, 1995

US-PAT-NO: 5441870
DOCUMENT-IDENTIFIER: US 5441870 A
**** See image for Certificate of Correction ****

TITLE: Methods for monitoring cellular processing of .beta.-amyloid precursor protein

DATE-ISSUED: August 15, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Seubert; Peter A.	South San Francisco	CA		
Schenk; Dale B.	Pacifica	CA		
Fritz; Lawrence C.	San Francisco	CA		

US-CL-CURRENT: 435/7.1; 435/7.21, 435/7.92, 436/518, 436/811

ABSTRACT:

Processing of .beta.-amyloid precursor protein (.beta.APP) is monitored by detecting the secretion of a soluble .beta.APP fragment resulting from cleavage of .beta.APP at the amino-terminus of .beta.-amyloid peptide. In vivo monitoring of secretion of

h e b b g e e e f e h ge ef b e

the .beta.APP fragment may be monitored for diagnosis and prognosis of Alzheimer's disease and other .beta.-amyloid-related diseases, while in vitro monitoring of such secretion from cultured cells may be monitored to identify inhibitors of .beta.-amyloid production. The .beta.APP fragment may be detected using antibodies and other specific binding substances which recognize a carboxy-terminal residue on the fragment.

26 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

35. Document ID: US 4745055 A

L1: Entry 35 of 46 File: USPT May 17, 1988

US-PAT-NO: 4745055
DOCUMENT-IDENTIFIER: US 4745055 A

TITLE: Fused protein for enzyme immunoassay system

DATE-ISSUED: May 17, 1988

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Campbell	CA		
Spratt; Sharon K.	Sunnyvale	CA		

US-CL-CURRENT: 435/7.6; 435/14, 435/188, 435/320.1, 435/488, 435/69.7, 435/69.8, 435/7.9, 435/810, 530/350, 930/220, 930/240, 930/50

ABSTRACT:

A fused protein for use in an enzyme immunoassay system. The protein comprises an enzymatically active .beta.-galactosidase fused, at its C terminus, to an immunologically active peptide. The protein is produced using a plasmid containing a complete .beta.-galactosidase gene fused, at its 3' end, with an oligonucleotide coding for the peptide. The fused protein is designed for use in a solid-phase enzyme immunoassay system, based on immunospecific binding of the fused protein to a solid support, or in a homogeneous enzyme immunoassay system, based on enzyme inhibition resulting from immunospecific binding of an antibody to the protein.

10 Claims, 4 Drawing figures
Exemplary Claim Number: 5,8
Number of Drawing Sheets: 1

36. Document ID: JP 2004121251 A

L1: Entry 36 of 46 File: JPAB Apr 22, 2004

PUB-NO: JP02004121251A
DOCUMENT-IDENTIFIER: JP 2004121251 A

h e b b g e e e f e h ge ef b e

TITLE: METHOD AND COMPOSITION FOR DETECTION OF SOLUBLE β-AMYLOID PEPTIDE

PUBN-DATE: April 22, 2004

INVENTOR-INFORMATION:

NAME	COUNTRY
SCHENK, DALE B	
SCHLOSSMACHER, MICHAEL G	
SELKOE, DENNIS J	
SEUBERT, PETER A	
VIGO-PELFREY, CARMEN	

INT-CL (IPC): C12 N 15/09; G01 N 33/48; G01 N 33/68; A61 K 45/00; A61 P 25/28

ABSTRACT:

PROBLEM TO BE SOLVED: To provide a new method and composition for identifying a soluble β-amyloid peptide.

SOLUTION: The method for identification of the β-amyloid peptide (βAP) production inhibitor comprises; administration of a test compound to a mammal host excluding human in which the mammal host is a transgenic host with consolidated susceptibility to deposition of βAP plaques; determines whether or not the test compound influences the amount of the soluble βAP peptide present in the humor.

☐ 37. Document ID: JP 2004077499 A

L1: Entry 37 of 46 File: JPAB Mar 11, 2004

PUB-NO: JP02004077499A
DOCUMENT-IDENTIFIER: JP 2004077499 A
TITLE: METHOD FOR AIDING IN DIAGNOSIS OF ALZHEIMER'S DISEASE BY MEASURING AMYLOID-BETA PEPTIDE (X-≥41) AND TAU

PUBN-DATE: March 11, 2004

INVENTOR-INFORMATION:

NAME	COUNTRY
SEUBERT, PETER A	
VIGO-PELFREY, CARMEN	
SCHENK, DALE B	
BARBOUR, ROBIN	

INT-CL (IPC): G01 N 33/53; C12 N 15/09

ABSTRACT:

PROBLEM TO BE SOLVED: To provide a method for aiding in diagnosis or monitoring of Alzheimer's disease in a patient.

SOLUTION: The method for aiding in diagnosis or monitoring of Alzheimer's disease in a patient includes a step for measuring the amount of one or more soluble amyloid-

h e b b g e e e f e h ge ef b e

beta (A-β)(x-≥41) in a patient sample, a step for comparing the measured amount with a predetermined amount of the one or more Aβ(x-≥41), and a step for assessing the patient's status according to the difference between the measured amount and the predetermined amount.

☐ 38. Document ID: WO 2004041067 A2

L1: Entry 38 of 46 File: EPAB May 21, 2004

PUB-NO: WO2004041067A2
DOCUMENT-IDENTIFIER: WO 2004041067 A2
TITLE: PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC DISEASE

PUBN-DATE: May 21, 2004

INVENTOR-INFORMATION:

NAME	COUNTRY
SCHENK, DALE B	
MASLIAH, ELIEZER	

INT-CL (IPC): A61 B 0/

ABSTRACT:

The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.

☐ 39. Document ID: EP 1298436 A2

L1: Entry 39 of 46 File: EPAB Apr 2, 2003

PUB-NO: EP001298436A2
DOCUMENT-IDENTIFIER: EP 1298436 A2
TITLE: Beta-amyloid peptide (BAP) release inhibitor compounds for treating BAP-related diseases and methods for their identification

PUBN-DATE: April 2, 2003

INVENTOR-INFORMATION:

NAME	COUNTRY
SCHENK, DALE B	US
SEUBERT, PETER A	US
VIGO-PELFREY, CARMEN	US

h e b b g e e e f e h ge ef b e

SELKOE, DENNIS J	US
SCHLOSSMACHER, MICHAEL G	AT

INT-CL (IPC): G01 N 33/50; G01 N 33/68; A61 K 38/00
EUR-CL (EPC): C07K014/47; C07K016/18, G01N033/68

ABSTRACT:

CHG DATE=20030507 STATUS=O>????Elevated levels of beta AP in body fluids, such as blood and cerebrospinal fluid, is associated with the presence of a beta AP-related condition in a patient, such as Alzheimer's Disease. Soluble beta -amyloid peptide (beta AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of beta AP concentrations in animals or conditioned medium from cultured cells is used for drug screening, where test compounds are administered to the animals or exposed to the cultured cells and the accumulation of beta AP in the animal or culture medium observed. ?□

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

---

☐ 40. Document ID: WO 9927944 A1

L1: Entry 40 of 46 File: EPAB Jun 10, 1999

PUB-NO: WO009927944A1
DOCUMENT-IDENTIFIER: WO 9927944 A1
TITLE: PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE

PUBN-DATE: June 10, 1999

INVENTOR-INFORMATION:

NAME	COUNTRY
SCHENK, DALE B	US

INT-CL (IPC): A61 K 38/00; A61 K 38/28; A61 K 9/26; A61 K 33/06
EUR-CL (EPC): A61K038/17; A61K039/00, C07K016/18

ABSTRACT:

CHG DATE=19990803 STATUS=O>The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A beta peptide or an antibody thereto.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

---

☐ 41. Document ID: WO 9640896 A1

L1: Entry 41 of 46 File: EPAB Dec 19, 1996

PUB-NO: WO009640896A1
DOCUMENT-IDENTIFIER: WO 9640896 A1

h e b b g e e e f e h ge ef b e

TITLE: METHOD FOR IDENTIFYING ALZHEIMER'S DISEASE THERAPEUTICS USING TRANSGENIC ANIMAL MODELS

PUBN-DATE: December 19, 1996

INVENTOR-INFORMATION:

NAME	COUNTRY
GAMES, KATE D	
SCHENK, DALE B	
MCCONLOGUE, LISA CLAIRE	
SEUBERT, PETER A	
RYDEL, RUSSELL E	

INT-CL (IPC): C12 N 15/00; C12 N 15/12; C12 N 15/62; C07 K 14/47; A01 K 67/027; C12 Q 1/68; G01 N 33/50
EUR-CL (EPC): A01K067/027; C07K014/47, A01K067/027

ABSTRACT:

CHG DATE=19990617 STATUS=O>The construction of transgenic animal models of human Alzheimer's disease, and methods of using the models to screen potential Alzheimer's disease therapeutics, are described. The models are characterized by pathologies similar to pathologies observed in Alzheimer's disease, based on expression of all three forms of the beta -amyloid precursor protein (APP), APP695, APP751, and APP770, as well as various point mutations based on naturally occurring mutations, such as the London and Indiana familial Alzheimer's diseae (FAD) mutations at amino acid 717, predicted mutations in the APP gene, and truncated forms of APP that contain the A beta region. Animal cells can be isolated from the transgenic animals or prepared using the same constructs with standard techniques such as lipofection or eletroporation. The transgenic animals, or animal cells, are used to screen for compounds altering the pathological course of Alzheimer's disease as measured by their effect on the amount of APP, beta -amyloid peptide, and numerous other Alzeimer's disease markers in the animals, the neuropathology of the animals, as well as by behavioral alterations in the animals.

☐ 42. Document ID: WO 9615452 A1

L1: Entry 42 of 46 File: EPAB May 23, 1996

PUB-NO: WO009615452A1
DOCUMENT-IDENTIFIER: WO 9615452 A1
TITLE: METHODS FOR AIDING IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE BY MEASURING AMYLOID- beta PEPTIDE (X- >/=41) AND TAU

PUBN-DATE: May 23, 1996

INVENTOR-INFORMATION:

NAME	COUNTRY
SEUBERT, PETER A	US
VIGO-PELFREY, CARMEN	US
SCHENK, DALE B	US
BARBOUR, ROBIN	US

h e b b g e e e f e h ge ef b e

INT-CL (IPC): G01 N 33/53; G01 N 33/537; G01 N 33/542; G01 N 33/543
EUR-CL (EPC): C07K014/47; C07K016/18, G01N033/68

ABSTRACT:

CHG DATE=19990617 STATUS=O>This invention provides methods useful in aiding in the diagnosis of Alzheimer's disease. The methods involve measuring the amount of amyloid- beta peptide (x- >/=41) in the cerebrospinal fluid of a patient. High levels of the peptide generally are inconsistent with a diagnosis of Alzheimer's. Low levels of the peptide are consistent with the disease and, with other tests, can provide a positive diagnosis. Other methods involve measuring the amounts of both A beta (x- >/=41) and tau. Low levels of A beta (x- >/=41) and high levels of tau are a positive indicator of Alzheimer's disease, while high levels of A beta (x- >/=41) and low levels of tau are a negative indication of Alzheimer's disease.

☐ 43. Document ID: WO 9511994 A1

L1: Entry 43 of 46 File: EPAB May 4, 1995

PUB-NO: WO009511994A1
DOCUMENT-IDENTIFIER: WO 9511994 A1
TITLE: METHODS OF SCREENING FOR BETA-AMYLOID PEPTIDE PRODUCTION INHIBITORS

PUBN-DATE: May 4, 1995

INVENTOR-INFORMATION:

NAME	COUNTRY
SEUBERT, PETER A	
SCHENK, DALE B	
FRITZ, LAWRENCE C	

INT-CL (IPC): C12 Q 1/68
EUR-CL (EPC): A01K067/027; C07K014/47, C07K016/18

ABSTRACT:

CHG DATE=20031129 STATUS=O>Processing of beta -amyloid precursor protein (beta APP) is monitored by detecting the secretion of a soluble amino-terminal fragment or beta APP (ATF- beta APP) resulting from cleavage of beta APP at the amino-terminus of beta -amyloid peptide. Secretion of ATF- beta APP in animal models may be monitored to identify inhibitors of beta -amyloid production. The ATF- beta APP may be detected using antibodies and other specific binding substances which recognize a carboxy terminal residue on the fragment. Animals expressing the Swedish mutation of beta APP are described which produce abundant amounts of ATF- beta APP.

☐ 44. Document ID: WO 9410569 A1

L1: Entry 44 of 46 File: EPAB May 11, 1994

h e b b g e e e f e h ge ef b e

PUB-NO: WO0009410569A1
DOCUMENT-IDENTIFIER: WO 9410569 A1
TITLE: METHODS AND COMPOSITIONS FOR THE DETECTION OF SOLUBLE beta -AMYLOID PEPTIDE

PUBN-DATE: May 11, 1994

INVENTOR-INFORMATION:

NAME	COUNTRY
SCHENK, DALE B	US
SCHLOSSMACHER, MICHAEL G	AT
SELKOE, DENNIS J	US
SEUBERT, PETER A	US
VIGO-PELFREY, CARMEN	US

US-CL-CURRENT: 435/6
INT-CL (IPC): G01N 33/53; C12N 15/00
EUR-CL (EPC): C07K014/47; C07K016/18, G01N033/68

ABSTRACT:

CHG DATE=20031112 STATUS=O>Soluble beta -amyloid peptide (beta AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of beta AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compounds are administered to the animals or exposed to the cultured cells and the accumulation of beta AP in the animal or culture medium observed. It has been found that elevated levels of beta AP in body fluids, such as blood and cerebrospinal fluid, is associated with the presence of a beta AP-related condition in a patient, such as Alzheimer's Disease. Methods for diagnosing and monitoring beta AP-related conditions comprise measuring the levels of beta AP in such body fluids from a patient.

☐ 45. Document ID: WO 8706938 A1

L1: Entry 45 of 46 File: EPAB Nov 19, 1987

PUB-NO: WO0008706938A1
DOCUMENT-IDENTIFIER: WO 8706938 A1
TITLE: ATRIAL NATRIURETIC PEPTIDE RECEPTOR PROTEIN AND ITS ENCODING DNA

PUBN-DATE: November 19, 1987

INVENTOR-INFORMATION:

NAME	COUNTRY
SCHENK, DALE B	US

US-CL-CURRENT: 435/6; 435/69.1
INT-CL (IPC): C07K 3/02; C07K 3/20; C07K 13/00; C07K 15/00; A61K 37/00; C12Q 1/68; C12P 21/00; C12P 21/02; C12N 15/00; C12N 1/20; C12N 1/00; C07H 21/04
EUR-CL (EPC): C07K014/72; C07K016/28

ABSTRACT:

CHG DATE=19990617 STATUS=O>Purified native Atrial Natriuretic Peptide (ANP) receptor

h e b b g e e e f e h ge ef b e

protein, as well as synthetic ANP receptor and methods of making and using ANP receptor protein and antibodies.

☐ 46. Document ID: WO 8606742 A1

L1: Entry 46 of 46 File: EPAB Nov 20, 1986

PUB-NO: WO008606742A1
DOCUMENT-IDENTIFIER: WO 8606742 A1
TITLE: FUSED PROTEINE FOR ENZYME IMMUNOASSAY SYSTEM

PUBN-DATE: November 20, 1986

INVENTOR-INFORMATION:

NAME	COUNTRY
SCHENK, DALE B	US
SPRATT, SHARON KAYE	US

US-CL-CURRENT: 435/14; 435/69.7, 435/69.8
INT-CL (IPC): C12N 1/00; C12N 15/00; G01N 33/535
EUR-CL (EPC): G01N033/535; C07K014/785, C07K014/11 , C07K014/58 , C12N009/38

ABSTRACT:

A fused protein for use in an enzyme immunoassay system. The protein comprises an enzymatically active beta -galactosidase fused, at its C terminus, to an immunologically active peptide. The protein is produced using a plasmid containing a complete beta -galactosidase gene fused, at its 3' end, with an oligonucleotide coding for the peptide. The fused protein is designed for use in a solid-phase enzyme immunoassay system, based on immunospecific binding of the fused protein to a solid support, or in a homogeneous enzyme immunoassay system, based on enzyme inhibition resulting from immunospecific binding of an antibody to the protein.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
(Schenk-Dale-B.IN.)	46

Display Format: - Change Format

h e b b g e e e f e h ge ef b e

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 3 of 3 returned.

☐ 1. Document ID: US 6610493 B1

Using default format because multiple data bases are involved.

L2: Entry 1 of 3 File: USPT Aug 26, 2003

US-PAT-NO: 6610493
DOCUMENT-IDENTIFIER: US 6610493 B1

TITLE: Screening compounds for the ability to alter the production of amyloid-.beta. peptide

DATE-ISSUED: August 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Citron; Martin	Thousands Oaks	CA		
Selkoe; Dennis J.	Jamaica Plain	MA		
Seubert; Peter A.	San Francisco	CA		
Schenk; Dale	Burlingame	CA		

US-CL-CURRENT: 435/7.1; 435/7.2, 435/7.21, 435/7.23, 435/7.8, 435/7.92

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

☐ 2. Document ID: US 5422244 A

L2: Entry 2 of 3 File: USPT Jun 6, 1995

US-PAT-NO: 5422244
DOCUMENT-IDENTIFIER: US 5422244 A

TITLE: Detection of brain .alpha.1-antichymotrypsin

DATE-ISSUED: June 6, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Johnson-Wood; Kelly	Belmont	CA		
Schenk; Dale	Pacifica	CA		

US-CL-CURRENT: 435/7.1; 435/7.92, 435/7.94, 435/971, 436/518, 436/536, 436/811, 436/827

ABSTRACT:

The present invention is related generally to methods and compositions for

h e b b g e e e f e h ge ef b e

identifying and quantitating particular .alpha.1-antichymotrypsin species in a biological sample. More particularly, the present invention is related to methods and compositions for detecting and measuring a brain .alpha.1-antichymotrypsin species that is produced in brain tissue of individuals having a neuropathological condition and which is detectable in accessible biological samples. The invention provides detection assays, such as sandwich binding assays, for detecting and quantitating brain .alpha.1-antichymotrypsin in a biological sample, such as blood, urine, cerebrospinal fluid, or tissue. These detection assays are useful for detecting and diagnosing neuropathological diseases and for identifying cells of a human central nervous system lineage, and for other medical applications. The invention also provides binding components, such as antibodies that bind to brain .alpha.1-antichymotrypsin, and which have potential therapeutic and diagnostic medical imaging applications.

26 Claims, 3 Drawing figures
Exemplary Claim Number: 17
Number of Drawing Sheets: 1

☐ 3. Document ID: WO 9748983 A1

L2: Entry 3 of 3 File: EPAB Dec 24, 1997

PUB-NO: WO009748983A1
DOCUMENT-IDENTIFIER: WO 9748983 A1
TITLE: SCREENING COMPOUNDS FOR THE ABILITY TO ALTER THE PRODUCTION OF AMYLOID- beta PEPTIDE (x->/=41)

PUBN-DATE: December 24, 1997

INVENTOR-INFORMATION:

NAME	COUNTRY
CITRON, MARTIN	US
SELKOE, DENNIS J	US
SEUBERT, PETER A	US
SCHENK, DALE	US

INT-CL (IPC): G01 N 33/68; G01 N 33/50
EUR-CL (EPC): G01N033/50; G01N033/68

ABSTRACT:

CHG DATE=19990617 STATUS=O>This invention provides methods of screening compounds for their ability to alter the production of A beta (x>/=41) alone or in combination with A beta (x/=41) produced by the cells, and comparing these amounts to that produced by the cells without administration of the compounds.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

h e b b g e e e f e h ge ef b e

Terms	Documents
Schenk-Dale.IN.	3

Display Format: - Change Format

Previous Page Next Page Go to Doc#

h e b b g e e e f e h ge ef b e

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 10 of 10 returned.

☐ 1. Document ID: EP 1452173 A1, WO 2004073696 A1

Using default format because multiple data bases are involved.

L3: Entry 1 of 10 File: DWPI Sep 1, 2004

DERWENT-ACC-NO: 2004-663177
DERWENT-WEEK: 200465
COPYRIGHT 2004 DERWENT INFORMATION LTD
TITLE: Transdermal therapeutic system showing good stabilization of e.g. light-sensitive hormone active material has a UV absorber-containing adhesive layer and a separating layer

INVENTOR: DITTGEN, M; INGWERSEN, J ; KAFFL, H ; LANGGUTH, T ; MILETZKO, S ; SCHENK, D ; SCHUMACHER, J ; SUESSE, M ; MLETZKO, S

PRIORITY-DATA: 2003EP-0004061 (February 25, 2003), 2003EP-0003888 (February 21, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1452173 A1	September 1, 2004	G	008	A61K009/70
WO 2004073696 A1	September 2, 2004	G	000	A61K009/70

INT-CL (IPC): A61 K 9/70

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Des

☐ 2. Document ID: EP 1449526 A1

L3: Entry 2 of 10 File: DWPI Aug 25, 2004

DERWENT-ACC-NO: 2004-636756
DERWENT-WEEK: 200465
COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Transdermal therapeutic system, used especially for delivering gestagenic hormones, includes ultraviolet light absorber in outer layer and barrier layer to inhibit outward diffusion of active agent

INVENTOR: DITTGEN, M; INGWERSEN, J ; KAFFL, H ; LANGGUTH, T ; MLETZKO, S ; SCHENK, D ; SCHUMACHER, J ; SUESSE, M

PRIORITY-DATA: 2003EP-0003888 (February 21, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1449526 A1	August 25, 2004	G	009	A61K009/70

h e b b g e e e f e h ge ef b e

INT-CL (IPC): A61 K 9/70

ABSTRACTED-PUB-NO: EP 1449526A
BASIC-ABSTRACT:

NOVELTY - Transdermal therapeutic system comprises a backing layer (BL), at least one matrix containing active agent and optionally a removable film, and also includes a UV absorber (I). Between BL and the matrix furthest from the skin, there is at least one (I)-containing adhesive layer (X) and between (X) and the matrix furthest from the skin there is a separation layer (SL), impermeable for both active agent and (I).

USE - Used for transdermal delivery of hormones, specifically gestodes or levonorgesterel.

ADVANTAGE - Inclusion of (I) improves stability of light sensitive active agents and irritation caused by contact between (I) and the skin is prevented. The degree of UV protection can be controlled precisely from the content of (I), contact between (I) and active agents is prevented and the separation layer prevents excessive diffusion of active agents to the outer surface.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

☐ 3. Document ID: EP 1444977 A1, CA 2456895 A1, DE 10305137 A1, US 20040166148 A1

L3: Entry 3 of 10 File: DWPI Aug 11, 2004

DERWENT-ACC-NO: 2004-582995
DERWENT-WEEK: 200457

TITLE: Transdermal therapeutic delivery system, useful in temperate climate and subtropical or tropical climate, comprises one or more drugs and butenolide

INVENTOR: MCLEOD, S; MEYER, E ; SCHENK, D ; WOESS, A

PRIORITY-DATA: 2003DE-1005137 (February 7, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1444977 A1	August 11, 2004	E	010	A61K009/70
CA 2456895 A1	August 7, 2004	E	000	A61K047/12
DE 10305137 A1	August 26, 2004		000	A61L015/44
US 20040166148 A1	August 26, 2004		000	A61K031/485

INT-CL (IPC): A61 K 9/70; A61 K 31/366; A61 K 31/48; A61 K 31/485; A61 K 47/12; A61 K 47/22; A61 L 15/44; A61 M 37/00; A61 P 25/16; A61 P 29/00

ABSTRACTED-PUB-NO: EP 1444977A
BASIC-ABSTRACT:

NOVELTY - Transdermal therapeutic delivery system (TTDS) (I) comprising one or more drugs (A) and a butenolide (B).

USE - (I) is useful in a temperate climate the molar ratio (A) and (B) is 1:4.1-1:5 and subtropical or tropical climate the molar ratio of (A) and (B) is 1:4.1-1:15.

ADVANTAGE - (I) has high potency of antioxidative effect.

h e b b g e e e f e h ge ef b e

☐ 4. Document ID: GB 2368794 B, WO 200072880 A2, AU 200053031 A, BR 200011000 A, EP 1185298 A2, NO 200105773 A, GB 2368794 A, DE 10084643 T, HU 200201250 A2, CN 1359301 A, KR 2002038585 A, SK 200101698 A3, CZ 200103824 A3, ZA 200109487 A, JP 2003517461 W, NZ 515403 A

L3: Entry 4 of 10 File: DWPI Oct 20, 2004

DERWENT-ACC-NO: 2001-032104
DERWENT-WEEK: 200469

TITLE: Preventing or treating a disease associated with amyloid deposits, especially Alzheimer's disease, comprises administering amyloid specific antibody

INVENTOR: BARD, F; SCHENK, D B ; VASQUEZ, N J ; YEDNOCK, T ; SCHENK, D ; VASQUEZ, N

PRIORITY-DATA: 1999US-0322289 (May 28, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
GB 2368794 B	October 20, 2004		000	A61K039/395
WO 200072880 A2	December 7, 2000	E	144	A61K039/395
AU 200053031 A	December 18, 2000		000	A61K039/395
BR 200011000 A	February 19, 2002		000	A61K039/395
EP 1185298 A2	March 13, 2002	E	000	A61K039/395
NO 200105773 A	January 25, 2002		000	A61K000/00
GB 2368794 A	May 15, 2002		000	A61K039/395
DE 10084643 T	July 11, 2002		000	A61K039/395
HU 200201250 A2	August 28, 2002		000	A61K039/395
CN 1359301 A	July 17, 2002		000	A61K039/395
KR 2002038585 A	May 23, 2002		000	A61K039/395
SK 200101698 A3	November 6, 2002		000	A61K039/395
CZ 200103824 A3	November 13, 2002		000	A61K039/395
ZA 200109487 A	April 30, 2003		182	A61K000/00
JP 2003517461 W	May 27, 2003		166	A61K039/395
NZ 515403 A	May 28, 2004		000	A61K039/395

2003517461 W , NZ 515403 A INT-CL (IPC): A61 K 0/00; A61 K 38/00; A61 K 38/17; A61 K 39/00; A61 K 39/39; A61 K 39/395; A61 K 48/00; A61 K 49/00; A61 P 25/28; C07 K 14/47; C07 K 16/18; C12 N 15/09; G01 N 33/15; G01 N 33/50; G01 N 33/53; G01 N 33/577; G01 N 33/68; C07 K 14:47; C07 K 16/18; A61 K 39/00; A61 K 39/39; A61 K 48/00; A61 P 25/28; C07 K 14/47; C07 K 16/18; G01 N 33/68; A61 K 39/00; A61 K 39/39; A61 K 48/00; A61 P 25/28; C07 K 14/47; C07 K 16/18; G01 N 33/68

ABSTRACTED-PUB-NO: WO 200072880A
BASIC-ABSTRACT:

NOVELTY - Preventing or treating a disease associated with amyloid deposits of A beta in the brain of a patient, comprising administering to the patient:

(a) an antibody that binds to A beta ;

(b) a polypeptide containing an N-terminal segment of at least residues 1-5 of A

h e b b g e e e f e h ge ef b e

beta ; or

(c) an agent that induces an immunogenic response against residues 1-3 to 7-11 of A beta , is new.

DETAILED DESCRIPTION - Preventing or treating a disease (M1) associated with amyloid deposits of A beta in the brain of a patient, comprising administering to the patient:

(a) an antibody (I) that binds to A beta ;

(b) a polypeptide (II) containing an N-terminal segment of at least residues 1-5 of A beta , the first residue of A beta being the N-terminal residue, where (II) is free of a C-terminal segment of A beta ; or

(c) an agent (III) that induces an immunogenic response against residue 1-3 to 7-11 of A beta without inducing an immunogenic response against residues 12-43 of A beta 43.

INDEPENDENT CLAIMS are also included for the following:

(1) screening an antibody (M2) for activity in treating a disease associated with amyloid deposits of A beta in the brain of a patient, comprising contacting the antibody with a polypeptide comprising at least five contiguous amino acids of an N-terminal segment of A beta beginning at residue 1-3 of A beta , the polypeptide being free of a C-terminal segment of A beta , and determining whether the antibody specifically binds to the polypeptide, where specific binding is indicative of activity in treating Alzheimer's disease (AD);

(2) screening an antibody (M3) for activity in clearing a biological entity physically associated with an antigen, comprising combining the antigen-associated biological entity, antibody and phagocytic cells bearing Fc receptors in a medium and monitoring the amount of biological entity remaining in the medium, where a reduction in the amount of biological entity is indicative the antibody has clearing activity against the antigen;

(3) detecting (M4) an amyloid deposit in a patient comprising administering an antibody which specifically binds to a group within 1-10 amino acids of A beta and detecting the antibody within the patient's brain; and

(4) a diagnostic kit (IV) comprising an antibody that specifically binds to a group with residues 1-10 of A beta .

ACTIVITY - Nootropic; neuroprotective.

MECHANISM OF ACTION - The antibody binds to an amyloid deposit and induces a clearing response (Fc receptor mediated phagocytosis) against it.

USE - To treat or prevent diseases associated with amyloid deposits of A beta in the brain (claimed). It is also useful for monitoring a course of treatment being administered to a patient e.g. active and passive immunization.

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 18 of 18 returned.

☐ 1. Document ID: AU 2003290548 A1, WO 2004041067 A2, US 20040136993 A1, US 20040146521 A1

Using default format because multiple data bases are involved.

L4: Entry 1 of 18 File: DWPI Jun 7, 2004

DERWENT-ACC-NO: 2004-411388
DERWENT-WEEK: 200469
COPYRIGHT 2004 DERWENT INFORMATION LTD
TITLE: Preventing or treating disease such as Parkinson's disease characterized by Lewy bodies or alpha-synuclein aggregation in brain by administering agent that induces immunogenic response against alpha-synuclein and/or beta-amyloid

INVENTOR: MASLIAH, E; SCHENK, D B

PRIORITY-DATA: 2002US-423012P (November 1, 2002), 2003US-0699517 (October 31, 2003), 1999US-137010P (June 1, 1999), 2000US-0580015 (May 26, 2000), 2000US-0585817 (June 1, 2000), 2003US-0698099 (October 31, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 2003290548 A1	June 7, 2004		000	A61B000/00
WO 2004041067 A2	May 21, 2004	E	078	A61B000/00
US 20040136993 A1	July 15, 2004		000	A61K039/395
US 20040146521 A1	July 29, 2004		000	A61K039/00

INT-CL (IPC): A61 B 0/00; A61 K 39/00; A61 K 39/395

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

☐ 2. Document ID: US 6717031 B2, US 20020104104 A1

L4: Entry 2 of 18 File: DWPI Apr 6, 2004

DERWENT-ACC-NO: 2002-697836
DERWENT-WEEK: 200425
COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Testing compounds for effect on Alzheimer's disease marker by using transgenic mammal into which nucleic acid encoding protein including APP770, APP751 or APP695 with/without specific mutations, has been incorporated

INVENTOR: GAMES, K D; MCCONLOGUE, L C ; RYDEL, R E ; SCHENK, D B ; SEUBERT, P A

PRIORITY-DATA: 1998US-0149718 (September 8, 1998), 1995US-0480653 (June 7, 1995), 1995US-0486538 (June 7, 1995), 1996US-0659797 (June 7, 1996), 1996US-0660487 (June 7, 1996), 1995US-0149748 (June 7, 1995)

h e b b g e e e f e h ge ef b e

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 6717031 B2	April 6, 2004		000	A01K067/00
US 20020104104 A1	August 1, 2002		062	A01K067/27

INT-CL (IPC): A01 K 67/00; A01 K 67/27; C12 Q 1/02; G01 N 33/00

ABSTRACTED-PUB-NO: US20020104104A
BASIC-ABSTRACT:

NOVELTY - Testing compounds (C1) for effect on Alzheimer's disease marker (ADM), by administering C1 to non-human transgenic mammal (I), where (I) has nucleic acid construct (II) stably incorporated into the genome, and (II) has promoter for expression of (II) in mammalian cell and region encoding protein that includes all or contiguous portion of APP770, APP751 or APP695, and detecting or measuring ADM.

DETAILED DESCRIPTION - Testing (M1) compounds for an effect on an Alzheimer's disease marker, comprises:

(a) administering the compound to be tested to a non-human transgenic mammal (I) or mammalian cells derived from (I), where (I) has a nucleic acid construct (II) stably incorporated into the genome, where (II) comprises a promoter for expression of the construct in a mammalian cell and a region encoding an A beta -containing protein, where the promoter is operatively linked to the region; and

(b) detecting or measuring ADM such that any difference between the marker in (I), or by mammalian cells derived from (I) in the presence and absence of the test compound indicates that the compound has an effect on the marker.

The region comprises DNA encoding the A beta -containing protein, where the A beta -containing protein consists of all or contiguous portion of a protein chosen from amyloid precursor protein (APP)770, APP770 bearing a mutation in one or more of the amino acids such as 669, 670, 671, 690, 692 or 717; APP751, APP751 bearing a mutation in one or more of the amino acids such as amino acid 669, 670, 671, 690, 692 or 717; APP695 and APP695 bearing a mutation in one or more of the amino acids chosen from 669, 670, 671, 690, 692 and 717.

The A beta -containing protein includes amino acids 672-714 of human APP, where the promoter mediates expression of the construct such that A beta (tot) is expressed at a level of at least 30 ng/g of brain tissue of the mammal when it is two to four months old, A beta (1-42) is expressed at a level of at least 8.5 ng/g of brain tissue of the mammal when it is two to four months old, APP and APP alpha combined are expressed at a level of at least 150 pM/g of brain tissue of the mammal when it is two to four months old, APP beta is expressed at a level of at least 40 pM/g of brain tissue of the mammal when it is two to four months old, and/or mRNA encoding the A beta -containing protein is expressed to a level at least twice that of mRNA encoding the endogenous APP of (I) in brain tissue of the mammal when it is two to four months old.

USE - The method is useful for testing compounds for effect on Alzheimer's disease marker (claimed).

☐ 3. Document ID: ZA 200305169 A, WO 200246237 A2, AU 200225921 A, NO 200302549 A, US 20030165496 A1, EP 1358213 A2, HU 200302589 A2, KR 2003066695 A, CZ 200301601 A3, SK 200300850 A3, US 20040087777 A1, US 20040171815 A1, US 20040171816 A1

L4: Entry 3 of 18 File: DWPI Sep 29, 2004

h e b b g e e e f e h ge ef b e

DERWENT-ACC-NO: 2002-519658
DERWENT-WEEK: 200468

TITLE: Novel light/heavy chain of humanized immunoglobulin for treating amyloidogenic disease, has 3D6/10D5 variable region complementarity determining regions and variable framework region from human acceptor immunoglobulin

INVENTOR: BASI, G; SALDANHA, J ; YEDNOCK, T ; SALDANHA, J W ; SCHENK, D B

PRIORITY-DATA: 2000US-251892P (December 6, 2000), 2001US-0010942 (December 6, 2001), 2003US-0388389 (March 12, 2003), 1998US-080970P (April 7, 1998), 1998US-0201430 (November 30, 1998), 1999US-0322289 (May 28, 1999), 2000US-0580015 (May 26, 2000), 2003US-0703713 (November 7, 2003), 2003US-0704070 (November 7, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
ZA 200305169 A	September 29, 2004		183	C07K000/00
WO 200246237 A2	June 13, 2002	E	171	C07K016/18
AU 200225921 A	June 18, 2002		000	C07K016/18
NO 200302549 A	August 5, 2003		000	C07K016/18
US 20030165496 A1	September 4, 2003		000	A61K039/395
EP 1358213 A2	November 5, 2003	E	000	C07K016/18
HU 200302589 A2	October 28, 2003		000	C07K016/18
KR 2003066695 A	August 9, 2003		000	C07K016/18
CZ 200301601 A3	December 17, 2003		000	C07K016/18
SK 200300850 A3	March 2, 2004		000	C07K016/18
US 20040087777 A1	May 6, 2004		000	C07K016/44
US 20040171815 A1	September 2, 2004		000	A61K039/395
US 20040171816 A1	September 2, 2004		000	C07K016/44

INT-CL (IPC): A61 K 39/395; A61 P 25/28; C07 K 0/00; C07 K 16/18; C07 K 16/44; C12 N 5/06; C12 N 5/10; C12 N 15/13; C12 N 15/85

ABSTRACTED-PUB-NO: WO 200246237A
BASIC-ABSTRACT:

NOVELTY - A humanized immunoglobulin (Ig) light chain (LC) or heavy chain (HC) (I) comprising variable region complementarity determining regions from 3D6/10D5 Ig LC or HC variable region sequence, where LC has a 131 or 132 amino acid (a.a) sequence (S1) and HC has a 138 or 142 a.a sequence (S2), and variable framework region from human acceptor Ig LC or HC sequence, where S1, S2 are given in specification.

DETAILED DESCRIPTION - A humanized immunoglobulin (Ig) light chain (LC) or heavy chain (HC) (I) comprising variable region complementarity determining regions from 3D6/10D5 Ig LC or HC variable region sequence, where LC has a 131 or 132 amino acid (a.a) sequence (S1) and HC has a 138 or 142 a.a sequence (S2), and variable framework region from human acceptor Ig LC or HC sequence, where S1, S2 are given in specification.

(I) comprises variable region complementarity determining regions (CDRs) from the 3D6 or 10D5 Ig light or heavy chain variable region sequence, where the light chain variable region has S1 and heavy chain variable region has S2, and a variable framework region from a human acceptor Ig light or heavy chain sequence, provided that at least one framework residue is substituted with the corresponding amino acid residue from the mouse 3D6 or 10D5 light or heavy chain variable region sequence, where the framework residue is selected from a residue that non-covalently binds antigen directly, a residue adjacent to a CDR, a CDR-interacting residue, and a residue participating in the VL-VH interface.

h e b b g e e e f e h ge ef b e

INDEPENDENT CLAIMS are also included for the following:

(1) a humanized Ig (II) comprising (I), or antigen binding fragment of (II);

(2) a humanized antibody (III) comprising CDR1, CDR2 and CDR3 of S1 or S2;

(3) a humanized antibody (IV) or its antigen-binding fragment, which specifically binds to beta amyloid peptide (A beta), comprising a variable region having CDRs corresponding to CDRs from the mouse 3D6 or 10D5 antibody;

(4) a humanized antibody which binds A beta with an affinity of at least 107 M-1 comprising a light chain variable domain having murine 3D6 CDR amino acid residues and human VL subgroup II variable domain framework region (FR) amino acid residues, and a heavy chain variable domain comprising murine 3D6 CDR amino acid residues and human VH subgroup III variable domain FR amino acid residues;

(5) a chimeric Ig (V) comprising variable region CDRs from S1 or S2, and variable FR regions from a human acceptor Ig or constant region sequence from a human Ig;

(6) an Ig or its antigen binding fragment, comprising a variable heavy chain region of 138 amino acids fully defined in the specification, and a variable light chain region of 132 amino acids fully defined in the specification, and constant regions from IgG1;

(7) a pharmaceutical composition (VI) comprising (II), (III) or (IV) and a pharmaceutical carrier;

(8) an isolated polypeptide (VII) comprising a fragment of the 132 amino acid sequence, where the fragment is selected from amino acids 24-39, 55-61, 94-102 and 1-112 of the 132 amino acid sequence;

(9) an isolated polypeptide (VIII) comprising a fragment of the 138 amino acid sequence, where the fragment is selected from amino acids 31-35, 50-66, 99-107, 1-119, 31-37, 52-67, 100-112 of the 138 amino acid sequence;

(10) an isolated polypeptide (IX) comprising S1 or S2;

(11) a variant (X) of (IX), comprising at least one conservative amino acid substitution, where (X) retains the ability to direct specific binding to A beta peptide with a binding affinity of at least 107 M-1;

(12) an isolated polypeptide (XI) comprising residues 1-112 of the 131 amino acid sequence or residues 1-123 of the 142 amino acid sequence;

(13) an isolated nucleic acid molecule (XII) encoding (I), (II), (III), (IV), (V), (VII), (VIII), (IX), (X) or (XI);

(14) an isolated nucleic acid molecule (XIII) comprising a sequence of 396, 414, 393 or 426 base pairs fully defined in the specification;

(15) a vector comprising (XII) or (XIII);

(16) a host cell (XIV) comprising (XII) or (XIII);

(17) production of (II), (III), (IV) or (V);

(18) identifying (M1) residues amenable to substitution in a humanized 3D6 or 10D5 Ig variable framework region, by modeling the three-dimensional structure of the 3D6 or 10D5 variable region based on a solved Ig structure and analyzing the model for residues capable of affecting 3D6 or 10D5 Ig variable region conformation or function, such that residues amenable to substitution are identified; and

(19) use of the variable region sequence such as S1 or S2, or any of its portion in

h e b b g e e e f e h ge ef b e

producing a three-dimensional image of a 3D6 or 10D5 Ig, 3D6 or 10D5 Ig chain, or domain.

ACTIVITY - Nootropic; neuroprotective.

MECHANISM OF ACTION - Inhibitor of beta amyloid peptide (A beta) accumulation.

Therapeutic efficiency of anti- beta amyloid peptide (A beta) was tested. The capacity of various monoclonal and polyclonal antibodies to A beta to inhibit accumulation of A beta in the brain of heterozygotic transgenic mice was tested. Sixty male and female heterozygous PDAPP transgenic mice, 8.5-10.5 months of age were obtained. The antibodies tested included four murine A beta -specific monoclonal antibodies, 2H3 (directed to A beta residues 1-12), 10D5 (directed to A beta residues 3-7), 266 (directed to A beta residues 13-28 and binds to soluble but not to aggregated AN1792), and 21F12 (directed to A beta residues 33-42). A fifth group was treated with an A beta -specific polyclonal antibody fraction (raised by immunization with aggregated AN1792). The negative control group received the diluent, phosphate buffered saline (PBS), alone without antibody. The monoclonal antibodies were injected at a dose of about 10 mg/kg. Antibody titers were monitored over the 28 weeks of treatment. Treatment was continued over a six-month period for a total of 196 days. Animals were euthanized one week after the final dose. Following about six months of treatment with the various anti-A beta antibody preparations, brains were removed from the animals following saline perfusion. The concentrations of various forms of beta amyloid peptide and amyloid precursor protein (APP) was measured in the hippocampal, cortical, and cerebellar regions of brain. The results showed that A beta levels were significantly reduced in the cortex, hippocampus and cerebellum in animals treated with the polyclonal antibody raised against AN1792.

USE - (II), (III) or (IV) is useful for preventing or treating an amyloidogenic disease or Alzheimer's disease in a patient (claimed). (II), (III) or (IV) is useful for in vivo imaging amyloid deposits in a patient.

☐ 4. Document ID: US 6287793 B1

L4: Entry 4 of 18 File: DWPI Sep 11, 2001

DERWENT-ACC-NO: 2001-647182
DERWENT-WEEK: 200174

TITLE: Diagnosing or aiding in diagnosing Alzheimer's disease (AD) by contacting a biological fluid with a monoclonal antibody that binds specifically to a complementary acute phase reactant antigen in the fluid of the patient

INVENTOR: BARBOUR, R M; JOHNSON, K L ; SCHENK, D B

PRIORITY-DATA: 1988US-0235055 (August 19, 1988), 1992US-0850142 (March 12, 1992)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 6287793 B1	September 11, 2001		014	G01N033/543

INT-CL (IPC): C12 P 21/08; G01 N 33/543

ABSTRACTED-PUB-NO: US 6287793B
BASIC-ABSTRACT:

NOVELTY - Diagnosis of Alzheimer's Disease (AD) comprising contacting a biological

h e b b g e e e f e h ge ef b e

fluid (I) from a subject with a monoclonal antibody (mAb) that binds specifically and to a statistically greater degree to a complementary acute phase reactant antigen (II) in a biological fluid obtained from a subject having AD than to an antigenic site in a biological fluid from a subject not having AD, is new.

DETAILED DESCRIPTION - Aiding in the diagnosis of Alzheimer's Disease comprises:

(a) contacting (I) from the subject with a mAb that binds specifically and to a statistically greater degree to (II) in a biological fluid obtained from a subject having AD, so that an antigen-antibody binding complex forms between the mAb and the complementary acute phase reactant antigen present in the fluid;

(b) detecting the binding complex; and

(c) correlating the formation of the binding complex with the presence of AD.

INDEPENDENT CLAIMS are also included for the following:

(1) a monoclonal antibody (mAb) that binds to (II);

(2) 3H6 hybridoma (ATCC Accession No. HB9789), 5D8 hybridoma (ATCC Accession No. HB9790) and 7-C1 hybridoma (ATCC Accession No. HB9791);

(3) the mAb produced by the hybridomas;

(4) a kit for aiding in diagnosing AD in a subject, comprising in separate compartments:

(i) mAb complementary to (II) that is statistically elevated in a biological fluid from a subject having AD as compared to a subject not having AD; and

(ii) optionally, labeled mAbs for detecting binding between the mAb and the complementary acute phase reactant antigen.

USE - The method and antibodies are useful for diagnosing Alzheimer's disease (claimed).

☐ 5. Document ID: WO 200072876 A2, AU 200053163 A, NO 200105758 A, EP 1185296 A2, BR 200011103 A, HU 200201205 A2, KR 2002025884 A, SK 200101718 A3, CZ 200104154 A3, CN 1377278 A, JP 2003516929 W, ZA 200109662 A, MX 2001012293 A1, US 20040146521 A1

L4: Entry 5 of 18 File: DWPI Dec 7, 2000

DERWENT-ACC-NO: 2001-070921
DERWENT-WEEK: 200450

TITLE: Pharmaceutical composition comprising immunogen against amyloid component such as fibril peptide or protein, or antibody against amyloid component useful for treating amyloid diseases or amyloidoses

INVENTOR: SCHENK, D B ; MASLIAH, E

PRIORITY-DATA: 1999US-137010P (June 1, 1999), 2000US-0580015 (May 26, 2000), 2000US-0585817 (June 1, 2000), 2002US-423012P (November 1, 2002), 2003US-0698099 (October 31, 2003)

h e b b g e e e f e h ge ef b e

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 200072876 A2	December 7, 2000	E	140	A61K039/00
AU 200053163 A	December 18, 2000		000	
NO 200105758 A	January 30, 2002		000	A61K000/00
EP 1185296 A2	March 13, 2002	E	000	A61K039/00
BR 200011103 A	March 19, 2002		000	A61K039/00
HU 200201205 A2	August 28, 2002		000	A61K039/00
KR 2002025884 A	April 4, 2002		000	A61K038/00
SK 200101718 A3	September 10, 2002		000	A61K039/00
CZ 200104154 A3	November 13, 2002		000	A61K039/00
CN 1377278 A	October 30, 2002		000	A61K039/00
JP 2003516929 W	May 20, 2003		166	A61K045/08
ZA 200109662 A	July 30, 2003		155	A61K000/00
MX 2001012293 A1	December 1, 2002		000	A61K039/00
US 20040146521 A1	July 29, 2004		000	A61K039/00

INT-CL (IPC): A61 K 0/00; A61 K 38/00; A61 K 39/00; A61 K 39/385; A61 K 39/39; A61 K 39/395; A61 K 39/44; A61 K 45/08; A61 K 47/48; A61 K 48/00; A61 P 1/04; A61 P 3/00; A61 P 17/00; A61 P 17/06; A61 P 19/00; A61 P 19/02; A61 P 25/28; A61 P 29/00; A61 P 35/00; A61 P 37/00; A61 P 43/00; C12 N 15/09; G01 N 33/68

ABSTRACTED-PUB-NO: WO 200072876A
BASIC-ABSTRACT:

NOVELTY - A pharmaceutical composition, comprising an agent (I) to induce an immune response against an amyloid component (AC), or an antibody or antibody fragment (II) that binds to an AC, for preventing or treating a disease characterized by an amyloid deposit in a patient, is new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for determining (M1) the prognosis of a patient undergoing treatment for an amyloid disorder which involves measuring a patient serum amount of immunoreactivity against a selected AC. A patient serum amount of immunoreactivity of at least four times a base line control level of serum immunoreactivity indicates a prognosis of improved status with respect to the disorder.

ACTIVITY - Antirheumatic; antiarthritic; antipsoriatic; immunosuppressive; antibacterial; antiulcer; antiinflammatory; tuberculostatic; neuroprotective; nootropic; uropathic; ophthalmological; vasotropic; osteopathic; nephrotropic; cytostatic.

The neuroprotective effect of A beta 42 peptide was tested in mice in which A beta 42 was administered to heterozygote transgenic mice that overexpress human APP with a mutation at position 717. These mice known as PDAPP mice, exhibit Alzheimer's like pathology and are considered to be an animal model for Alzheimer's disease. These mice exhibit A beta plaque neuropathology in their brains beginning at 6 months, with plaque deposition progressing over time. Aggregated A beta 42 was administered to the mice. Most of the treated mice had no detectable amyloid in their brains at 13 months, in contrast to control mice, all of which showed significant brain amyloid burden at this age. These differences were even more pronounced in the hippocampus. Treated mice also exhibited significant serum antibody titers against A beta . Generally saline treated mice exhibited less than 4-5 times background levels of antibodies against A beta at a dilution of 1:100 at all times tested. These studies demonstrated that injection with the specific fibril forming peptide A beta provides protection against deposition of A beta amyloid plaques.

MECHANISM OF ACTION - Gene therapy; immune response stimulator.

h e b b g e e e f e h ge ef b e

USE - (I) or (II) is useful for treating a disorder characterized by amyloid deposition in a mammalian subject (claimed). The pharmaceutical compositions are useful for treating AA (reactive) amyloidoses such as rheumatoid arthritis, juvenile chronic arthritis, ankylosing spondylitis, psoriasis, psoriatic arthropathy, Reiter's syndrome, Adult Still disease, Behcet's syndrome, and Crohn's disease. AA deposits are also produced as a result of chronic microbial infections, such as leprosy, tuberculosis, bronchiectasis, decubitus ulcers, chronic pyelonephritis, osteomyelitis, and Whipple's disease, malignant neoplasms such as Hodgkin's lymphoma, renal carcinoma, carcinomas of gut, lung and urogenital tract, basal cell carcinoma and hairy cell leukemia. They are also useful for treating AL Amyloidoses, Hereditary Systemic Amyloidoses, Senile Systemic Amyloidosis, Cerebral Amyloidosis, Dialysis related Amyloidosis, Hormone-derived Amyloidoses.

☐ 6. Document ID: GB 2368794 B, WO 200072880 A2, AU 200053031 A, BR 200011000 A, EP 1185298 A2, NO 200105773 A, GB 2368794 A, DE 10084643 T, HU 200201250 A2, CN 1359301 A, KR 2002038585 A, SK 200101698 A3, CZ 200103824 A3, ZA 200109487 A, JP 2003517461 W, NZ 515403 A

L4: Entry 6 of 18 File: DWPI Oct 20, 2004

DERWENT-ACC-NO: 2001-032104
DERWENT-WEEK: 200469

TITLE: Preventing or treating a disease associated with amyloid deposits, especially Alzheimer's disease, comprises administering amyloid specific antibody

INVENTOR: BARD, F; SCHENK, D B ; VASQUEZ, N J ; YEDNOCK, T ; SCHENK, D ; VASQUEZ, N

PRIORITY-DATA: 1999US-0322289 (May 28, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
GB 2368794 B	October 20, 2004		000	A61K039/395
WO 200072880 A2	December 7, 2000	E	144	A61K039/395
AU 200053031 A	December 18, 2000		000	A61K039/395
BR 200011000 A	February 19, 2002		000	A61K039/395
EP 1185298 A2	March 13, 2002	E	000	A61K039/395
NO 200105773 A	January 25, 2002		000	A61K000/00
GB 2368794 A	May 15, 2002		000	A61K039/395
DE 10084643 T	July 11, 2002		000	A61K039/395
HU 200201250 A2	August 28, 2002		000	A61K039/395
CN 1359301 A	July 17, 2002		000	A61K039/395
KR 2002038585 A	May 23, 2002		000	A61K039/395
SK 200101698 A3	November 6, 2002		000	A61K039/395
CZ 200103824 A3	November 13, 2002		000	A61K039/395
ZA 200109487 A	April 30, 2003		182	A61K000/00
JP 2003517461 W	May 27, 2003		166	A61K039/395
NZ 515403 A	May 28, 2004		000	A61K039/395

2003517461 W , NZ 515403 A INT-CL (IPC): A61 K 0/00; A61 K 38/00; A61 K 38/17; A61 K 39/00; A61 K 39/39; A61 K 39/395; A61 K 48/00; A61 K 49/00; A61 P 25/28; C07 K 14/47; C07 K 16/18; C12 N 15/09; G01 N 33/15; G01 N 33/50; G01 N 33/53; G01 N 33/577; G01 N

h e b b g e e e f e h ge ef b e

33/68; C07 K 14:47; C07 K 16/18; A61 K 39/00; A61 K 39/39; A61 K 48/00; A61 P 25/28; C07 K 14/47; C07 K 16/18; G01 N 33/68; A61 K 39/00; A61 K 39/39; A61 K 48/00; A61 P 25/28; C07 K 14/47; C07 K 16/18; G01 N 33/68

ABSTRACTED-PUB-NO: WO 200072880A
BASIC-ABSTRACT:

NOVELTY - Preventing or treating a disease associated with amyloid deposits of A beta in the brain of a patient, comprising administering to the patient:

(a) an antibody that binds to A beta ;

(b) a polypeptide containing an N-terminal segment of at least residues 1-5 of A beta ; or

(c) an agent that induces an immunogenic response against residues 1-3 to 7-11 of A beta , is new.

DETAILED DESCRIPTION - Preventing or treating a disease (M1) associated with amyloid deposits of A beta in the brain of a patient, comprising administering to the patient:

(a) an antibody (I) that binds to A beta ;

(b) a polypeptide (II) containing an N-terminal segment of at least residues 1-5 of A beta , the first residue of A beta being the N-terminal residue, where (II) is free of a C-terminal segment of A beta ; or

(c) an agent (III) that induces an immunogenic response against residue 1-3 to 7-11 of A beta without inducing an immunogenic response against residues 12-43 of A beta 43.

INDEPENDENT CLAIMS are also included for the following:

(1) screening an antibody (M2) for activity in treating a disease associated with amyloid deposits of A beta in the brain of a patient, comprising contacting the antibody with a polypeptide comprising at least five contiguous amino acids of an N-terminal segment of A beta beginning at residue 1-3 of A beta , the polypeptide being free of a C-terminal segment of A beta , and determining whether the antibody specifically binds to the polypeptide, where specific binding is indicative of activity in treating Alzheimer's disease (AD);

(2) screening an antibody (M3) for activity in clearing a biological entity physically associated with an antigen, comprising combining the antigen-associated biological entity, antibody and phagocytic cells bearing Fc receptors in a medium and monitoring the amount of biological entity remaining in the medium, where a reduction in the amount of biological entity is indicative the antibody has clearing activity against the antigen;

(3) detecting (M4) an amyloid deposit in a patient comprising administering an antibody which specifically binds to a group within 1-10 amino acids of A beta and detecting the antibody within the patient's brain; and

(4) a diagnostic kit (IV) comprising an antibody that specifically binds to a group with residues 1-10 of A beta .

ACTIVITY - Nootropic; neuroprotective.

MECHANISM OF ACTION - The antibody binds to an amyloid deposit and induces a clearing response (Fc receptor mediated phagocytosis) against it.

USE - To treat or prevent diseases associated with amyloid deposits of A beta in the brain (claimed). It is also useful for monitoring a course of treatment being administered to a patient e.g. active and passive immunization.

h e b b g e e e f e h ge ef b e

☐ 7. Document ID: US 6808712 B2, WO 9927944 A1, AU 9917061 A, ZA 9810932 A, EP 1033996 A1, NO 200002784 A, BR 9815357 A, CZ 200001706 A3, CN 1281366 A, HU 200100627 A2, KR 2001032635 A, JP 2002502802 W, MX 2000005426 A1, US 6710226 B1, US 20040081657 A1, US 6743427 B1, US 6750324 B1, US 6761888 B1, US 20040157779 A1, AU 2003203740 A1, US 20040166119 A1, US 20040170641 A1, US 20040171815 A1, US 20040171816 A1, US 20040175394 A1, US 6787138 B1, US 6787139 B1, US 6787140 B1, US 6787143 B1, US 6787144 B1, US 6787523 B1, US 6787637 B1

L4: Entry 7 of 18 File: DWPI Oct 26, 2004

DERWENT-ACC-NO: 1999-385320
DERWENT-WEEK: 200470

TITLE: New composition for treating Alzheimer's disease

INVENTOR: SCHENK, D B ; BASI, G ; YEDNOCK, T ; BARD, F

PRIORITY-DATA: 1998US-080970P (April 7, 1998), 1997US-067740P (December 2, 1997), 1998US-0201430 (November 30, 1998), 1999US-0322289 (May 28, 1999), 2000US-0723384 (November 27, 2000), 2003US-0429216 (May 2, 2003), 2000US-0580015 (May 26, 2000), 2000US-0724961 (November 28, 2000), 2000US-0580018 (May 26, 2000), 2000US-0724552 (November 28, 2000), 2004US-0816022 (March 31, 2004), 2003AU-0203740 (April 16, 2003), 2004US-0816529 (March 31, 2004), 2000US-0723927 (November 28, 2000), 2004US-0815353 (March 31, 2004), 2000US-251892P (December 6, 2000), 2001US-0010942 (December 6, 2001), 2003US-0388389 (March 12, 2003), 2003US-0703713 (November 7, 2003), 2003US-0704070 (November 7, 2003), 2004US-0815391 (March 31, 2004), 2000US-0724102 (November 28, 2000), 2000US-0724489 (November 28, 2000), 2000US-0724477 (November 28, 2000), 2000US-0723762 (November 28, 2000), 2000US-0724551 (November 28, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 6808712 B2	October 26, 2004		000	A61K039/385
WO 9927944 A1	June 10, 1999	E	113	A61K038/00
AU 9917061 A	June 16, 1999		000	
ZA 9810932 A	September 29, 1999		109	A01N000/00
EP 1033996 A1	September 13, 2000	E	000	
NO 200002784 A	July 31, 2000		000	A61K038/17
BR 9815357 A	October 24, 2000		000	A61K038/00
CZ 200001706 A3	November 15, 2000		000	A61K038/00
CN 1281366 A	January 24, 2001		000	A61K038/00
HU 200100627 A2	June 28, 2001		000	A61K038/00
KR 2001032635 A	April 25, 2001		000	A61K039/00
JP 2002502802 W	January 29, 2002		116	A61K039/395
MX 2000005426 A1	February 1, 2002		000	A61K033/06
US 6710226 B1	March 23, 2004		000	A01K067/00
US 20040081657 A1	April 29, 2004		000	A61K039/00
US 6743427 B1	June 1, 2004		000	C07K016/00
US 6750324 B1	June 15, 2004		000	C07K016/00
US 6761888 B1	July 13, 2004		000	C07K016/00
US 20040157779 A1	August 12, 2004		000	A61K038/17

h e b b g e e e f e h ge ef b e

AU 2003203740 A1	June 12, 2003	000	A61K038/00
US 20040166119 A1	August 26, 2004	000	A61K039/00
US 20040170641 A1	September 2, 2004	000	A61K039/00
US 20040171815 A1	September 2, 2004	000	A61K039/395
US 20040171816 A1	September 2, 2004	000	C07K016/44
US 20040175394 A1	September 9, 2004	000	A61K039/00
US 6787138 B1	September 7, 2004	000	A61K038/00
US 6787139 B1	September 7, 2004	000	A61K038/00
US 6787140 B1	September 7, 2004	000	A61K038/00
US 6787143 B1	September 7, 2004	000	A61K039/00
US 6787144 B1	September 7, 2004	000	A61K039/00
US 6787523 B1	September 7, 2004	000	A61K038/00
US 6787637 B1	September 7, 2004	000	C07K016/00

A1 , US 6743427 B1 , US 6750324 B1 INT-CL (IPC): A01 K 67/00; A01 N 0/00; A01 N 37/18; A61 K 9/14; A61 K 9/26; A61 K 31/739; A61 K 33/06; A61 K 38/00; A61 K 38/17; A61 K 38/28; A61 K 39/00; A61 K 39/05; A61 K 39/106; A61 K 39/38; A61 K 39/385; A61 K 39/39; A61 K 39/395; A61 K 47/02; A61 K 47/24; A61 K 47/34; A61 K 48/00; A61 P 25/28; C07 K 16/00; C07 K 16/18; C07 K 16/44; C12 N 1/20; C12 N 15/09; G01 N 33/00; G01 N 33/15; G01 N 33/50; G01 N 33/543

ABSTRACTED-PUB-NO: WO 9927944A
BASIC-ABSTRACT:

NOVELTY - A therapeutical composition comprising an agent capable of inducing an immunogenic response against beta -amyloid (A beta) in a patient, and an adjuvant is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) preventing or treating a disease characterized by amyloid deposit in a patient, comprising administering an agent to induce an immune response against a peptide component of an amyloid deposit in the patient;

(2) preventing or treating Alzheimer's disease comprising administering a dose of A beta peptide to a patient;

(3) use of A beta peptide, or its antibody to produce a therapeutic for prevention or treatment of Alzheimer's disease;

(4) a composition comprising A beta or a fragment linked to a conjugate molecule that promotes delivery of A beta to the bloodstream of a patient and/or promotes an immune response against A beta ;

(5) a composition comprising an agent capable of inducing an immunogenic response against A beta in a patient with the proviso that the composition is free of Complete Freund's adjuvant;

(6) a composition comprising a viral vector encoding A beta or its fragment effective to induce an immune response against A beta ;

(7) assessing efficacy of an Alzheimer's treatment comprising;

(i) determining a baseline amount of antibody specific for AO peptide in tissue sample from the patient before treatment with an agent; and

(ii) comparing an amount of antibody specific for AO peptide in the tissue sample from the patient after treatment with the agent to the baseline amount of AO peptide-specific antibody, where an amount of AO peptide-specific antibody measured after the treatment that is significantly greater than the baseline amount of AO peptide-

h e b b g e e e f e h ge ef b e

specific antibody indicates a positive treatment outcome;

(8) assessing efficacy of an Alzheimer's treatment comprising as in (7a) and (7b), but where a reduction or lack of significant difference between the amount of A beta peptide-specific antibody measured after the treatment compared to the baseline amount of A beta peptide-specific antibody indicates a negative treatment outcome;

(9) assessing efficacy of an Alzheimer's treatment comprising:

(i) determining a control amount of antibody specific for A beta peptide in tissue samples from a control population; and

(ii) comparing an amount of antibody specific for A beta peptide in a tissue sample from the patient after administering an agent to the control amount of A beta peptide-specific antibody, wherein an amount of A beta peptide-specific antibody measured after the treatment that is significantly greater than the control amount of A beta peptide-specific antibody indicates a positive treatment outcome;

(10) assessing efficacy of an Alzheimer's treatment comprising:

(i) as in (9a) and (9b), but where a lack of significant difference between the amount of A beta peptide-specific antibody measured after beginning said treatment compared to the control amount of A beta peptide-specific antibody indicates a negative treatment outcome;

(11) monitoring Alzheimer's disease or susceptibility to it comprising detecting an immune response against A beta peptide in a patient sample;

(12) assessing efficacy of an Alzheimer's treatment comprising:

(i) determining a value for an amount of antibody specific for A beta peptide in tissue sample from a patient who has been treated with an agent; and

(ii) comparing the value with a control value determined from a population of patient experiencing amelioriation of, or freedom from, symptoms of Alzheimer's disease due to treatment with the agent, where a value in the patient at least equal to the control value indicates a positive response to treatment;

(13) use of A beta peptide in monitoring treatment of Alzheimer's disease in a patient; and

(14) diagnostic kit for monitoring treatment of Alzheimer's disease, comprising an agent that binds to antibodies specific for AO peptide.

MECHANISM OF ACTION - The composition causes an immune response. The immune response comprises antibodies that bind to the A beta peptide. The immune response comprises T-cells that bind to the A beta peptide as a component of an MHC I or MHC II complex. The agent is an antibody to A beta which induces an immune response by binding to A beta in the patient. The T-cells are removed from the patient, contacted with A beta peptide under conditions in which the T-cells are primed, and the primed T cells are administered to the patient.

USE - The composition is used to treat a human with Alzheimer's disease, especially the patient that, is asymptomatic, is under 50, has inherited risk factors indicating susceptibility to Alzheimer's disease or has no known risk factors for Alzheimer's disease.

☐ 8. Document ID: WO 9748983 A1, AU 9735727 A, EP 906577 A1, JP 2000514178 W, US 6610493 B1, US 20030148392 A1

h e b b g e e e f e h ge ef b e

L4: Entry 8 of 18 File: DWPI Dec 24, 1997

DERWENT-ACC-NO: 1998-063287
DERWENT-WEEK: 200439

TITLE: Identifying compounds that alter cellular production of amyloid-beta 42 fragment - in vitro or in transgenic animal models, potentially useful for treatment of Alzheimer's and other amyloid deposition diseases

INVENTOR: CITRON, M; SCHENK, D ; SELKOE, D J ; SEUBERT, P A ; SCHENK, D B

PRIORITY-DATA: 1996US-0665649 (June 18, 1996), 1993US-0079511 (June 17, 1993), 1992US-0911647 (July 10, 1992), 1992US-0965972 (October 26, 1992), 2002US-0335035 (December 30, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9748983 A1	December 24, 1997	E	086	G01N033/68
AU 9735727 A	January 7, 1998		000	
EP 906577 A1	April 7, 1999	E	000	G01N033/68
JP 2000514178 W	October 24, 2000		090	G01N033/50
US 6610493 B1	August 26, 2003		000	G01N033/53
US 20030148392 A1	August 7, 2003		000	G01N033/53

INT-CL (IPC): A01 K 67/027; C12 N 15/09; C12 P 21/02; G01 N 33/15; G01 N 33/50; G01 N 33/53; G01 N 33/537; G01 N 33/543 ; G01 N 33/567; G01 N 33/68; C12 P 21/02; C12 R 1:91

ABSTRACTED-PUB-NO: WO 9748983A
BASIC-ABSTRACT:

A compound (A) that alters the amount of at least one A beta (amyloid beta) (x - at least 41) peptide (I) produced by a cell is identified by treating a cell culture with test compound and measuring specifically the amount of (I) produced. This amount is compared with that produced by the culture in absence of test compound. The assay may be extended to include comparison of the amounts of total A beta (II) or A beta (x - at most 40) peptide (III) produced by the cells in absence/presence of test compound.

Also new are: (1) kits for these assays; and (2) similar in vivo assay in transgenic animals that are models of Alzheimer's disease (AD).

USE - Agents that reduce production of (I) are potentially useful for treatment of AD or other diseases involving amyloid deposition such as Down's syndrome; hereditary cerebral haemorrhage with amyloidosis of Dutch type and advanced aging of the brain.

ADVANTAGE - Unlike known methods of screening, which identify agents that decrease (II), this method is specific for inhibitors of (I), the major component of neuritic plaques.

☐ 9. Document ID: WO 9640896 A1, AU 9661683 A, EP 833901 A1, JP 11507821 W

L4: Entry 9 of 18 File: DWPI Dec 19, 1996

DERWENT-ACC-NO: 1997-052309

h e b b g e e e f e h ge ef b e

DERWENT-WEEK: 200276

TITLE: Testing compounds for an effect on an Alzheimer's disease marker - uses non-human transgenic animals which can control expression of major forms of beta-amyloid precursor protein

INVENTOR: GAMES, K D; MCCONLOGUE, L C ; RYDEL, R E ; SCHENK, D B ; SEUBERT, P A

PRIORITY-DATA: 1995US-0480653 (June 7, 1995)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9640896 A1	December 19, 1996	E	139	C12N015/00
AU 9661683 A	December 30, 1996		000	C12N015/00
EP 833901 A1	April 8, 1998	E	000	C12N015/00
JP 11507821 W	July 13, 1999		149	C12N015/09

INT-CL (IPC): A01 K 67/027; C07 K 14/47; C12 N 15/00; C12 N 15/09; C12 N 15/12; C12 N 15/62; C12 Q 1/68; G01 N 33/15; G01 N 33/50

ABSTRACTED-PUB-NO: WO 9640896A
BASIC-ABSTRACT:

A novel method for testing compounds for an effect on an Alzheimer's disease (AD) marker comprises: (a) administering the compound to be tested to a non-human transgenic mammal, or mammalian cells derived from the transgenic mammal, where the transgenic mammal has a nucleic acid construct (I) stably incorporated into the genome which comprises a promoter for expression of the construct in a mammalian cell operably linked to a region (R) encoding an Ab-containing protein; and (b) detecting or measuring the AD marker such that any difference between the marker in the transgenic animal, or mammalian cells derived from the transgenic mammal, and the marker in a transgenic mammal, or mammalian cells derived from the transgenic mammal, to which the compound has not been administered, is observed, where an observed difference in the marker indicates that the compound has an effect on the marker; whereby: (i) (R) comprises DNA encoding the Ab-containing protein which consists of all or a contiguous part of a protein selected from: (x) amyloid precursor protein, APP770 or an APP770 mutant bearing a mutation in one or more amino acids selected from residues 669, 670, 671, 690 692 and 717; (y) APP751 or an APP751 mutant bearing a mutation in one or more amino acids selected from residues 669, 670, 671, 690 692 and 717; and (z) APP695 or an APP695 mutant bearing a mutation in one or more amino acids selected from residues 669, 670, 671, 690 692 and 717; (ii) the Ab-containing protein includes amino acids 672-714 of human APP (beta -amyloid precursor protein); and (iii) the promoter mediates expression of (I) such that A beta tot is expressed at a level of at least 30 ng/g of brain tissue of the mammal when it is 2-4 months old, Ab1-42 is expressed at a level of at least 8.5 ng/g of brain tissue when the mammal is 2-4 months old, APP and APPa combined are expressed at a level of at least 150 p-moles/g of brain tissue when the mammal is 2-4 months old, and/or mRNA encoding the Ab-containing protein is expressed to a level at least twice that of mRNA encoding the endogenous APP of the transgenic mammal in brain tissue when the mammal is 2-4 months old.

USE - The transgenic animals, or cells are used to screen for compounds which alter the pathological course of AD as measured by their effect on the amount and/or histopathology of AD markers in animals as well as behavioural alterations.

☐ 10. Document ID: EP 792458 B1, WO 9615452 A1, AU 9641544 A, EP 792458 A1, JP

h e b b g e e e f e h ge ef b e

10509797 W, AU 705907 B, US 6114133 A, JP 2004077499 A

L4: Entry 10 of 18 File: DWPI Oct 6, 2004

DERWENT-ACC-NO: 1996-260003
DERWENT-WEEK: 200466

TITLE: Diagnosis and monitoring of Alzheimer's disease - by detecting abnormally low concentration of A-beta peptide extending beyond amino acid 41 in cerebrospinal fluid

INVENTOR: BARBOUR, R; SCHENK, D B ; SEUBERT, P A ; VIGO-PELFREY, C

PRIORITY-DATA: 1995US-0419008 (April 7, 1995), 1994US-0339141 (November 14, 1994)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 792458 B1	October 6, 2004	E	000	G01N033/53
WO 9615452 A1	May 23, 1996	E	057	G01N033/53
AU 9641544 A	June 6, 1996		000	G01N033/53
EP 792458 A1	September 3, 1997	E	000	G01N033/53
JP 10509797 W	September 22, 1998		057	G01N033/53
AU 705907 B	June 3, 1999		000	G01N033/53
US 6114133 A	September 5, 2000		000	G01N033/53
JP 2004077499 A	March 11, 2004		030	G01N033/53

INT-CL (IPC): G01 N 33/53; G01 N 33/537; G01 N 33/542; G01 N 33/543

ABSTRACTED-PUB-NO: US 6114133A
BASIC-ABSTRACT:

Diagnosis and monitoring of Alzheimer's disease (AD) is aided by: (a) measuring the amount of at least one soluble A beta (x- at least 41) peptide (I) in a test sample; (b) comparing the result with a predetermined amount of the same peptide; and (c) assessing patient status from the difference.

USE - Although a low level of (I) is not by itself a deterministic diagnosis of AD, it is useful when taken together with other clinical symptoms. Low levels of (I) may also indicate increased risk of developing AD later in life; the monitoring process may be used to follow progression or therapy. The screening assay can identify cpds. that might be useful in treating AD, or those that worsen the disease.
ABSTRACTED-PUB-NO:

WO 9615452A EQUIVALENT-ABSTRACTS:

Diagnosis and monitoring of Alzheimer's disease (AD) is aided by: (a) measuring the amount of at least one soluble A beta (x- at least 41) peptide (I) in a test sample; (b) comparing the result with a predetermined amount of the same peptide; and (c) assessing patient status from the difference.

USE - Although a low level of (I) is not by itself a deterministic diagnosis of AD, it is useful when taken together with other clinical symptoms. Low levels of (I) may also indicate increased risk of developing AD later in life; the monitoring process may be used to follow progression or therapy. The screening assay can identify cpds. that might be useful in treating AD, or those that worsen the disease.

h e b b g e e e f e h ge ef b e

☐ 11. Document ID: US 5512455 A

L4: Entry 11 of 18 File: DWPI Apr 30, 1996

DERWENT-ACC-NO: 1996-229865
DERWENT-WEEK: 199623

TITLE: New isolated atrial natriuretic peptide receptor DNA - used for the prodn. of ANP receptor proteins for use in e.g. diagnosis, therapy or antibody prodn.

INVENTOR: SCHENK, D B

PRIORITY-DATA: 1987US-0048296 (May 11, 1987), 1986US-0861529 (May 9, 1986)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 5512455 A	April 30, 1996		036	C12P021/02

INT-CL (IPC): C12 N 1/21; C12 N 5/10; C12 N 15/12; C12 N 15/70; C12 P 21/02

ABSTRACTED-PUB-NO: US 5512455A
BASIC-ABSTRACT:

A novel compsn. comprises a recombinant DNA molecule (I) encoding the amino acid sequence of the 60.5 kD bovine or the human atrial natriuretic peptide (ANP) receptor protein subunit, the compsn. being free of DNA molecules that do not encode the amino acid sequence.

USE - The ANP receptor proteins can be used to determine levels of ANP in assays, e.g. to diagnose conditions such as hypertension. They can also be used therapeutically to reduce levels of ANP to achieve a desired extracellular fluid vol. and electrolytic haemostasis. They can also be used to produce antibodies which can be used for detection and purification.

☐ 12. Document ID: JP 3552112 B2, WO 9511994 A1, EP 736106 A1, EP 736106 A4, JP 09508196 W, EP 736106 B1

L4: Entry 12 of 18 File: DWPI Aug 11, 2004

DERWENT-ACC-NO: 1995-178886
DERWENT-WEEK: 200453

TITLE: In vivo monitoring of processing of the beta-amyloid precursor - using transgenic animal expressing the Swedish mutation of the precursor, for detecting potential agents for treating Alzheimer's disease

INVENTOR: MCCONLOGUE, L C; SCHENK, D B ; SEUBERT, P A ; SINHA, S ; ZHAO, J ; MCLONLOGUE, L C ; ZHOA, J ; FRITZ, L C

PRIORITY-DATA: 1993US-0143697 (October 27, 1993)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC

h e b b g e e e f e h ge ef b e

JP 3552112 B2	August 11, 2004		025	G01N033/53
WO 9511994 A1	May 4, 1995	E	059	C12Q001/68
EP 736106 A1	October 9, 1996	E	000	C12Q001/68
EP 736106 A4	January 15, 1997		000	C12N015/00
JP 09508196 W	August 19, 1997		051	G01N033/53
EP 736106 B1	September 10, 2003	E	000	C12Q001/68

INT-CL (IPC): A01 K 67/027; C07 K 14/47; C07 K 16/18; C12 N 15/00; C12 N 15/02; C12 P 21/08; C12 Q 1/68; G01 N 33/53

ABSTRACTED-PUB-NO: WO 9511994A
BASIC-ABSTRACT:

Processing of beta -amyloid precursor protein (beta APP) is monitored in vivo by detecting an N-terminal fragment of beta APP in a sample from an animal transformed to express the Swedish mutation of human beta APP. The N-terminal fragment is released by cleavage between Leu596 and Asp597.

USE - The method is partic. used to screen/evaluate cpds. for possible therapeutic/prophylactic use in diseases related to beta A plaque deposition (Alzheimer's disease and Downs syndrome) or for inhibition of beta A prodn. in cell cultures. The method can also be used for diagnosis, prognosis and monitoring of treatment.

ADVANTAGE - Animals are able to generate large amts. of the beta APP N-terminal fragment, i.e. they process the Swedish mutation more efficiently than either endogenous or human wild-type beta APP.

☐ 13. Document ID: ES 2206470 T3, WO 9511968 A1, AU 9480798 A, AU 9480809 A, EP 730643 A1, EP 730643 A4, US 5604102 A, US 5612486 A, JP 09507746 W, US 5850003 A, AU 702293 B, EP 1001019 A1, EP 730643 B1, DE 69426571 E, US 6245964 B1, ES 2155099 T3, US 20020049988 A1, US 6586656 B2, DE 69433139 E

L4: Entry 13 of 18 File: DWPI May 16, 2004

DERWENT-ACC-NO: 1995-178862
DERWENT-WEEK: 200434

TITLE: Transgenic non-human animals for studying neuro-degenerative diseases - contg. a trans-gene encoding an amyloid precursor protein comprising the Swedish mutation

INVENTOR: FRITZ, L C; SCHENK, D B ; SEUBERT, P A ; MCLONLOGUE, L C ; ZHOA, J ; MCCONLOGUE, L C ; SUKANTO, S ; MCCONLOGUE, L ; SINHA, S ; ZHAO, J ; ZHAO, ; MCLONLOGUE, L

PRIORITY-DATA: 1993US-0148211 (November 1, 1993), 1993US-0143697 (October 27, 1993), 1992US-0868949 (April 15, 1992), 1992US-0965971 (October 26, 1992), 1997US-0785943 (January 22, 1997), 1998US-0209647 (December 10, 1998), 2001US-0838556 (April 18, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
ES 2206470 T3	May 16, 2004		000	C12Q001/68
WO 9511968 A1	May 4, 1995	E	054	C12N015/00

h e b b g e e e f e h ge ef b e

AU 9480798 A	May 22, 1995		000	C12Q001/68
AU 9480809 A	May 22, 1995		000	C12N015/00
EP 730643 A1	September 11, 1996	E	000	C12N015/00
EP 730643 A4	November 27, 1996		000	C12N015/00
US 5604102 A	February 18, 1997		022	C12N015/00
US 5612486 A	March 18, 1997		000	C12N015/00
JP 09507746 W	August 12, 1997		053	A01K067/027
US 5850003 A	December 15, 1998		000	C12N005/00
AU 702293 B	February 18, 1999		000	C12N015/00
EP 1001019 A1	May 17, 2000	E	000	C12N015/00
EP 730643 B1	January 10, 2001	E	000	C12N015/00
DE 69426571 E	February 15, 2001		000	C12N015/00
US 6245964 B1	June 12, 2001		000	A01K067/00
ES 2155099 T3	May 1, 2001		000	C12N015/00
US 20020049988 A1	April 25, 2002		000	A01K067/27
US 6586656 B2	July 1, 2003		000	G01N033/00
DE 69433139 E	October 16, 2003		000	C12Q001/68

US 20020049988 A1 INT-CL (IPC): A01 K 67/00; A01 K 67/027; A01 K 67/033; A01 K 67/27; A61 K 49/00; C07 H 21/04; C07 K 14/47; C07 K 16/18; C12 N 5/00; C12 N 5/10; C12 N 15/00; C12 N 15/09; C12 N 15/12; C12 Q 1/68; G01 N 33/00; G01 N 33/53; G01 N 33/567

ABSTRACTED-PUB-NO: EP 730643B
BASIC-ABSTRACT:

A transgenic nonhuman animal or stem cell is claimed comprising a diploid genome which contains a transgene encoding a heterologous amyloid precursor protein (APP) comprising the Swedish mutation, where the amino acid residues at positions corresponding to positions 595 and 596 in human APP695 are Asn and Leu, respectively. Also claimed is a transgene comprising a polynucleotide encoding human APP comprising the Swedish mutation operably linked to a transcriptional control element capable of producing transcription of the human APP in a host transgenic animal.

USE - The transgenic animals are used in pharmaceutical screening and as commercial research animals for modelling neurodegenerative diseases such as Alzheimer's disease and for studying APP biochemistry in vivo.

ADVANTAGE - Animal models expressing the Swedish mutation of human beta APP produce the amino-terminal fragment form of beta APP (ATF- beta APP) at levels at least 2-fold higher than wild type human beta APP expressed in animals, greatly simplifying screening for drugs and other therapies for inhibiting prodn. of pathogenic beta amyloid plaque.
ABSTRACTED-PUB-NO:

US 5604102A EQUIVALENT-ABSTRACTS:

A transgenic nonhuman animal or stem cell is claimed comprising a diploid genome which contains a transgene encoding a heterologous amyloid precursor protein (APP) comprising the Swedish mutation, where the amino acid residues at positions corresponding to positions 595 and 596 in human APP695 are Asn and Leu, respectively. Also claimed is a transgene comprising a polynucleotide encoding human APP comprising the Swedish mutation operably linked to a transcriptional control element capable of producing transcription of the human APP in a host transgenic animal.

USE - The transgenic animals are used in pharmaceutical screening and as commercial research animals for modelling neurodegenerative diseases such as Alzheimer's disease and for studying APP biochemistry in vivo.

ADVANTAGE - Animal models expressing the Swedish mutation of human beta APP produce

h e b b g e e e f e h ge ef b e

the amino-terminal fragment form of beta APP (ATF- beta APP) at levels at least 2-fold higher than wild type human beta APP expressed in animals, greatly simplifying screening for drugs and other therapies for inhibiting prodn. of pathogenic beta amyloid plaque.

A method for monitoring beta-amyloid precursor protein (bAPP) processing in vivo, said method comprising specifically detecting the presence of Swedish variant amino terminal fragment of bAPP (ATF-bAPP) in a specimen from rodent transformed to express the Swedish mutation of human bAPP, wherein the amino terminal fragment has been cleaved between Leu596 and Asp597.

US 5612486A

A transgenic rodent comprising a diploid genome comprising a transgene encoding a heterologous APP polypeptide having the Swedish mutation wherein the amino acid residues at positions corresponding to positions 595 and 596 in human APP695 are asparagine and leucine, respectively, wherein the transgene is expressed to produce a human APP polypeptide having the Swedish mutation, and wherein said polypeptide is processed to ATF-betaAPP in a sufficient amount to be detectable in a brain homogenate of said transgenic rodent.

US 5850003A

A transgenic nonhuman animal or stem cell is claimed comprising a diploid genome which contains a transgene encoding a heterologous amyloid precursor protein (APP) comprising the Swedish mutation, where the amino acid residues at positions corresponding to positions 595 and 596 in human APP695 are Asn and Leu, respectively. Also claimed is a transgene comprising a polynucleotide encoding human APP comprising the Swedish mutation operably linked to a transcriptional control element capable of producing transcription of the human APP in a host transgenic animal.

USE - The transgenic animals are used in pharmaceutical screening and as commercial research animals for modelling neurodegenerative diseases such as Alzheimer's disease and for studying APP biochemistry in vivo.

ADVANTAGE - Animal models expressing the Swedish mutation of human beta APP produce the amino-terminal fragment form of beta APP (ATF- beta APP) at levels at least 2-fold higher than wild type human beta APP expressed in animals, greatly simplifying screening for drugs and other therapies for inhibiting prodn. of pathogenic beta amyloid plaque.

US 6245964B

A transgenic nonhuman animal or stem cell is claimed comprising a diploid genome which contains a transgene encoding a heterologous amyloid precursor protein (APP) comprising the Swedish mutation, where the amino acid residues at positions corresponding to positions 595 and 596 in human APP695 are Asn and Leu, respectively. Also claimed is a transgene comprising a polynucleotide encoding human APP comprising the Swedish mutation operably linked to a transcriptional control element capable of producing transcription of the human APP in a host transgenic animal.

USE - The transgenic animals are used in pharmaceutical screening and as commercial research animals for modelling neurodegenerative diseases such as Alzheimer's disease and for studying APP biochemistry in vivo.

ADVANTAGE - Animal models expressing the Swedish mutation of human beta APP produce the amino-terminal fragment form of beta APP (ATF- beta APP) at levels at least 2-fold higher than wild type human beta APP expressed in animals, greatly simplifying screening for drugs and other therapies for inhibiting prodn. of pathogenic beta amyloid plaque.

US20020049988A

A transgenic nonhuman animal or stem cell is claimed comprising a diploid genome

h e b b g e e e f e h ge ef b e

which contains a transgene encoding a heterologous amyloid precursor protein (APP) comprising the Swedish mutation, where the amino acid residues at positions corresponding to positions 595 and 596 in human APP695 are Asn and Leu, respectively. Also claimed is a transgene comprising a polynucleotide encoding human APP comprising the Swedish mutation operably linked to a transcriptional control element capable of producing transcription of the human APP in a host transgenic animal.

USE - The transgenic animals are used in pharmaceutical screening and as commercial research animals for modelling neurodegenerative diseases such as Alzheimer's disease and for studying APP biochemistry in vivo.

ADVANTAGE - Animal models expressing the Swedish mutation of human beta APP produce the amino-terminal fragment form of beta APP (ATF- beta APP) at levels at least 2-fold higher than wild type human beta APP expressed in animals, greatly simplifying screening for drugs and other therapies for inhibiting prodn. of pathogenic beta amyloid plaque.

WO 9511968A

☐ 14. Document ID: JP 3553592 B2, WO 9410569 A1, CA 2105903 A, AU 9348444 A, EP 667959 A1, JP 08502587 W, US 5593846 A, AU 687747 B, US 5766846 A, US 5837672 A, AU 9873223 A, AU 722044 B, AU 200066628 A, US 6284221 B1, EP 1298436 A2, EP 667959 B1, DE 69333144 E, ES 2203620 T3, JP 2004121251 A

L4: Entry 14 of 18 File: DWPI Aug 11, 2004

DERWENT-ACC-NO: 1994-167654
DERWENT-WEEK: 200453

TITLE: Detecting soluble beta-amyloid peptide concns. e.g. for diagnosing and assessing progression of Alzheimer's disease - by exposing cultured cells to test cpd. to determine effect of cpd. on produced soluble beta-amyloid peptide

INVENTOR: SCHENK, D B ; SCHLOSSMACHER, M G ; SELKOE, D J ; SEUBERT, P A ; VIGO-PELFREY, C

PRIORITY-DATA: 1992US-0965972 (October 26, 1992), 1992US-0911647 (July 10, 1992), 1995US-0437067 (May 9, 1995), 1993US-0079511 (June 17, 1993), 1995US-0456347 (June 1, 1995), 2000AU-0066628 (October 19, 2000), 1996US-0733202 (October 18, 1996)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 3553592 B2	August 11, 2004		025	G01N033/53
WO 9410569 A1	May 11, 1994	E	054	G01N033/53
CA 2105903 A	April 27, 1994		000	C12Q001/02
AU 9348444 A	May 24, 1994		000	
EP 667959 A1	August 23, 1995	E	000	
JP 08502587 W	March 19, 1996		054	G01N033/53
US 5593846 A	January 14, 1997		023	G01N033/53
AU 687747 B	March 5, 1998		000	G01N033/68
US 5766846 A	June 16, 1998		000	G01N033/53
US 5837672 A	November 17, 1998		000	A61K031/00
AU 9873223 A	November 26, 1998		000	A61K049/00
AU 722044 B	July 20, 2000		000	A61K049/00

h e b b g e e e f e h ge ef b e

AU 200066628 A	January 11, 2001		000	A61K049/00
US 6284221 B1	September 4, 2001		000	A61K049/00
EP 1298436 A2	April 2, 2003	E	000	G01N033/50
EP 667959 B1	August 13, 2003	E	000	G01N033/53
DE 69333144 E	September 18, 2003		000	G01N033/53
ES 2203620 T3	April 16, 2004		000	G01N033/53
JP 2004121251 A	April 22, 2004		031	C12N015/09

DE 69333144 E INT-CL (IPC): A01 K 67/027; A61 K 31/00; A61 K 38/00; A61 K 49/00; A61 P 25/28; C12 N 5/10; C12 N 15/00; C12 N 15/09; C12 P 21/02; C12 Q 1/02; C12 Q 1/68; G01 N 33/48; G01 N 33/50; G01 N 33/53; G01 N 33/537; G01 N 33/543; G01 N 33/566; G01 N 33/577; G01 N 33/68

ABSTRACTED-PUB-NO: US 5593846A
BASIC-ABSTRACT:

Identifying beta-amyloid peptide (beta-AP) prodn. inhibitors comprises: (a) culturing mammalian cells in a culture medium under conditions which result in generation of soluble beta-AP peptide which can be detected in the culture medium; (b) exposing the cultured cells to a test cpd.; and (c) determining the effect of the cpd. on the amt. of soluble beta-AP in the medium.

Also claimed is (1) method for assaying test cpd. for ability to inhibit beta-AP prodn. by cells comprising: (a) culturing 1st population of mammalian cells in culture medium to generate soluble beta-AP which can be detected; (b) culturing 2nd population of same cells in 2nd culture medium under identical conditions to 1st, but with addn. of test cpd.; (c) measuring amts. of soluble beta-AP in both culture media; and (d) comparing amts. of soluble beta-AP to see if test cpd. has effect on soluble beta-AP generation by culture.

USE - Soluble beta-AP is measured in biological fluids at low concn. (0.1-10 ng/ml). The measurement of beta-AP concns. in animals or cells can be used for drug screening. Elevated levels of beta-AP in body fluids is associated with the presence of beta-AP related conditions, e.g. Alzheimer's disease. (I) can be used for diagnosing and monitoring conditions in patients.
ABSTRACTED-PUB-NO:

US 5766846A EQUIVALENT-ABSTRACTS:

A novel method for detecting a soluble beta-amyloid peptide (betaAP) in a fluid sample which may contain betaAP and betaAP fragments as well as soluble fragments of beta-amyloid precursor protein (APP) other than betaAP, comprises:

exposing the fluid sample to a first binding substance under conditions in which the first binding substance will bind to an epitope on soluble betaAP and betaAP fragments but will not bind to epitopes on APP fragments which may be present in the sample; and

detecting binding between the first binding substance and the soluble betaAP and betaAP fragments.

Identifying beta-amyloid peptide (beta-AP) prodn. inhibitors comprises: (a) culturing mammalian cells in a culture medium under conditions which result in generation of soluble beta-AP peptide which can be detected in the culture medium; (b) exposing the cultured cells to a test cpd.; and (c) determining the effect of the cpd. on the amt. of soluble beta-AP in the medium.

Also claimed is (1) method for assaying test cpd. for ability to inhibit beta-AP prodn. by cells comprising: (a) culturing 1st population of mammalian cells in culture medium to generate soluble beta-AP which can be detected; (b) culturing 2nd population of same cells in 2nd culture medium under identical conditions to 1st, but with addn. of test cpd.; (c) measuring amts. of soluble beta-AP in both culture

h e b b g e e e f e h ge ef b e

media; and (d) comparing amts. of soluble beta-AP to see if test cpd. has effect on soluble beta-AP generation by culture.

USE - Soluble beta-AP is measured in biological fluids at low concn. (0.1-10 ng/ml). The measurement of beta-AP concns. in animals or cells can be used for drug screening. Elevated levels of beta-AP in body fluids is associated with the presence of beta-AP related conditions, e.g. Alzheimer's disease. (I) can be used for diagnosing and monitoring conditions in patients.

US 5837672A

Identifying beta-amyloid peptide (beta-AP) prodn. inhibitors comprises: (a) culturing mammalian cells in a culture medium under conditions which result in generation of soluble beta-AP peptide which can be detected in the culture medium; (b) exposing the cultured cells to a test cpd.; and (c) determining the effect of the cpd. on the amt. of soluble beta-AP in the medium.

Also claimed is (1) method for assaying test cpd. for ability to inhibit beta-AP prodn. by cells comprising: (a) culturing 1st population of mammalian cells in culture medium to generate soluble beta-AP which can be detected; (b) culturing 2nd population of same cells in 2nd culture medium under identical conditions to 1st, but with addn. of test cpd.; (c) measuring amts. of soluble beta-AP in both culture media; and (d) comparing amts. of soluble beta-AP to see if test cpd. has effect on soluble beta-AP generation by culture.

USE - Soluble beta-AP is measured in biological fluids at low concn. (0.1-10 ng/ml). The measurement of beta-AP concns. in animals or cells can be used for drug screening. Elevated levels of beta-AP in body fluids is associated with the presence of beta-AP related conditions, e.g. Alzheimer's disease. (I) can be used for diagnosing and monitoring conditions in patients.

US 6284221B

Identifying beta-amyloid peptide (beta-AP) prodn. inhibitors comprises: (a) culturing mammalian cells in a culture medium under conditions which result in generation of soluble beta-AP peptide which can be detected in the culture medium; (b) exposing the cultured cells to a test cpd.; and (c) determining the effect of the cpd. on the amt. of soluble beta-AP in the medium.

Also claimed is (1) method for assaying test cpd. for ability to inhibit beta-AP prodn. by cells comprising: (a) culturing 1st population of mammalian cells in culture medium to generate soluble beta-AP which can be detected; (b) culturing 2nd population of same cells in 2nd culture medium under identical conditions to 1st, but with addn. of test cpd.; (c) measuring amts. of soluble beta-AP in both culture media; and (d) comparing amts. of soluble beta-AP to see if test cpd. has effect on soluble beta-AP generation by culture.

USE - Soluble beta-AP is measured in biological fluids at low concn. (0.1-10 ng/ml). The measurement of beta-AP concns. in animals or cells can be used for drug screening. Elevated levels of beta-AP in body fluids is associated with the presence of beta-AP related conditions, e.g. Alzheimer's disease. (I) can be used for diagnosing and monitoring conditions in patients.

WO 9410569A

☐ 15. Document ID: ES 2206455 T3, WO 9321526 A1, AU 9337827 A, FI 9404847 A, NO 9403912 A, EP 638172 A1, US 5441870 A, JP 07506967 W, NZ 251053 A, US 5605811 A, EP 638172 A4, US 5721130 A, AU 688726 B, US 6018024 A, FI 111546 B1, EP 638172 B1, DE 69333225 E

h e b b g e e e f e h ge ef b e

L4: Entry 15 of 18 File: DWPI May 16, 2004

DERWENT-ACC-NO: 1993-351873
DERWENT-WEEK: 200434

TITLE: Monitoring beta amyloid precursor protein processing - involves detecting soluble fragments from cleavage at amino terminals of peptide, used to study Alzeheimer's disease and potential drugs for it

INVENTOR: FRITZ, L C; SCHENK, D B ; SEUBERT, P A ; FRITZ, L

PRIORITY-DATA: 1992US-0965971 (October 26, 1992), 1992US-0868949 (April 15, 1992), 1995US-0440261 (May 12, 1995), 1995US-0440423 (May 12, 1995), 1997US-0846444 (May 1, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
ES 2206455 T3	May 16, 2004		000	G01N033/53
WO 9321526 A1	October 28, 1993	E	038	G01N033/53
AU 9337827 A	November 18, 1993		000	G01N033/53
FI 9404847 A	October 14, 1994		000	C07K000/00
NO 9403912 A	November 10, 1994		000	G01N033/53
EP 638172 A1	February 15, 1995	E	000	G01N033/53
US 5441870 A	August 15, 1995		016	G01N033/53
JP 07506967 W	August 3, 1995		012	C12P021/08
NZ 251053 A	November 26, 1996		000	G01N033/53
US 5605811 A	February 25, 1997		016	C12Q001/02
EP 638172 A4	March 19, 1997		000	G01N033/53
US 5721130 A	February 24, 1998		016	C12N005/12
AU 688726 B	March 19, 1998		000	G01N033/68
US 6018024 A	January 25, 2000		000	C07K002/00
FI 111546 B1	August 15, 2003		000	C07K014/47
EP 638172 B1	October 1, 2003	E	000	G01N033/53
DE 69333225 E	November 6, 2003		000	G01N033/53

69333225 E INT-CL (IPC): A61 K 39/395; C07 K 0/00; C07 K 2/00; C07 K 13/00; C07 K 14/435; C07 K 14/47; C07 K 15/00; C07 K 15/06; C07 K 15/12; C07 K 16/18; C12 N 5/12; C12 P 21/08; C12 Q 1/02; G01 N 33/50; G01 N 33/53; G01 N 33/564; G01 N 33/577; G01 N 33/68

ABSTRACTED-PUB-NO: US 5441870A
BASIC-ABSTRACT:

Method (I) for monitoring the processing of beta-amyloid precursor protein (beta APP) in cells comprises detecting a soluble beta APP fragment derived from cleavage of beta APP at the amino terminus of beta-amyloid peptide (beta AP). The fragment is secreted.

Also new are (1) a method for identifying beta-amyloid prodn. inhibitors comprising (a) culturing cells under conditions for secretion of beta APP; (b) exposing the cells to a plurality of test cpds.; (c) identifying cpds. which cause a change in the amt. of secreted beta APP. (2) an antibody compsn. comprising antibodies which bind specifically to beta APP fragments; and (3) the soluble, purified, isolated beta APP fragment of (I).

USE - (I) can be used to diagnose or monitor amyloid-related disease in a patient

h e b b g e e e f e h ge ef b e

e.g. Alzheimer's disease. It can also be used to screen and evaluate potential drugs for the treatment of these diseases.
ABSTRACTED-PUB-NO:

US 5605811A EQUIVALENT-ABSTRACTS:

Processing of beta-amyloid precursor protein in cells, is monitored by detection of soluble fragment of this protein (secreted from the cells) by complex formation with selective binding partner. Aminoacid sequence of soluble fragment extends from N-terminus of parent protein to N-terminus of beta-amyloid peptide.

Fragment pref. has a COOH terminus at Met (596) or Leu (596).

USE/ADVANTAGE - Process facilitates diagnosis, prognosis and monitoring of Alzheimer's disease and other beta-amyloid-related disorders; and also the screening of potential drugs for treatment of Alzheimer's disease.

ADVANTAGE - Process is specific for beta-amyloid related diseases.

An in vitro method of screening compounds to identify beta-amyloid production inhibitors, said method comprising:

(a) culturing cells Under conditions which result in a secretion of a soluble fragment of beta-amyloid precursor protein (bAPP), wherein an amino acid sequence of said soluble bAPP fragment extends substantially from the amino-terminus of bAPP to the amino-terminus of beta-amyloid peptide;

(b) exposing the cultured cells to a test compound; and

(c) detecting an amount of said soluble bAPP fragment; whereby a decrease in the amount of said soluble bAPP fragment as compared to the amount of soluble bAPP fragment from cells not exposed to the compound indicates that the compound is a beta-amyloid production inhibitor.

US 5721130A

Method (I) for monitoring the processing of beta-amyloid precursor protein (beta APP) in cells comprises detecting a soluble beta APP fragment derived from cleavage of beta APP at the amino terminus of beta-amyloid peptide (beta AP). The fragment is secreted.

Also new are (1) a method for identifying beta-amyloid prodn. inhibitors comprising (a) culturing cells under conditions for secretion of beta APP; (b) exposing the cells to a plurality of test cpds.; (c) identifying cpds. which cause a change in the amt. of secreted beta APP. (2) an antibody compsn. comprising antibodies which bind specifically to beta APP fragments; and (3) the soluble, purified, isolated beta APP fragment of (I).

USE - (I) can be used to diagnose or monitor amyloid-related disease in a patient e.g. Alzheimer's disease. It can also be used to screen and evaluate potential drugs for the treatment of these diseases.

US 6018024A

Method (I) for monitoring the processing of beta-amyloid precursor protein (beta APP) in cells comprises detecting a soluble beta APP fragment derived from cleavage of beta APP at the amino terminus of beta-amyloid peptide (beta AP). The fragment is secreted.

Also new are (1) a method for identifying beta-amyloid prodn. inhibitors comprising (a) culturing cells under conditions for secretion of beta APP; (b) exposing the cells to a plurality of test cpds.; (c) identifying cpds. which cause a change in the amt. of secreted beta APP. (2) an antibody compsn. comprising antibodies which bind specifically to beta APP fragments; and (3) the soluble, purified, isolated beta APP

h e b b g e e e f e h ge ef b e

fragment of (I).

USE - (I) can be used to diagnose or monitor amyloid-related disease in a patient e.g. Alzheimer's disease. It can also be used to screen and evaluate potential drugs for the treatment of these diseases.

WO 9321526A

☐ 16. Document ID: US 4745055 A

L4: Entry 16 of 18 File: DWPI May 17, 1988

DERWENT-ACC-NO: 1988-154914
DERWENT-WEEK: 198822

TITLE: fused protein for enzyme immunoassay system - comprises enzymatically active beta-galactosidase fused to immunologically active peptide

INVENTOR: SCHENK, D B ; SPRATT, S K

PRIORITY-DATA: 1986US-0868393 (May 28, 1986), 1985US-0731853 (May 7, 1985)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 4745055 A	May 17, 1988		010	

INT-CL (IPC): C12N 15/00; G01N 33/53

ABSTRACTED-PUB-NO: US 4745055A
BASIC-ABSTRACT:

Fused protein (I) comprises an enzymatically active beta-galactosidase fused, as its C terminus, to an immunologically active peptide of human surfactant apoprotein (HSA), which has the property that binding of anti-HSA antibody to the immunoloqically active peptide inhibits the B-galactosidase activity of (I). Also claimed are a plasmid for producing (I) in a bacterial host, prodn. of (I) by recombinant methods and a homogenous enzyme immunoassay system for determination of a peptide or protein analyte.

USE/ADVANTAGE - (I) is useful in homogeneous enzyme immunoassays and is capable of producing a highly sensitive linear- range assay for determin. of a polypeptide analyte.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Drawi Desc

☐ 17. Document ID: WO 8706938 A, AU 8774810 A, EP 267272 A, EP 267272 A4, JP 63503309 W

L4: Entry 17 of 18 File: DWPI Nov 19, 1987

DERWENT-ACC-NO: 1987-334947
DERWENT-WEEK: 198747

h e b b g e e e f e h ge ef b e

TITLE: Purified atrial natriuretic receptor peptide - for diagnosing, hypertension, and corresp. DNA coding sequences, recombinant vectors, transformed cells and antibodies etc.

INVENTOR: SCHENK, D B

PRIORITY-DATA: 1986US-0861529 (May 9, 1986)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 8706938 A	November 19, 1987	E	062	
AU 8774810 A	December 1, 1987		000	
EP 267272 A	May 18, 1988	E	000	
EP 267272 A4	May 2, 1990		000	

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: US 6528269 B1

Using default format because multiple data bases are involved.

L7: Entry 1 of 1 File: USPT Mar 4, 2003

US-PAT-NO: 6528269
DOCUMENT-IDENTIFIER: US 6528269 B1

TITLE: Immunological agents specific for prion protein (PRP)

DATE-ISSUED: March 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sy; Man-Sun	Shaker Heights	OH		
Gambetti; Pierluigi	Shaker Heights	OH		

US-CL-CURRENT: 435/7.1; 424/130.1, 424/133.1, 424/134.1, 424/137.1, 424/138.1, 424/139.1, 424/141.1, 424/145.1, 424/9.1 , 436/501, 436/513, 436/536, 436/547

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Des

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
L6 AND prion disorder	1

Display Format: - Change Format

Previous Page Next Page Go to Doc#

h e b b g e e e f e h ge ef b e

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 29 of 29 returned.

☐ 1. Document ID: US 20040208875 A1

Using default format because multiple data bases are involved.

L10: Entry 1 of 29 File: PGPB Oct 21, 2004

PGPUB-DOCUMENT-NUMBER: 20040208875
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040208875 A1

TITLE: Method for treating amyloidosis

PUBLICATION-DATE: October 21, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kisilevsky, Robert	Kingston		CA	
Szarek, Walter	Kingston		CA	
Weaver, Donald	Kingston		CA	

US-CL-CURRENT: 424/145.1; 514/8

Full | Title | Citation | Front | ---- | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

☐ 2. Document ID: US 20040198832 A1

L10: Entry 2 of 29 File: PGPB Oct 7, 2004

PGPUB-DOCUMENT-NUMBER: 20040198832
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040198832 A1

TITLE: Compositions and methods for treating amyloidosis

PUBLICATION-DATE: October 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Szarek, Walter A.	Kingston		CA	
Weaver, Donald F.	Kingston		CA	
Kong, Xianqi	Dollard-des-Ormeaux		CA	
Gordon, Heather	North Thorold		CA	

US-CL-CURRENT: 514/599; 514/602, 514/616

ABSTRACT:

h e b b g e e e f e h ge ef b e

Therapeutic compounds and methods for modulating amyloid aggregation in a subject, whatever its clinical setting, are described. Amyloid aggregation is modulated by the administration to a subject of an effective amount of a therapeutic compound of the formula 1

or a pharmaceutically acceptable salt or ester, such that modulation of amyloid aggregation occurs. R.sup.1 and R.sup.2 are each independently a hydrogen atom or a substituted or unsubstituted aliphatic or aryl group. Z and Q are each independently a carbonyl (C.dbd.O), thiocarbonyl (C.dbd.S), sulfonyl (SO.sub.2), or sulfoxide (S.dbd.O) group. "k" and "m" are 0 or 1, provided when k is 1, R.sup.1 is not a hydrogen atom, and when m is 1, R.sup.2 is not a hydrogen atom. In an embodiment, at least one of k or m must equal 1. "p" and "s" are each independently positive integers selected such that the biodistribution of the therapeutic compound for an intended target site is not prevented while maintaining activity of the therapeutic compound. T is a linking group and Y is a group of the formula -A X wherein A is an anionic group at physiological pH, and X is a cationic group.

Full | Title | Citation | Front | ..... | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 3. Document ID: US 20040147531 A1

L10: Entry 3 of 29 File: PGPB Jul 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040147531
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040147531 A1

TITLE: Amidine derivatives for treating amyloidosis

PUBLICATION-DATE: July 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chalifour, Robert J.	Ile Bizard		CA	
Kong, Xianqi	Pierrefonds		CA	
Wu, Xinfu	Dollard-des-Ormeaux		CA	
Lu, Wenshuo	LaSalle		CA	

US-CL-CURRENT: 514/256; 514/397, 514/636

ABSTRACT:

The present invention relates to the use of amidine compounds in the treatment of amyloid-related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound. Among the compounds for use according to the invention are those according to the following Formula, such that, when administered, amyloid fibril formation, neurodegeneration, or cellular toxicity is reduced or inhibited: 1

Full | Title | Citation | Front | ..... | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 4. Document ID: US 20040138178 A1

h e b b g e e e f e h ge ef b e

L10: Entry 4 of 29 File: PGPB Jul 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040138178
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040138178 A1

TITLE: Phosphono-carboxylate compounds for treating amyloidosis

PUBLICATION-DATE: July 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Szarek, Walter A.	Kingston		CA	
Kong, Xianqi	Pierrefonds		CA	
Thatcher, Gregory R.J.	Kingston		CA	
Gorine, Boris	Edmonton		CA	

US-CL-CURRENT: 514/79; 514/114, 514/141

ABSTRACT:

Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.

☐ 5. Document ID: US 20040048279 A1

L10: Entry 5 of 29 File: PGPB Mar 11, 2004

PGPUB-DOCUMENT-NUMBER: 20040048279
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040048279 A1

TITLE: Method for detecting methylation states for a toxicological diagnostic

PUBLICATION-DATE: March 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Olek, Alexander	Berlin		DE	
Piepenbrock, Christian	Berlin		DE	
Berlin, Kurt	Stahnsdorf		DE	

US-CL-CURRENT: 435/6

ABSTRACT:

The present invention concerns a method for toxicological diagnosis. A DNA sample is

h e b b g e e e f e h ge ef b e

taken from an organism or a cell culture, which has previously been subjected to a specific substance that is to be investigated for its toxicological effect. The DNA contained in this sample is chemically pretreated and the base sequence of a part of the modified DNA is determined. A methylation state characteristic for the sample or a characteristic methylation pattern is concluded from this. The effect of a substance on the organism or the cell culture is concluded by comparison with data of the methylation states of other samples and/or compared with other substances from a toxicological point of view.

Full | Title | Citation | Front | ..... | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 6. Document ID: US 20040006092 A1

L10: Entry 6 of 29 File: PGPB Jan 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040006092
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040006092 A1

TITLE: Amidine derivatives for treating amyloidosis

PUBLICATION-DATE: January 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chalifour, Robert J.	Ile Bizard		CA	
Kong, Xianqi	Dollard-des-Ormeaux		CA	
Wu, Xinfu	Dollard-des-Ormeaux		CA	
Lu, Wenshuo	Montreal		CA	

US-CL-CURRENT: 514/256; 514/397, 514/632

ABSTRACT:

The present invention relates to the use of amidine compounds in the treatment of amyloid-related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound. Among the compounds for use according to the invention are those according to the following Formula, such that, when administered, amyloid fibril formation, neurodegeneration, or cellular toxicity is reduced or inhibited: 1

Full | Title | Citation | Front | ..... | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 7. Document ID: US 20030236392 A1

L10: Entry 7 of 29 File: PGPB Dec 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030236392
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030236392 A1

TITLE: Novel full length cDNA

h e b b g e e e f e h ge ef b e

PUBLICATION-DATE: December 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Isogai, Takao	Ibaraki		JP	
Sugiyama, Tomoyasu	Tokyo		JP	
Otsuki, Tetsuji	Chiba		JP	
Wakamatsu, Ai	Chiba		JP	
Sato, Hiroyuki	Osaka		JP	
Ishii, Shizuko	Chiba		JP	
Yamamoto, Jun-lchi	Chiba		JP	
lsono, Yuuko	Chiba		JP	
Hio, Yuri	Chiba		JP	
Otsuka, Kaoru	Saitama		JP	
Nagai, Keiichi	Tokyo		JP	
lrie, Ryotaro	Chiba		JP	
Tamechika, lchiro	Osaka		JP	
Seki, Naohiko	Chiba		JP	
Yoshikawa, Tsutomu	Chiba		JP	
Otsuka, Motoyuki	Tokyo		JP	
Nagahari, Kenji	Tokyo		JP	
Masuho, Yasuhiko	Tokyo		JP	

US-CL-CURRENT: 536/23.1; 435/183, 435/325, 435/6, 435/69.1, 530/350, 702/19

ABSTRACT:

Novel full-length cDNAs are provided.

1970 cDNA derived from human have been isolated. The full-length nucleotide sequences of the cDNA and amino acid sequences encoded by the nucleotide sequences have been determined. Because the cDNA of the present invention are full-length and contain the translation start site, they provide information useful for analyzing the functions of the polypeptide.

8. Document ID: US 20030232758 A1

L10: Entry 8 of 29 File: PGPB Dec 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030232758
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030232758 A1

TITLE: Immunological methods and compositions for the treatment of Alzheimer's disease

PUBLICATION-DATE: December 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
St. George-Hyslop, Peter H.	Toronto		CA	

h e b b g e e e f e h ge ef b e

McLaurin, JoAnne Toronto CA

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/324, 536/23.1

ABSTRACT:

The present invention relates to immunogenic compositions and peptides comprising residues 4-10 (FRHDSGY) of the amyloid peptide Abeta.sub.42. The invention further relates to antibodies that bind to the Abeta.sub.(4-10) antigenic determinant. The invention provides methods for treating Alzheimer's disease and for reducing the amyloid load in Alzheimers patients. The invention also relates to methods for designing small molecule inhibitors of amyloid deposition.

Full | Title | Citation | Front | ..... | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw. Desc

☐ 9. Document ID: US 20030185808 A1

L10: Entry 9 of 29 File: PGPB Oct 2, 2003

PGPUB-DOCUMENT-NUMBER: 20030185808
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030185808 A1

TITLE: Prostate cell lines

PUBLICATION-DATE: October 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Thraves, Peter	London		GB	
Sutton, Andrew	London		GB	

US-CL-CURRENT: 424/93.21; 424/85.2, 435/366, 514/44

ABSTRACT:

An increasingly aged population and better diagnosis has lead to an apparent increase in the prevalence of prostate cancer in men. There is an acute need to better understand the progression of this disease from its locally confined site of initiation to the end stage widely metastatic disease with attendant morbidity and mortality. It has historically been difficult to raise and maintain immortalised prostate cell lines in culture. We have derived a cell line selected from the group consisting of clones ONYCAP 1 and ONYCAP23. The cell lines arc characterised as being prostate epithelial in origin.

Full | Title | Citation | Front | ..... | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw. Desc

☐ 10. Document ID: US 20030108595 A1

L10: Entry 10 of 29 File: PGPB Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030108595
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030108595 A1

h e b b g e e e f e h ge ef b e

TITLE: Method for treating amyloidosis

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kisilevsky, Robert	Kingston		CA	
Szarek, Walter	Kingston		CA	
Weaver, Donald	Kingston		CA	

US-CL-CURRENT: 424/450; 514/12, 514/23, 514/378, 514/381, 514/460, 514/79

ABSTRACT:

Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

☐ 11. Document ID: US 20030027796 A1

L10: Entry 11 of 29 File: PGPB Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027796
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030027796 A1

TITLE: Phosphono-carboxylate compounds for treating amyloidosis

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Szarek, Walter A.	Kingston		CA	
Kong, Xianqi	Dollard-des-Ormeaux		CA	
Thatcher, Gregory R.J.	Kingston		CA	
Gorine, Boris	Edmonton		CA	

US-CL-CURRENT: 514/79; 514/114, 514/141

ABSTRACT:

Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is

h e b b g e e e f e h ge ef b e

modulated.

Full | Title | Citation | Front | ..... | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc

☐ 12. Document ID: US 20020119926 A1

L10: Entry 12 of 29 File: PGPB Aug 29, 2002

PGPUB-DOCUMENT-NUMBER: 20020119926
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020119926 A1

TITLE: Inhibitors of IAPP fibril formation and uses thereof

PUBLICATION-DATE: August 29, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fraser, Paul	Toronto		CA	

US-CL-CURRENT: 514/12; 435/184, 514/14, 514/15, 514/16, 514/17

ABSTRACT:

New antifibrillogenic agents and compositions containing same, methods of using the antifibrillogenic agents and compositions for inhibiting amyloid fibril formation, and effective therapeutics for preventing or delaying the progression of, e g., Alzheimer's disease and diabetes.

Full | Title | Citation | Front | ..... | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc

☐ 13. Document ID: US 20020115717 A1

L10: Entry 13 of 29 File: PGPB Aug 22, 2002

PGPUB-DOCUMENT-NUMBER: 20020115717
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020115717 A1

TITLE: Amyloid targeting imaging agents and uses thereof

PUBLICATION-DATE: August 22, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gervais, Francine	Ile Bizard		CA	
Kong, Xianqi	Dollard-des-Ormeaux		CA	
Chalifour, Robert	Ile Bizard		CA	
Migneault, David	Laval		CA	

US-CL-CURRENT: 514/553; 424/1.11

h e b b g e e e f e h ge ef b e

ABSTRACT:

Amyloid-targeting imaging agents such as radiolabeled amyloid targeting molecules and amyloid targeting molecule-chelator conjugates for imaging, e.g., amyloid plaques in vivo, and/or for the treatment of amyloidosis disorders. The invention provides amyloid-targeting imaging agents that are useful for imaging sites of amyloid disease. Imaging agents of the invention are capable of binding specifically to amyloid plaques, as an aid in diagnosis and/or early treatment of amyloidosis disorders.

☐ 14. Document ID: US 20020094335 A1

L10: Entry 14 of 29 File: PGPB Jul 18, 2002

PGPUB-DOCUMENT-NUMBER: 20020094335
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020094335 A1

TITLE: Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases

PUBLICATION-DATE: July 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chalifour, Robert	Ile Bizard		CA	
Hebert, Lise	Brossard		CA	
Kong, Xianqi	Dollard-des-Oremaux		CA	
Gervais, Francine	Ile Bizard		CA	

US-CL-CURRENT: 424/185.1

ABSTRACT:

The present invention relates to a stereochemically based "non-self" antigen vaccine for the prevention and/or treatment of Alzheimer's and other amyloid related diseases. The present invention provides a vaccine for the prevention and treatment of Alzheimer's and other amyloid related diseases, which overcomes the drawbacks associated with using naturally occurring peptides, proteins or immunogens.

☐ 15. Document ID: US 20020009730 A1

L10: Entry 15 of 29 File: PGPB Jan 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020009730
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020009730 A1

TITLE: Human stress array

h e b b g e e e f e h ge ef b e

PUBLICATION-DATE: January 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chenchik, Alex	Palo Alto	CA	US	
Lukashev, Matvey E.	Newton	MA	US	

US-CL-CURRENT: 435/6; 536/24.3

ABSTRACT:

Human stress arrays and methods for their use are provided. The subject arrays include a plurality of polynucleotide spots, each of which is made up of a polynucleotide probe composition of unique polynucleotides corresponding to a human stress gene. The subject arrays find use in hybridization assays, particularly in assays for the identification of differential gene expression of human stress genes.

Full | Title | Citation | Front | ..... | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

☐ 16. Document ID: US 20010048941 A1

L10: Entry 16 of 29 File: PGPB Dec 6, 2001

PGPUB-DOCUMENT-NUMBER: 20010048941
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010048941 A1

TITLE: Method for treating amyloidosis

PUBLICATION-DATE: December 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kisilevsky, Robert	Kingston		CA	
Szarek, Walter	Kingston		CA	
Weaver, Donald	Kingston		CA	

US-CL-CURRENT: 424/450; 514/2, 514/378, 514/381, 514/460, 514/54

ABSTRACT:

Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amnyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof

Full | Title | Citation | Front | ..... | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

h e b b g e e e f e h ge ef b e

☐ 17. Document ID: US 20010027186 A1

L10: Entry 17 of 29 File: PGPB Oct 4, 2001

PGPUB-DOCUMENT-NUMBER: 20010027186
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010027186 A1

TITLE: Phosphono-carboxylate compounds for treating amyloidosis

PUBLICATION-DATE: October 4, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Szarek, Walter A.	Kingston		CA	
Kong, Xianqi	Dollard-des-Ormeaux		CA	
Thatcher, Gregory R.J	Kingston		CA	
Gorine, Boris	Edmonton		CA	

US-CL-CURRENT: 514/79; 514/114, 514/129, 514/142

ABSTRACT:

Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.

Full | Title | Citation | Front | ..... | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Drawi Desc

---

☐ 18. Document ID: US 6632808 B1

L10: Entry 18 of 29 File: USPT Oct 14, 2003

US-PAT-NO: 6632808
DOCUMENT-IDENTIFIER: US 6632808 B1
**** See image for Certificate of Correction ****

TITLE: Inhibitors of amyloid formation

DATE-ISSUED: October 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Caughey; Winslow S.	Hamilton	MT		
Caughey; Byron	Hamilton	MT		

US-CL-CURRENT: 514/185; 514/410, 540/122, 540/145

ABSTRACT:

Methods, compounds and compositions are disclosed for treating amyloidogenic

h e b b g e e e f e h ge ef b e

diseases, like Alzheimer's disease and type 2 diabetes, and particularly prion diseases associated with conversion of protease sensitive PrP (PrP-sen) to protease resistant PrP (PrP-res), by administering therapeutically effective amounts of a tetrapyrrole. Particular disclosed tetrapyrroles having this activity include phthalocyanines, deuteroporphyrins, and meso-substituted porphines. Complexes of certain of the pyrroles with metals or metal ions produce compounds that are particularly effective in converting the conversion of PrP-sen to PrP-sen. The treatment of the present invention is particularly suited for preventing or inhibiting the progression of prion related diseases, such as transmissible spongiform encephalopathies.

70 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

☐ 19. Document ID: US 6562836 B1

L10: Entry 19 of 29 File: USPT May 13, 2003

US-PAT-NO: 6562836
DOCUMENT-IDENTIFIER: US 6562836 B1
**** See image for Certificate of Correction ****

TITLE: Methods and compounds for inhibiting amyloid deposits

DATE-ISSUED: May 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Szarek; Walter A.	Kingston			CA
Weaver; Donald F.	Kingston			CA
Kong; Xianqi	Dollard-des-Ormeaux			CA
Gupta; Ajay	Pointe-Claire			CA
Migneault; David	Laval			CA

US-CL-CURRENT: 514/307; 514/308, 514/311, 514/313, 514/314

ABSTRACT:

Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.

172 Claims, 14 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 14

h e b b g e e e f e h ge ef b e

☐ 20. Document ID: US 6440952 B2

L10: Entry 20 of 29 File: USPT Aug 27, 2002

US-PAT-NO: 6440952
DOCUMENT-IDENTIFIER: US 6440952 B2

TITLE: Phosphono-carboxylate compounds for treating amyloidosis

DATE-ISSUED: August 27, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Szarek; Walter A.	Kingston			CA
Kong; Xianqi	Dollard-des-Ormeaux			CA
Thatcher; Gregory R. J.	Kingston			CA
Gorine; Boris	Edmonton			CA

US-CL-CURRENT: 514/120; 558/110, 558/70

ABSTRACT:

Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.

20 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | ..... | Classification | Date | Reference | Claims | KWMC | Draw Desc

☐ 21. Document ID: US 6355784 B1

L10: Entry 21 of 29 File: USPT Mar 12, 2002

US-PAT-NO: 6355784
DOCUMENT-IDENTIFIER: US 6355784 B1
**** See image for Certificate of Correction ****

TITLE: Methods and compositions for the manufacture of halogenated anthracyclines with increased antitumor activity, other anthracyclines, halogenated sugars, and glycosyl donors

DATE-ISSUED: March 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Priebe; Waldemar	Houston	TX	77005	

h e b b g e e e f e h ge ef b e

Krawczyk; Marta	Lexington	KY	40503	
Skibicki; Piotr	Warsaw 04015			PL
Fokt; Izabela	The Woodlands	TX	77380	
Dziewiszek; Krzysztof	The Woodlands	TX	77380	
Grynkiewicz; Grzegorz	05-092 Lomianki			PL
Perez-Soler; Roman	New York	NY	10016	

US-CL-CURRENT: 536/6.4; 536/122, 536/17.2, 536/18.4, 536/18.7, 536/4.1

ABSTRACT:

The present invention discloses new and novel halogenated anthracyclines linked through the saccharide portions. These congeners show high activity in vitro against several tumor cell lines. In doxorubicin (DOX) sensitive cell lines, they are at least as cytotoxic as DOX and in some cases more so. Many of these 4'- and 6'-fluorinated anthracyclines are more effective against multidrug-resistant tumors than was DOX, and/or have greater effectiveness than DOX against DOX sensitive cells. The compounds of this invention also have anti-amyloidogenic effects and the use of these compounds in the treatment of Alzheimer's disease is contemplated.

7 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

☐ 22. Document ID: US 6329356 B1

L10: Entry 22 of 29 File: USPT Dec 11, 2001

US-PAT-NO: 6329356
DOCUMENT-IDENTIFIER: US 6329356 B1

TITLE: Phosphono-carboxylate compounds for treating amyloidosis

DATE-ISSUED: December 11, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Szarek; Walter A.	Kingston			CA
Kong; Xianqi	Dollard-des-Ormeaux			CA

US-CL-CURRENT: 514/120

ABSTRACT:

Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.

31 Claims, 0 Drawing figures
Exemplary Claim Number: 1

h e b b g e e e f e h ge ef b e

Full | Title | Citation | Front | ..... | Classification | Date | Reference | ... | Claims | KWIC | Draw. Des

☐ 23. Document ID: US 5972328 A

L10: Entry 23 of 29 File: USPT Oct 26, 1999

US-PAT-NO: 5972328
DOCUMENT-IDENTIFIER: US 5972328 A
**** See image for Certificate of Correction ****

TITLE: Method for treating amyloidosis

DATE-ISSUED: October 26, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kisilevsky; Robert	Kingston			CA
Szarek; Walter	Kingston			CA
Weaver; Donald	Kingston			CA

US-CL-CURRENT: 424/78.31; 424/423, 424/427, 424/430, 424/434, 424/436, 424/441, 424/450, 424/78.35, 514/772.4, 526/286, 526/287

ABSTRACT:

Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

58 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8

Full | Title | Citation | Front | ..... | Classification | Date | Reference | ... | Claims | KWIC | Draw. Des

☐ 24. Document ID: US 5869469 A

L10: Entry 24 of 29 File: USPT Feb 9, 1999

US-PAT-NO: 5869469
DOCUMENT-IDENTIFIER: US 5869469 A

TITLE: Phosphonocarboxylate compounds for treating amyloidosis

DATE-ISSUED: February 9, 1999

INVENTOR-INFORMATION:

h e b b g e e e f e h ge ef b e

NAME	CITY	STATE	ZIP CODE	COUNTRY
Szarek; Walter A.	Kingston			CA
Kong; Xianqi	Kingston			CA

US-CL-CURRENT: 514/120

ABSTRACT:

Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.

25 Claims, 0 Drawing figures
Exemplary Claim Number: 1

25. Document ID: US 5858326 A

L10: Entry 25 of 29 File: USPT Jan 12, 1999

US-PAT-NO: 5858326
DOCUMENT-IDENTIFIER: US 5858326 A

TITLE: Methods of increasing amyloid deposition

DATE-ISSUED: January 12, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kisilevsky; Robert	Kingston			CA
Szarek; Walter	Kingston			CA
Weaver; Donald	Kingston			CA
Fraser; Paul	Toronto			CA
Kong; Xianqi	Kingston			CA

US-CL-CURRENT: 424/9.2; 424/78.31, 424/78.35, 435/7.8, 435/7.92, 435/7.93, 435/7.95, 514/772.4, 530/350, 800/9

ABSTRACT:

In vivo and in vitro methods of increasing amyloid deposition using amyloid-enhancing compounds are described. Methods of forming amyloid fibrils and screening for agents useful in treating amyloidosis are also described. Animals having non-naturally occurring amyloid deposits produced using the amyloid-enhancing compounds even further are described.

5 Claims, 2 Drawing figures
Exemplary Claim Number: 5
Number of Drawing Sheets: 2

h e b b g e e e f e h ge ef b e

26. Document ID: US 5840294 A

L10: Entry 26 of 29 File: USPT Nov 24, 1998

US-PAT-NO: 5840294
DOCUMENT-IDENTIFIER: US 5840294 A
**** See image for Certificate of Correction ****

TITLE: Method for treating amyloidosis

DATE-ISSUED: November 24, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kisilevsky; Robert	Kingston			CA
Szarek; Walter	Kingston			CA
Weaver; Donald	Kingston			CA

US-CL-CURRENT: 424/78.31; 424/423, 424/427, 424/430, 424/434, 424/436, 424/441, 424/450, 424/78.35, 514/772.4, 526/286, 526/287

ABSTRACT:

Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

66 Claims, 14 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

Full | Title | Citation | Front | ..... | Classification | Date | Reference | | | Claims | KWIC | Draw Desc

27. Document ID: US 5728375 A

L10: Entry 27 of 29 File: USPT Mar 17, 1998

US-PAT-NO: 5728375
DOCUMENT-IDENTIFIER: US 5728375 A

TITLE: Method for treating amyloidosis

DATE-ISSUED: March 17, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY

h e b b g e e e f e h ge ef b e

Kisilevsky; Robert	Kingston	CA
Szarek; Walter	Kingston	CA
Weaver; Donald	Kingston	CA

US-CL-CURRENT: 424/78.31; 424/450, 424/78.35, 514/772.4, 526/286, 526/287

ABSTRACT:

Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

71 Claims, 12 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

☐ 28. Document ID: US 5643562 A

L10: Entry 28 of 29 File: USPT Jul 1, 1997

US-PAT-NO: 5643562
DOCUMENT-IDENTIFIER: US 5643562 A

TITLE: Method for treating amyloidosis

DATE-ISSUED: July 1, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kisilevsky; Robert	Kingston			CA
Szarek; Walter	Kingston			CA
Weaver; Donald	Kingston			CA

US-CL-CURRENT: 424/78.31; 424/423, 424/427, 424/430, 424/434, 424/436, 424/441, 424/78.35, 514/772.4, 526/286, 526/287

ABSTRACT:

Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

h e b b g e e e f e h ge ef b e

55 Claims, 12 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

Full | Title | Citation | Front | ..... | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 29. Document ID: US 5276059 A

L10: Entry 29 of 29 File: USPT Jan 4, 1994

US-PAT-NO: 5276059
DOCUMENT-IDENTIFIER: US 5276059 A
**** See image for Certificate of Correction ****

TITLE: Inhibition of diseases associated with amyloid formation

DATE-ISSUED: January 4, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Caughey; Byron	Hamilton	MT		
Race; Richard	Hamilton	MT		

US-CL-CURRENT: 514/647

ABSTRACT:

The invention provides a method of treating a mammal having a condition associated with formation of amyloidogenic protein without deposition of amyloid plaques. This treatment includes administering to the mammal a pharmacologically effective amount of Congo Red or a pharmaceutically acceptable salt or derivative thereof to interfere with amyloidogenic protein formation or to destabilize amyloidogenic protein structures already formed in said mammal. The invention also provides a method of treating a mammal having a condition associated with deposition of amyloidogenic protein in plaques, and a method of inhibiting the transformation of PrP-sen to PrP-res in a tissue culture sample containing PrP-sen.

34 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full | Title | Citation | Front | ..... | Classification | Date | Reference | Claims | KWIC | Draw Desc

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
L9 AND AScr	29

Display Format: - Change Format

h e b b g ee e f e h ge ef b e

Previous Page Next Page Go to Doc#

h e b b g e e e f e h ge ef b e

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 25 of 25 returned.

☐ 1. Document ID: US 20040208875 A1

Using default format because multiple data bases are involved.

L11: Entry 1 of 25 File: PGPB Oct 21, 2004

PGPUB-DOCUMENT-NUMBER: 20040208875
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040208875 A1

TITLE: Method for treating amyloidosis

PUBLICATION-DATE: October 21, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kisilevsky, Robert	Kingston		CA	
Szarek, Walter	Kingston		CA	
Weaver, Donald	Kingston		CA	

US-CL-CURRENT: 424/145.1; 514/8

Full | Title | — | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 2. Document ID: US 20040198832 A1

L11: Entry 2 of 25 File: PGPB Oct 7, 2004

PGPUB-DOCUMENT-NUMBER: 20040198832
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040198832 A1

TITLE: Compositions and methods for treating amyloidosis

PUBLICATION-DATE: October 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Szarek, Walter A.	Kingston		CA	
Weaver, Donald F.	Kingston		CA	
Kong, Xianqi	Dollard-des-Ormeaux		CA	
Gordon, Heather	North Thorold		CA	

US-CL-CURRENT: 514/599; 514/602, 514/616

ABSTRACT:

h e b b g e e e f e h ge ef b e

Therapeutic compounds and methods for modulating amyloid aggregation in a subject, whatever its clinical setting, are described. Amyloid aggregation is modulated by the administration to a subject of an effective amount of a therapeutic compound of the formula 1

or a pharmaceutically acceptable salt or ester, such that modulation of amyloid aggregation occurs. R.sup.1 and R.sup.2 are each independently a hydrogen atom or a substituted or unsubstituted aliphatic or aryl group. Z and Q are each independently a carbonyl (C.dbd.O), thiocarbonyl (C.dbd.S), sulfonyl (SO.sub.2), or sulfoxide (S.dbd.O) group. "k" and "m" are 0 or 1, provided when k is 1, R.sup.1 is not a hydrogen atom, and when m is 1, R.sup.2 is not a hydrogen atom. In an embodiment, at least one of k or m must equal 1. "p" and "s" are each independently positive integers selected such that the biodistribution of the therapeutic compound for an intended target site is not prevented while maintaining activity of the therapeutic compound. T is a linking group and Y is a group of the formula -A X wherein A is an anionic group at physiological pH, and X is a cationic group.

☐ 3. Document ID: US 20040147531 A1

L11: Entry 3 of 25 File: PGPB Jul 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040147531
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040147531 A1

TITLE: Amidine derivatives for treating amyloidosis

PUBLICATION-DATE: July 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chalifour, Robert J.	Ile Bizard		CA	
Kong, Xianqi	Pierrefonds		CA	
Wu, Xinfu	Dollard-des-Ormeaux		CA	
Lu, Wenshuo	LaSalle		CA	

US-CL-CURRENT: 514/256; 514/397, 514/636

ABSTRACT:

The present invention relates to the use of amidine compounds in the treatment of amyloid-related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound. Among the compounds for use according to the invention are those according to the following Formula, such that, when administered, amyloid fibril formation, neurodegeneration, or cellular toxicity is reduced or inhibited: 1

☐ 4. Document ID: US 20040138178 A1

h e b b g e e e f e h ge ef b e

L11: Entry 4 of 25 File: PGPB Jul 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040138178
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040138178 A1

TITLE: Phosphono-carboxylate compounds for treating amyloidosis

PUBLICATION-DATE: July 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Szarek, Walter A.	Kingston		CA	
Kong, Xianqi	Pierrefonds		CA	
Thatcher, Gregory R.J.	Kingston		CA	
Gorine, Boris	Edmonton		CA	

US-CL-CURRENT: 514/79; 514/114, 514/141

ABSTRACT:

Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.

5. Document ID: US 20040006092 A1

L11: Entry 5 of 25 File: PGPB Jan 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040006092
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040006092 A1

TITLE: Amidine derivatives for treating amyloidosis

PUBLICATION-DATE: January 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chalifour, Robert J.	Ile Bizard		CA	
Kong, Xianqi	Dollard-des-Ormeaux		CA	
Wu, Xinfu	Dollard-des-Ormeaux		CA	
Lu, Wenshuo	Montreal		CA	

US-CL-CURRENT: 514/256; 514/397, 514/632

ABSTRACT:

h e b b g e e e f e h ge ef b e

The present invention relates to the use of amidine compounds in the treatment of amyloid-related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound. Among the compounds for use according to the invention are those according to the following Formula, such that, when administered, amyloid fibril formation, neurodegeneration, or cellular toxicity is reduced or inhibited: 1

6. Document ID: US 20030236392 A1

L11: Entry 6 of 25 File: PGPB Dec 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030236392
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030236392 A1

TITLE: Novel full length cDNA

PUBLICATION-DATE: December 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Isogai, Takao	Ibaraki		JP	
Sugiyama, Tomoyasu	Tokyo		JP	
Otsuki, Tetsuji	Chiba		JP	
Wakamatsu, Ai	Chiba		JP	
Sato, Hiroyuki	Osaka		JP	
Ishii, Shizuko	Chiba		JP	
Yamamoto, Jun-lchi	Chiba		JP	
lsono, Yuuko	Chiba		JP	
Hio, Yuri	Chiba		JP	
Otsuka, Kaoru	Saitama		JP	
Nagai, Keiichi	Tokyo		JP	
lrie, Ryotaro	Chiba		JP	
Tamechika, lchiro	Osaka		JP	
Seki, Naohiko	Chiba		JP	
Yoshikawa, Tsutomu	Chiba		JP	
Otsuka, Motoyuki	Tokyo		JP	
Nagahari, Kenji	Tokyo		JP	
Masuho, Yasuhiko	Tokyo		JP	

US-CL-CURRENT: 536/23.1; 435/183, 435/325, 435/6, 435/69.1, 530/350, 702/19

ABSTRACT:

Novel full-length cDNAs are provided.

1970 cDNA derived from human have been isolated. The full-length nucleotide sequences of the cDNA and amino acid sequences encoded by the nucleotide sequences have been determined. Because the cDNA of the present invention are full-length and contain the translation start site, they provide information useful for analyzing the functions of the polypeptide.

h e b b g e e e f e h ge ef b e

Full | Title | --- | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 7. Document ID: US 20030232758 A1

L11: Entry 7 of 25 File: PGPB Dec 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030232758
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030232758 A1

TITLE: Immunological methods and compositions for the treatment of Alzheimer's disease

PUBLICATION-DATE: December 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
St. George-Hyslop, Peter H.	Toronto		CA	
McLaurin, JoAnne	Toronto		CA	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/324, 536/23.1

ABSTRACT:

The present invention relates to immunogenic compositions and peptides comprising residues 4-10 (FRHDSGY) of the amyloid peptide Abeta.sub.42. The invention further relates to antibodies that bind to the Abeta.sub.(4-10) antigenic determinant. The invention provides methods for treating Alzheimer's disease and for reducing the amyloid load in Alzheimers patients. The invention also relates to methods for designing small molecule inhibitors of amyloid deposition.

Full | Title | --- | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 8. Document ID: US 20030185808 A1

L11: Entry 8 of 25 File: PGPB Oct 2, 2003

PGPUB-DOCUMENT-NUMBER: 20030185808
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030185808 A1

TITLE: Prostate cell lines

PUBLICATION-DATE: October 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Thraves, Peter	London		GB	
Sutton, Andrew	London		GB	

US-CL-CURRENT: 424/93.21; 424/85.2, 435/366, 514/44

h e b b g e e e f e h ge ef b e

ABSTRACT:

An increasingly aged population and better diagnosis has lead to an apparent increase in the prevalence of prostate cancer in men. There is an acute need to better understand the progression of this disease from its locally confined site of initiation to the end stage widely metastatic disease with attendant morbidity and mortality. It has historically been difficult to raise and maintain immortalised prostate cell lines in culture. We have derived a cell line selected from the group consisting of clones ONYCAP 1 and ONYCAP23. The cell lines arc characterised as being prostate epithelial in origin.

☐ 9. Document ID: US 20030108595 A1

L11: Entry 9 of 25 File: PGPB Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030108595
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030108595 A1

TITLE: Method for treating amyloidosis

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kisilevsky, Robert	Kingston		CA	
Szarek, Walter	Kingston		CA	
Weaver, Donald	Kingston		CA	

US-CL-CURRENT: 424/450; 514/12, 514/23, 514/378, 514/381, 514/460, 514/79

ABSTRACT:

Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

☐ 10. Document ID: US 20030027796 A1

L11: Entry 10 of 25 File: PGPB Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027796
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030027796 A1

h e b b g e e e f e h ge ef b e

TITLE: Phosphono-carboxylate compounds for treating amyloidosis

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Szarek, Walter A.	Kingston		CA	
Kong, Xianqi	Dollard-des-Ormeaux		CA	
Thatcher, Gregory R.J.	Kingston		CA	
Gorine, Boris	Edmonton		CA	

US-CL-CURRENT: 514/79; 514/114, 514/141

ABSTRACT:

Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.

Full | Title | ---- | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

---

☐ 11. Document ID: US 20020119926 A1

L11: Entry 11 of 25 File: PGPB Aug 29, 2002

PGPUB-DOCUMENT-NUMBER: 20020119926
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020119926 A1

TITLE: Inhibitors of IAPP fibril formation and uses thereof

PUBLICATION-DATE: August 29, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fraser, Paul	Toronto		CA	

US-CL-CURRENT: 514/12; 435/184, 514/14, 514/15, 514/16, 514/17

ABSTRACT:

New antifibrillogenic agents and compositions containing same, methods of using the antifibrillogenic agents and compositions for inhibiting amyloid fibril formation, and effective therapeutics for preventing or delaying the progression of, e g., Alzheimer's disease and diabetes.

Full | Title | ---- | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

---

h e b b g e e e f e h ge ef b e

☐ 12. Document ID: US 20020115717 A1

L11: Entry 12 of 25 File: PGPB Aug 22, 2002

PGPUB-DOCUMENT-NUMBER: 20020115717
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020115717 A1

TITLE: Amyloid targeting imaging agents and uses thereof

PUBLICATION-DATE: August 22, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gervais, Francine	Ile Bizard		CA	
Kong, Xianqi	Dollard-des-Ormeaux		CA	
Chalifour, Robert	Ile Bizard		CA	
Migneault, David	Laval		CA	

US-CL-CURRENT: 514/553; 424/1.11

ABSTRACT:

Amyloid-targeting imaging agents such as radiolabeled amyloid targeting molecules and amyloid targeting molecule-chelator conjugates for imaging, e.g., amyloid plaques in vivo, and/or for the treatment of amyloidosis disorders. The invention provides amyloid-targeting imaging agents that are useful for imaging sites of amyloid disease. Imaging agents of the invention are capable of binding specifically to amyloid plaques, as an aid in diagnosis and/or early treatment of amyloidosis disorders.

Full | Title | ..... | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

☐ 13. Document ID: US 20020094335 A1

L11: Entry 13 of 25 File: PGPB Jul 18, 2002

PGPUB-DOCUMENT-NUMBER: 20020094335
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020094335 A1

TITLE: Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases

PUBLICATION-DATE: July 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chalifour, Robert	Ile Bizard		CA	
Hebert, Lise	Brossard		CA	
Kong, Xianqi	Dollard-des-Oremaux		CA	
Gervais, Francine	Ile Bizard		CA	

US-CL-CURRENT: 424/185.1

h e b b g e e e f e h ge ef b e

ABSTRACT:

The present invention relates to a stereochemically based "non-self" antigen vaccine for the prevention and/or treatment of Alzheimer's and other amyloid related diseases. The present invention provides a vaccine for the prevention and treatment of Alzheimer's and other amyloid related diseases, which overcomes the drawbacks associated with using naturally occurring peptides, proteins or immunogens.

Full | Title | ..... | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 14. Document ID: US 20020009730 A1

L11: Entry 14 of 25 File: PGPB Jan 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020009730
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020009730 A1

TITLE: Human stress array

PUBLICATION-DATE: January 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chenchik, Alex	Palo Alto	CA	US	
Lukashev, Matvey E.	Newton	MA	US	

US-CL-CURRENT: 435/6; 536/24.3

ABSTRACT:

Human stress arrays and methods for their use are provided. The subject arrays include a plurality of polynucleotide spots, each of which is made up of a polynucleotide probe composition of unique polynucleotides corresponding to a human stress gene. The subject arrays find use in hybridization assays, particularly in assays for the identification of differential gene expression of human stress genes.

Full | Title | ..... | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 15. Document ID: US 20010048941 A1

L11: Entry 15 of 25 File: PGPB Dec 6, 2001

PGPUB-DOCUMENT-NUMBER: 20010048941
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010048941 A1

TITLE: Method for treating amyloidosis

PUBLICATION-DATE: December 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47

h e b b g e e e f e h ge ef b e

Kisilevsky, Robert	Kingston	CA
Szarek, Walter	Kingston	CA
Weaver, Donald	Kingston	CA

US-CL-CURRENT: 424/450; 514/2, 514/378, 514/381, 514/460, 514/54

ABSTRACT:

Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amnyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof

☐ 16. Document ID: US 20010027186 A1

L11: Entry 16 of 25 File: PGPB Oct 4, 2001

PGPUB-DOCUMENT-NUMBER: 20010027186
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010027186 A1

TITLE: Phosphono-carboxylate compounds for treating amyloidosis

PUBLICATION-DATE: October 4, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Szarek, Walter A.	Kingston		CA	
Kong, Xianqi	Dollard-des-Ormeaux		CA	
Thatcher, Gregory R.J	Kingston		CA	
Gorine, Boris	Edmonton		CA	

US-CL-CURRENT: 514/79; 514/114, 514/129, 514/142

ABSTRACT:

Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.

h e b b g e e e f e h ge ef b e

☐ 17. Document ID: US 6632808 B1

L11: Entry 17 of 25 File: USPT Oct 14, 2003

US-PAT-NO: 6632808
DOCUMENT-IDENTIFIER: US 6632808 B1
**** See image for Certificate of Correction ****

TITLE: Inhibitors of amyloid formation

DATE-ISSUED: October 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Caughey; Winslow S.	Hamilton	MT		
Caughey; Byron	Hamilton	MT		

US-CL-CURRENT: 514/185; 514/410, 540/122, 540/145

ABSTRACT:

Methods, compounds and compositions are disclosed for treating amyloidogenic diseases, like Alzheimer's disease and type 2 diabetes, and particularly prion diseases associated with conversion of protease sensitive PrP (PrP-sen) to protease resistant PrP (PrP-res), by administering therapeutically effective amounts of a tetrapyrrole. Particular disclosed tetrapyrroles having this activity include phthalocyanines, deuteroporphyrins, and meso-substituted porphines. Complexes of certain of the pyrroles with metals or metal ions produce compounds that are particularly effective in converting the conversion of PrP-sen to PrP-sen. The treatment of the present invention is particularly suited for preventing or inhibiting the progression of prion related diseases, such as transmissible spongiform encephalopathies.

70 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full | Title | ..... | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw. Des.

☐ 18. Document ID: US 6562836 B1

L11: Entry 18 of 25 File: USPT May 13, 2003

US-PAT-NO: 6562836
DOCUMENT-IDENTIFIER: US 6562836 B1
**** See image for Certificate of Correction ****

TITLE: Methods and compounds for inhibiting amyloid deposits

DATE-ISSUED: May 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Szarek; Walter A.	Kingston			CA
Weaver; Donald F.	Kingston			CA
Kong; Xianqi	Dollard-des-Ormeaux			CA

h e b b g e e e f e h ge ef b e

Gupta; Ajay	Pointe-Claire	CA
Migneault; David	Laval	CA

US-CL-CURRENT: 514/307; 514/308, 514/311, 514/313, 514/314

ABSTRACT:

Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.

172 Claims, 14 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 14

19. Document ID: US 6440952 B2

L11: Entry 19 of 25 File: USPT Aug 27, 2002

US-PAT-NO: 6440952
DOCUMENT-IDENTIFIER: US 6440952 B2

TITLE: Phosphono-carboxylate compounds for treating amyloidosis

DATE-ISSUED: August 27, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Szarek; Walter A.	Kingston			CA
Kong; Xianqi	Dollard-des-Ormeaux			CA
Thatcher; Gregory R. J.	Kingston			CA
Gorine; Boris	Edmonton			CA

US-CL-CURRENT: 514/120; 558/110, 558/70

ABSTRACT:

Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.

20 Claims, 0 Drawing figures
Exemplary Claim Number: 1

h e b b g e e e f e h ge ef b e

Full | Title | ---- | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 20. Document ID: US 6329356 B1

L11: Entry 20 of 25 File: USPT Dec 11, 2001

US-PAT-NO: 6329356
DOCUMENT-IDENTIFIER: US 6329356 B1

TITLE: Phosphono-carboxylate compounds for treating amyloidosis

DATE-ISSUED: December 11, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Szarek; Walter A.	Kingston			CA
Kong; Xianqi	Dollard-des-Ormeaux			CA

US-CL-CURRENT: 514/120

ABSTRACT:

Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.

31 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | ---- | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 21. Document ID: US 5972328 A

L11: Entry 21 of 25 File: USPT Oct 26, 1999

US-PAT-NO: 5972328
DOCUMENT-IDENTIFIER: US 5972328 A
**** See image for Certificate of Correction ****

TITLE: Method for treating amyloidosis

DATE-ISSUED: October 26, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kisilevsky; Robert	Kingston			CA
Szarek; Walter	Kingston			CA
Weaver; Donald	Kingston			CA

h e b b g e e e f e h ge ef b e

US-CL-CURRENT: 424/78.31; 424/423, 424/427, 424/430, 424/434, 424/436, 424/441, 424/450, 424/78.35, 514/772.4, 526/286, 526/287

ABSTRACT:

Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

58 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8

☐ 22. Document ID: US 5869469 A

L11: Entry 22 of 25 File: USPT Feb 9, 1999

US-PAT-NO: 5869469
DOCUMENT-IDENTIFIER: US 5869469 A

TITLE: Phosphonocarboxylate compounds for treating amyloidosis

DATE-ISSUED: February 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Szarek; Walter A.	Kingston			CA
Kong; Xianqi	Kingston			CA

US-CL-CURRENT: 514/120

ABSTRACT:

Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.

25 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 23. Document ID: US 5840294 A

h e b b g e e e f e h ge ef b e

L11: Entry 23 of 25 File: USPT Nov 24, 1998

US-PAT-NO: 5840294
DOCUMENT-IDENTIFIER: US 5840294 A
**** See image for Certificate of Correction ****

TITLE: Method for treating amyloidosis

DATE-ISSUED: November 24, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kisilevsky; Robert	Kingston			CA
Szarek; Walter	Kingston			CA
Weaver; Donald	Kingston			CA

US-CL-CURRENT: 424/78.31; 424/423, 424/427, 424/430, 424/434, 424/436, 424/441, 424/450, 424/78.35, 514/772.4, 526/286, 526/287

ABSTRACT:

Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

66 Claims, 14 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

☐ 24. Document ID: US 5728375 A

L11: Entry 24 of 25 File: USPT Mar 17, 1998

US-PAT-NO: 5728375
DOCUMENT-IDENTIFIER: US 5728375 A

TITLE: Method for treating amyloidosis

DATE-ISSUED: March 17, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kisilevsky; Robert	Kingston			CA
Szarek; Walter	Kingston			CA
Weaver; Donald	Kingston			CA

US-CL-CURRENT: 424/78.31; 424/450, 424/78.35, 514/772.4, 526/286, 526/287

h e b b g e e e f e h ge ef b e

ABSTRACT:

Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

71 Claims, 12 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

☐ 25. Document ID: US 5643562 A

L11: Entry 25 of 25 File: USPT Jul 1, 1997

US-PAT-NO: 5643562
DOCUMENT-IDENTIFIER: US 5643562 A

TITLE: Method for treating amyloidosis

DATE-ISSUED: July 1, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kisilevsky; Robert	Kingston			CA
Szarek; Walter	Kingston			CA
Weaver; Donald	Kingston			CA

US-CL-CURRENT: 424/78.31; 424/423, 424/427, 424/430, 424/434, 424/436, 424/441, 424/78.35, 514/772.4, 526/286, 526/287

ABSTRACT:

Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

55 Claims, 12 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

h e b b g e e e f e h ge ef b e

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
L10 AND antibody	25

Display Format: - Change Format

Previous Page Next Page Go to Doc#

h e b b g e e e f e h ge ef b e

Items 1 - 72 of 72 One p

1: Verma P, Baldrian P, Gabriel J, Trnka T, Nerud F. Related Articles, Li

Copper-ligand complex for the decolorization of synthetic dyes.
Chemosphere. 2004 Dec;57(9):1207-11.
PMID: 15504481 [PubMed - in process]

2: Mares JJ, Stavek J, Sestak J. Related Articles, Li

Quantum aspects of self-organized periodic chemical reactions.
J Chem Phys. 2004 Jul 15;121(3):1499-503.
PMID: 15260695 [PubMed - in process]

3: Perez Martinez A, Quintero Calcano V, Gonzalez Vicent M, Contra Gomez T, Diaz Perez MA, Madero Lopez L, Sevilla Navarro J. Related Articles, Li

[High-dose chemotherapy with autologous stem cell rescue in children with high-risk and recurrent brain tumors]
An Pediatr (Barc). 2004 Jul;61(1):8-15. Spanish.
PMID: 15228928 [PubMed - indexed for MEDLINE]

4: Tousova K, Susankova K, Teisinger J, Vyklicky L, Vlachova V. Related Articles, Li

Oxidizing reagent copper-o-phenanthroline is an open channel blocker of the vanilloid receptor TRPV1.
Neuropharmacology. 2004 Aug;47(2):273-85.
PMID: 15223306 [PubMed - indexed for MEDLINE]

5: Cejchan PA. Related Articles, Li

LUCA, or just a conserved Archaeon?: comments on Xue et al.
Gene. 2004 May 26;333:47-50.
PMID: 15177679 [PubMed - indexed for MEDLINE]

6: Cerna A, Cuadrado A, Jouve N, Diaz de la Espina SM, De la Torre C. Related Articles, Li

Z-DNA, a new in situ marker for transcription.
Eur J Histochem. 2004;48(1):49-56.
PMID: 15145775 [PubMed - in process]

7: Modak S, Gardner S, Dunkel IJ, Balmaceda C, Rosenblum MK, Miller DC, Halpern S, Finlay JL. Related Articles, Li

Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors.
J Clin Oncol. 2004 May 15;22(10):1934-43.
PMID: 15143087 [PubMed - indexed for MEDLINE]

8: Gaziova I, Bonnette PC, Henrich VC, Jindra M. Related Articles, Li

Cell-autonomous roles of the ecdysoneless gene in Drosophila development a oogenesis.
Development. 2004 Jun;131(11):2715-25. Epub 2004 May 05.
PMID: 15128659 [PubMed - indexed for MEDLINE]

9: Gardner SL. Related Articles, Li

Application of stem cell transplant for brain tumors.

h cb h g e e e fcg e ch b e

Pediatr Transplant. 2004 Jun;8 Suppl 5:28-32. Review.
PMID: 15125703 [PubMed - indexed for MEDLINE]

10: Krusek J, Dittert I, Hendrych T, Hnik P, Horak M, Petrovic M, Sedlacek M, Susankova K, Svobodova L, Tousova K, Ujec E, Vlachova V, Vyklicky L, Vyskocil F, Vyklicky L Jr. Related Articles, Li

Activation and modulation of ligand-gated ion channels.
Physiol Res. 2004;53 Suppl 1:S103-13.
PMID: 15119941 [PubMed - in process]

11: Frydrychova R, Grossmann P, Trubac P, Vitkova M, Marec F. Related Articles, Li

Phylogenetic distribution of TTAGG telomeric repeats in insects.
Genome. 2004 Feb;47(1):163-78.
PMID: 15060613 [PubMed - indexed for MEDLINE]

12: Broniscer A, Nicolaides TP, Dunkel IJ, Gardner SL, Johnson J Jr, Allen JC, Sposto R, Finlay JL. Related Articles, Li

High-dose chemotherapy with autologous stem-cell rescue in the treatment o patients with recurrent non-cerebellar primitive neuroectodermal tumors.
Pediatr Blood Cancer. 2004 Mar;42(3):261-7.
PMID: 14752864 [PubMed - indexed for MEDLINE]

13: Rego A, Marec F. Related Articles, Li

Telomeric and interstitial telomeric sequences in holokinetic chromosomes o Lepidoptera: telomeric DNA mediates association between postpachytene bivalents in achiasmatic meiosis of females.
Chromosome Res. 2003;11(7):681-94.
PMID: 14606630 [PubMed - indexed for MEDLINE]

14: Eguchi M, Miyazaki T, Masatsuji-Kato E, Tsuzuki T, Oribe T, Miwa N. Related Articles, Li

Cytoprotection against ischemia-induced DNA cleavages and cell injuries in the rat liver by pro-vitamin C via hydrolytic conversion into ascorbate.
Mol Cell Biochem. 2003 Oct;252(1-2):17-23.
PMID: 14577572 [PubMed - indexed for MEDLINE]

15: Verma P, Shah V, Baldrian P, Gabriel J, Stopka P, Trnka T, Nerud F. Related Articles, Li

Decolorization of synthetic dyes using a copper complex with glucaric acid.
Chemosphere. 2004 Jan;54(3):291-5.
PMID: 14575741 [PubMed - indexed for MEDLINE]

16: Adamova D, Agakichiev G, Appelshauser H, Belaga V, Braun-Munzinger P, Cherlin A, Damjanovic S, Dietel T, Dietrich L, Drees A, Esumi SI, Filimonov K, Fomenko K, Fraenkel Z, Garabatos C, Glassel P, Hering G, Holeczek J, Kushpil V, Lenkeit B, Maas A, Marin A, Milosevic J, Milov A, Miskowiec D, Panebrattsev Y, Petchenova O, Petracek V, Pfeiffer A, Rak J, Ravinovich I, Rehak P, Richter M, Sako H, Schmitz W, Sedykh S, Seipp W, Sharma A, Shimansky S, Slivova J, Specht HJ, Stachel J, Sumbera M, Tilsner H, Tserruya I, Wessels JP, Wienold T, Windelband B, Wurm JP, Xie W, Yurevich S, Yurevich V; CERES/NA45 Collaboration. Related Articles, Li

Enhanced production of low-mass electron-positron pairs in 40-AGeV Pb-A collisions at the CERN SPS.
Phys Rev Lett. 2003 Jul 25;91(4):042301. Epub 2003 Jul 22.
PMID: 12906652 [PubMed]

17: Petrickova K, Petricek M. Related Articles, Li

Eukaryotic-type protein kinases in Streptomyces coelicolor: variations on a common theme.
Microbiology. 2003 Jul;149(Pt 7):1609-21. Review.
PMID: 12855714 [PubMed - indexed for MEDLINE]

18: Grunclova L, Fouquier H, Hypsa V, Kopacek P. Related Articles, Li

Lysozyme from the gut of the soft tick Ornithodoros moubata: the sequence, phylogeny and post-feeding regulation.
Dev Comp Immunol. 2003 Sep;27(8):651-60.
PMID: 12798362 [PubMed - indexed for MEDLINE]

19: Skrbek L, Gordeev AV, Soukup F. Related Articles, Li

Decay of counterflow He II turbulence in a finite channel: possibility of missing links between classical and quantum turbulence.
Phys Rev E Stat Nonlin Soft Matter Phys. 2003 Apr;67(4 Pt 2):047302. Epub 2003 Apr 21.
PMID: 12786535 [PubMed]

20: Gururangan S, McLaughlin C, Quinn J, Rich J, Reardon D, Halperin EC, Herndon J 2nd, Fuchs H, George T, Provenzale J, Watral M, McLendon RE, Friedman A, Friedman HS, Kurtzberg J, Vredenbergh J, Martin PL. Related Articles, Li

High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas.
J Clin Oncol. 2003 Jun 1;21(11):2187-91.
PMID: 12775745 [PubMed - indexed for MEDLINE]

21: Adamova D, Agakichiev G, Appelshauser H, Belaga V, Braun-Munzinger P, Castillo A, Cherlin A, Damjanovic S, Dietel T, Dietrich L, Drees A, Esumi SI, Filimonov K, Fomenko K, Fraenkel Z, Garabatos C, Glassel P, Hering G, Holeczek J, Kushpil V, Lenkeit B, Ludolphs W, Maas A, Marin A, Milosevic J, Milov A, Miskowiec D, Panebrattsev Y, Petchenova O, Petracek V, Pfeiffer A, Rak J, Ravinovich I, Rehak P, Sako H, Schmitz W, Schukraft J, Sedykh S, Shimansky S, Slivova J, Specht HJ, Stachel J, Sumbera M, Tilsner H, Tserruya I, Wessels JP, Wienold T, Windelband B, Wurm JP, Xie W, Yurevich S, Yurevich V; CERES Collaboration. Related Articles, Li

Universal pion freeze-out in heavy-ion collisions.
Phys Rev Lett. 2003 Jan 17;90(2):022301. Epub 2003 Jan 15.
PMID: 12570540 [PubMed]

22: Verma P, Baldrian P, Nerud F. Related Articles, Li

Decolorization of structurally different synthetic dyes using cobalt(II)/ascorb acid/hydrogen peroxide system.
Chemosphere. 2003 Mar;50(8):975-9.
PMID: 12531702 [PubMed - indexed for MEDLINE]

23: Frydrychova R, Marec F. Related Articles, Li

Repeated losses of TTAGG telomere repeats in evolution of beetles (Coleoptera).
Genetica. 2002 Jun;115(2):179-87.
PMID: 12403172 [PubMed - indexed for MEDLINE]

24: Krasa J, Cejnarova A, Juha L, Ryc L, Scholz M, Kubes P. Related Articles, Li

Semiconductor and thermoluminescent dosimetry of pulsed soft X ray plasm sources.
Radiat Prot Dosimetry. 2002;100(1-4):429-32.
PMID: 12382914 [PubMed - indexed for MEDLINE]

25: Rihova B. Related Articles, Li

Immunomodulating activities of soluble synthetic polymer-bound drugs.
Adv Drug Deliv Rev. 2002 Sep 13;54(5):653-74. Review.
PMID: 12204597 [PubMed - indexed for MEDLINE]

26: Sastre A, Kavet R. Related Articles, Li

h cb h g e e e fcg e ch b e

Candidate sites of action for microdosimetry associated with exposure to extremely-low-frequency magnetic fields, electric fields and contact currents
Health Phys. 2002 Sep;83(3):387-94.
PMID: 12199552 [PubMed - indexed for MEDLINE]

27: Rolcik J, Lenobel R, Siglerová V, Strnad M. Related Articles, Li

Isolation of melatonin by immunoaffinity chromatography.
J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jul 25;775(1):9-15.
PMID: 12101055 [PubMed - indexed for MEDLINE]

28: St'astny M, Plocova D, Etrych T, Ulbrich K, Rihova B. Related Articles, Li

HPMA-hydrogels result in prolonged delivery of anticancer drugs and are a promising tool for the treatment of sensitive and multidrug resistant leukaem
Eur J Cancer. 2002 Mar;38(4):602-8.
PMID: 11872356 [PubMed - indexed for MEDLINE]

29: Sykova E, Fiala J, Antonova T, Vorisek I. Related Articles, Li

Extracellular space volume changes and diffusion barriers in rats with kaolin induced and inherited hydrocephalus.
Eur J Pediatr Surg. 2001 Dec;11 Suppl 1:S34-7. No abstract available.
PMID: 11848042 [PubMed - indexed for MEDLINE]

30: Baldrian P, Gabriel J. Related Articles, Li

Copper and cadmium increase laccase activity in Pleurotus ostreatus.
FEMS Microbiol Lett. 2002 Jan 2;206(1):69-74.
PMID: 11786259 [PubMed - indexed for MEDLINE]

31: Jungwirth T, MacDonald AH. Related Articles, Li

Resistance spikes and domain wall loops in Ising quantum Hall ferromagnets
Phys Rev Lett. 2001 Nov 19;87(21):216801. Epub 2001 Oct 30.
PMID: 11736361 [PubMed]

32: Wilder RB, Rodriguez MA, Tucker SL, Ha CS, Hess MA, Cabanillas FF, Cox JD. Related Articles, Li

Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas.
Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):743-9.
PMID: 11395243 [PubMed - indexed for MEDLINE]

33: Simon V, Vacik J, Michalek J, Novak V, Lopour P, Spunda M. Related Articles, Li

[Surgical treatment of recurrent urethral strictures in males after unsuccessfu operations]
Cas Lek Cesk. 2000 Dec 6;139(24):767-71. Czech.
PMID: 11262915 [PubMed - indexed for MEDLINE]

34: Bendjelloul F, Rossmann P, Maly P, Mandys V, Jirkovska M, Prokesova L, Tuckova L, Tlaskalova-Hogenova H. Related Articles, Li

Detection of ICAM-1 in experimentally induced colitis of ICAM-1-deficient and wild-type mice: an immunohistochemical study.
Histochem J. 2000 Dec;32(12):703-9.
PMID: 11254085 [PubMed - indexed for MEDLINE]

35: Kolacek J, Lipavsky P, Brandt EH. Related Articles, Li

Charge profile in vortices.
Phys Rev Lett. 2001 Jan 8;86(2):312-5.
PMID: 11177819 [PubMed]

36: Petrickova K, Tichy P, Petricek M. Related Articles, Li

Cloning and characterization of the pknA gene from Streptomyces coelicolo A3(2), coding for the Mn2+ dependent protein Ser/Thr kinase.
Biochem Biophys Res Commun. 2000 Dec 29;279(3):942-8.
PMID: 11162454 [PubMed - indexed for MEDLINE]

37: Dunkel IJ, Aledo A, Kernan NA, Kushner B, Bayer L, Gollamudi SV, Finlay JL, Abramson DH. Related Articles, Li

Successful treatment of metastatic retinoblastoma.
Cancer. 2000 Nov 15;89(10):2117-21.
PMID: 11066053 [PubMed - indexed for MEDLINE]

38: Tonka T, Weiser J. Related Articles, Li

Iridovirus infection in mayfly larvae.
J Invertebr Pathol. 2000 Oct;76(3):229-31. No abstract available.
PMID: 11023753 [PubMed - indexed for MEDLINE]

39: Yamada M. Related Articles, Li

Cerebral amyloid angiopathy: an overview.
Neuropathology. 2000 Mar;20(1):8-22. Review.
PMID: 10935432 [PubMed - indexed for MEDLINE]

40: Brockstein BE, Smiley C, Al-Sadir J, Williams SF. Related Articles, Li

Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors.
Bone Marrow Transplant. 2000 Apr;25(8):885-94.
PMID: 10808211 [PubMed - indexed for MEDLINE]

41: Havranek V, Kucera J, Horakova J, Vosecek V, Smolik J, Schwarz J, Sykorova I. Related Articles, Li

Matrix effects in PIXE analysis of aerosols and ashes.
Biol Trace Elem Res. 1999 Winter;71-72:431-42.
PMID: 10676519 [PubMed - indexed for MEDLINE]

42: Kucera J, Havranek V, Smolik J, Schwarz J, Vesely V, Kugler J, Sykorova I, Santroch J. Related Articles, Li

INAA and PIXE of atmospheric and combustion aerosols.
Biol Trace Elem Res. 1999 Winter;71-72:233-45.
PMID: 10676497 [PubMed - indexed for MEDLINE]

43: Abrey LE, Rosenblum MK, Papadopoulos E, Childs BH, Finlay JL. Related Articles, Li

High dose chemotherapy with autologous stem cell rescue in adults with malignant primary brain tumors.
J Neurooncol. 1999 Sep;44(2):147-53.
PMID: 10619498 [PubMed - indexed for MEDLINE]

44: Bendjelloul F, Maly P, Mandys V, Jirkovska M, Prokesova L, Tuckova L, Tlaskalova-Hogenova H. Related Articles, Li

Intercellular adhesion molecule-1 (ICAM-1) deficiency protects mice agains severe forms of experimentally induced colitis.
Clin Exp Immunol. 2000 Jan;119(1):57-63.
PMID: 10606964 [PubMed - indexed for MEDLINE]

45: Tada T, Takizawa T, Nakazato F, Kobayashi S, Koike K, Oguchi M, Ishii E, Amano Y. Related Articles, Li

Treatment of intracranial nongerminomatous germ-cell tumor by high-dose chemotherapy and autologous stem-cell rescue.
J Neurooncol. 1999 Aug;44(1):71-6.
PMID: 10582672 [PubMed - indexed for MEDLINE]

46: Related Articles, Li

Grovas AC, Boyett JM, Lindsley K, Rosenblum M, Yates AJ, Finlay

JL.

Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: report from the Children's Cancer Group.
Med Pediatr Oncol. 1999 Aug;33(2):83-7.
PMID: 10398181 [PubMed - indexed for MEDLINE]

47: Subramanyan S, Kennedy MJ. Related Articles, Li

Breast Cancer: High-Dose Therapy.
Oncologist. 1998;3(5):289-299.
PMID: 10388119 [PubMed - as supplied by publisher]

48: Hann DM, Garovoy N, Finkelstein B, Jacobsen PB, Azzarello LM, Fields KK Related Articles, Li

Fatigue and quality of life in breast cancer patients undergoing autologous st cell transplantation: a longitudinal comparative study.
J Pain Symptom Manage. 1999 May;17(5):311-9.
PMID: 10355210 [PubMed - indexed for MEDLINE]

49: Czyzewski EA, Goldman S, Mundt AJ, Nachman J, Rubin C, Hallahan DE Related Articles, Li

Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and stem cell rescue. A feasibil study.
Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):569-77.
PMID: 10348286 [PubMed - indexed for MEDLINE]

50: Bilgrami S, Chakraborty NG, Rodriguez-Pinero F, Khan AM, Feingold JM, Bona RD, Edwards RL, Dorsky D, Clive J, Mukherji B, Tutschka PJ Related Articles, Li

Varicella zoster virus infection associated with high-dose chemotherapy and autologous stem-cell rescue.
Bone Marrow Transplant. 1999 Mar;23(5):469-74.
PMID: 10100561 [PubMed - indexed for MEDLINE]

51: Hou JW, Wang TR. Related Articles, Li

Unusual features in children with inv dup(15) supernumerary marker: a study of genotype-phenotype correlation in Taiwan.
Eur J Pediatr. 1998 Feb;157(2):122-7.
PMID: 9504785 [PubMed - indexed for MEDLINE]

52: Maurer K, Heitger A, Schwaighofer H, Fink FM, Niederweiser D. Related Articles, Li

Double high-dose chemotherapy with autologous peripheral stem cell rescue relapsed Wilms' tumor.
Bone Marrow Transplant. 1997 Dec;20(12):1111-3.
PMID: 9466289 [PubMed - indexed for MEDLINE]

53: Zujewski J, Nelson A, Abrams J. Related Articles, Li

Much ado about not...enough data: high-dose chemotherapy with autologous stem cell rescue for breast cancer.
J Natl Cancer Inst. 1998 Feb 4;90(3):200-9. Review.
PMID: 9462677 [PubMed - indexed for MEDLINE]

54: Dunkel IJ, Boyett JM, Yates A, Rosenblum M, Garvin JH Jr, Bostrom BC, Goldman S, Sender LS, Gardner SL, Li H, Allen JC, Finlay JL Related Articles, Li

High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group
J Clin Oncol. 1998 Jan;16(1):222-8.

PMID: 9440746 [PubMed - indexed for MEDLINE]

☐ **55:** Kleiner S, Kirsch A, Schwaner I, Kingreen D, Schwella N, Huhn D, Siegert W. Related Articles, Li

High-dose chemotherapy with carboplatin, etoposide and ifosfamide followe by autologous stem cell rescue in patients with relapsed or refractory malign lymphomas: a phase I/II study.
Bone Marrow Transplant. 1997 Dec;20(11):953-9.
PMID: 9422474 [PubMed - indexed for MEDLINE]

☐ **56:** Ladenstein R, Peters C, Gadner H. Related Articles, Li

The present role of bone marrow and stem cell transplantation in the therapy children with acute leukemia.
Ann N Y Acad Sci. 1997 Sep 17;824:38-64. Review.
PMID: 9382454 [PubMed - indexed for MEDLINE]

☐ **57:** Meisenberg BR, Miller WE, McMillan R, Callaghan M, Sloan C, Brehm T, Kosty MP, Kroener J, Longmire R, Saven A, Piro LD. Related Articles, Li

Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies.
J Clin Oncol. 1997 Jan;15(1):11-7.
PMID: 8996119 [PubMed - indexed for MEDLINE]

☐ **58:** Beyer J, Kingreen D, Krause M, Schleicher J, Schwaner I, Schwella N, Huhn D, Siegert W. Related Articles, Li

Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy.
Cancer. 1997 Jan 1;79(1):161-8.
PMID: 8988741 [PubMed - indexed for MEDLINE]

☐ **59:** Brockstein BE, Ross AA, Moss TJ, Kahn DG, Hollingsworth K, Williams SF. Related Articles, Li

Tumor cell contamination of bone marrow harvest products: clinical consequences in a cohort of advanced-stage breast cancer patients undergoin high-dose chemotherapy.
J Hematother. 1996 Dec;5(6):617-24.
PMID: 9117250 [PubMed - indexed for MEDLINE]

☐ **60:** Pakandl M, Eid Ahmed N, Licois D, Coudert P. Related Articles, Li

Eimeria magna Perard, 1925: study of the endogenous development of paren and precocious strains.
Vet Parasitol. 1996 Oct 25;65(3-4):213-22.
PMID: 8983147 [PubMed - indexed for MEDLINE]

☐ **61:** Siegert W, Beyer J. Related Articles, Li

High-dose chemotherapy and ASCR of patients with relapsed or refractory germ cell tumors: long-term follow-up.
Bone Marrow Transplant. 1996 Sep;18 Suppl 1:S60. No abstract available.
PMID: 8899176 [PubMed - indexed for MEDLINE]

☐ **62:** Meisenberg B, Gollard R, Brehm T, McMillan R, Miller W. Related Articles, Li

Prophylactic antibiotics eliminate bacteremia and allow safe outpatient management following high-dose chemotherapy and autologous stem cell rescue.
Support Care Cancer. 1996 Sep;4(5):364-9.
PMID: 8883230 [PubMed - indexed for MEDLINE]

☐ **63:** Dunkel IJ, Finlay JL. Related Articles, Li

High dose chemotherapy with autologous stem cell rescue for patients with

medulloblastoma.
J Neurooncol. 1996 Jul;29(1):69-74. Review.
PMID: 8817417 [PubMed - indexed for MEDLINE]

64: Hempel L, Kremens B, Weirich A, Graf N, Zintl F, Ludwig R. Related Articles, Li

High dose consolidation with autologous stem cell rescue (ASCR) for nephroblastoma initially treated according to the SIOP 9/GPOH trial and stu
Klin Padiatr. 1996 Jul-Aug;208(4):186-9.
PMID: 8776705 [PubMed - indexed for MEDLINE]

65: Brockstein BE, Williams SF. Related Articles, Li

High-dose chemotherapy with autologous stem cell rescue for breast cancer: yesterday, today and tomorrow.
Stem Cells. 1996 Jan;14(1):79-89. Review.
PMID: 8820954 [PubMed - indexed for MEDLINE]

66: Pakandl M, Gaca K, Drouet-viard F, Coudert P. Related Articles, Li

Eimeria coecicola Cheissin 1947: endogenous development in gut-associatec lymphoid tissue.
Parasitol Res. 1996;82(4):347-51.
PMID: 8740551 [PubMed - indexed for MEDLINE]

67: Fields KK, Elfenbein GJ, Lazarus HM, Cooper BW, Perkins JB, Creger RJ, Ballester OF, Hiemenz JH, Janssen WE, Zorsky PE. Related Articles, Li

Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given ov 6 days followed by autologous stem-cell rescue: toxicity profile.
J Clin Oncol. 1995 Feb;13(2):323-32.
PMID: 7844593 [PubMed - indexed for MEDLINE]

68: Miksits K, Beyer J, Siegert W. Related Articles, Li

Serum concentrations of G-CSF during high-dose chemotherapy with autologous stem cell rescue.
Bone Marrow Transplant. 1993 May;11(5):375-7.
PMID: 7684939 [PubMed - indexed for MEDLINE]

69: Manzo J, Amodio-Groton MA, Kleinmann K. Related Articles, Li

Antibiotic cost control measures in a hospital pharmacy.
Clin Ther. 1993;15 Suppl A:37-43.
PMID: 8513460 [PubMed - indexed for MEDLINE]

70: Fields KK, Perkins JP, Hiemenz JW, Zorsky PE, Janssen WE, Kronish LE, Machak MC, Elfenbein GJ Related Articles, Li

Intensive dose ifosfamide, carboplatin, and etoposide followed by autologou stem cell rescue: results of a phase I/II study in breast cancer patients.
Surg Oncol. 1993;2(1):87-95.
PMID: 7902764 [PubMed - indexed for MEDLINE]

71: Williams SF, Gilewski T, Mick R, Bitran JD. Related Articles, Li

High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report.
J Clin Oncol. 1992 Nov;10(11):1743-7.
PMID: 1357109 [PubMed - indexed for MEDLINE]

72: Williams SF, Mick R, Desser R, Golick J, Beschorner J, Bitran JD. Related Articles, Li

High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer.
J Clin Oncol. 1989 Dec;7(12):1824-30.
PMID: 2511276 [PubMed - indexed for MEDLINE]

h cb hg e e e fcg e ch b e

h cb hg e e e fcg e ch b e

Items 1 - 157 of 157 One p

1: Vaccaro L, Cross K, Kleinjung J, Strauss S, Thomas D, Wharton S, Skehel J, Fraternali F. Related Articles, Li

Plasticity of Influenza Haemagglutinin Fusion Peptides and their Interaction with Lipid Bilayers.
Biophys J. 2004 Oct 8 [Epub ahead of print]
PMID: 15475582 [PubMed - as supplied by publisher]

2: Kovacs GG, Kalev O, Budka H. Related Articles, Li

Contribution of neuropathology to the understanding of human prion disease.
Folia Neuropathol. 2004;42 Suppl A:69-76. Review.
PMID: 15449461 [PubMed - indexed for MEDLINE]

3: Gruys E. Related Articles, Li

Protein folding pathology in domestic animals.
J Zhejiang Univ Sci. 2004 Oct;5(10):1226-38.
PMID: 15362194 [PubMed - in process]

4: Broxmeyer L. Related Articles, Li

Is mad cow disease caused by a bacteria?
Med Hypotheses. 2004;63(4):731-9.
PMID: 15325025 [PubMed - in process]

5: Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Related Articles, Li

Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient.
Lancet. 2004 Aug 7;364(9433):527-9.
PMID: 15302196 [PubMed - indexed for MEDLINE]

6: Dimcheff DE, Faasse MA, McAtee FJ, Portis JL. Related Articles, Li

Endoplasmic reticulum (ER) stress induced by a neurovirulent mouse retrovir is associated with prolonged BiP binding and retention of a viral protein in the ER.
J Biol Chem. 2004 Aug 6;279(32):33782-90. Epub 2004 Jun 03.
PMID: 15178688 [PubMed - indexed for MEDLINE]

7: Head MW, Bunn TJ, Bishop MT, McLoughlin V, Lowrie S, McKimmie CS, Williams MC, McCardle L, MacKenzie J, Knight R, Will RG, Ironside JW. Related Articles, Li

Prion protein heterogeneity in sporadic but not variant Creutzfeldt-Jakob disease: UK cases 1991-2002.
Ann Neurol. 2004 Jun;55(6):851-9.
PMID: 15174020 [PubMed - indexed for MEDLINE]

8: Petzold GC, Westner I, Bohner G, Einhaupl KM, Kretzschmar HA, Valdueza JM. Related Articles, Li

False-positive pulvinar sign on MRI in sporadic Creutzfeldt-Jakob disease.
Neurology. 2004 Apr 13;62(7):1235-6. No abstract available.
PMID: 15079042 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg

9: Tsuchiya K, Yagishita S, Ikeda K, Sano M, Taki K, Hashimoto K, Watabiki S, Mizusawa H. Related Articles, Li

Coexistence of CJD and Alzheimer's disease: an autopsy case showing typical clinical features of CJD.
Neuropathology. 2004 Mar;24(1):46-55.
PMID: 15068172 [PubMed - indexed for MEDLINE]

10: Richardson JP, Mohammad SS, Pavitt GD. Related Articles, Li

Mutations causing childhood ataxia with central nervous system hypomyelination reduce eukaryotic initiation factor 2B complex formation a activity.
Mol Cell Biol. 2004 Mar;24(6):2352-63.
PMID: 14993275 [PubMed - indexed for MEDLINE]

11: Hamir AN, Miller JM, O'Rourke KI, Bartz JC, Stack MJ, Chaplin MJ. Related Articles, Li

Transmission of transmissible mink encephalopathy to raccoons (Procyon lotor) by intracerebral inoculation.
J Vet Diagn Invest. 2004 Jan;16(1):57-63.
PMID: 14974848 [PubMed - indexed for MEDLINE]

12: Casalone C, Zanusso G, Acutis P, Ferrari S, Capucci L, Tagliavini F, Monaco S, Caramelli M. Related Articles, Li

Identification of a second bovine amyloidotic spongiform encephalopathy: molecular similarities with sporadic Creutzfeldt-Jakob disease.
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3065-70. Epub 2004 Feb 17.
PMID: 14970340 [PubMed - indexed for MEDLINE]

13: Porter SR. Related Articles, Li

Prion disease: possible implications for oral health care.
J Am Dent Assoc. 2003 Nov;134(11):1486-91. Review.
PMID: 14664268 [PubMed - indexed for MEDLINE]

14: Will RG. Related Articles, Li

Acquired prion disease: iatrogenic CJD, variant CJD, kuru.
Br Med Bull. 2003;66:255-65. Review.
PMID: 14522863 [PubMed - indexed for MEDLINE]

15: Cambier DM, Kantarci K, Worrell GA, Westmoreland BF, Aksamit AJ. Related Articles, Li

Lateralized and focal clinical, EEG, and FLAIR MRI abnormalities in Creutzfeldt-Jakob disease.
Clin Neurophysiol. 2003 Sep;114(9):1724-8.
PMID: 12948802 [PubMed - indexed for MEDLINE]

16: Hamir AN, Miller JM, Cutlip RC, Stack MJ, Chaplin MJ, Jenny AL, Williams ES. Related Articles, Li

Experimental inoculation of scrapie and chronic wasting disease agents in raccoons (Procyon lotor).
Vet Rec. 2003 Jul 26;153(4):121-3. No abstract available.
PMID: 12918830 [PubMed - indexed for MEDLINE]

17: Berest V, Rutkowski M, Rolka K, Legowska A, Debska G, Stepkowski D, Szewczyk A. Related Articles, Li

The prion peptide forms ion channels in planar lipid bilayers.
Cell Mol Biol Lett. 2003;8(2):353-62.
PMID: 12813570 [PubMed - indexed for MEDLINE]

18: Chiesa R, Piccardo P, Quaglio E, Drisaldi B, Si-Hoe SL, Takao M, Ghetti B, Harris DA. Related Articles, Li

Molecular distinction between pathogenic and infectious properties of the pri

protein.
J Virol. 2003 Jul;77(13):7611-22.
PMID: 12805461 [PubMed - indexed for MEDLINE]

19: Lewis V, Collins S, Hill AF, Boyd A, McLean CA, Smith M, Masters CL. Related Articles, Li

Novel prion protein insert mutation associated with prolonged neurodegenerative illness.
Neurology. 2003 May 27;60(10):1620-4.
PMID: 12771252 [PubMed - indexed for MEDLINE]

20: Harris DA, Chiesa R, Drisaldi B, Quaglio E, Migheli A, Piccardo P, Ghetti B. Related Articles, Li

A murine model of a familial prion disease.
Clin Lab Med. 2003 Mar;23(1):175-86. Review.
PMID: 12733431 [PubMed - indexed for MEDLINE]

21: Rusu V. Related Articles, Li

["Nosologic crisis" in the era of molecular medicine]
Rev Med Chir Soc Med Nat Iasi. 2002 Jan-Mar;106(1):7-9. Romanian. No abstract availabl
PMID: 12635352 [PubMed - indexed for MEDLINE]

22: [No authors listed] Related Articles, Li

Fatal degenerative neurologic illnesses in men who participated in wild game feasts--Wisconsin, 2002.
MMWR Morb Mortal Wkly Rep. 2003 Feb 21;52(7):125-7.
PMID: 12617536 [PubMed - indexed for MEDLINE]

23: Irani DN. Related Articles, Li

The classic and variant forms of Creutzfeldt-Jakob disease.
Semin Clin Neuropsychiatry. 2003 Jan;8(1):71-9. Review.
PMID: 12567334 [PubMed - indexed for MEDLINE]

24: van Roon-Mom WM, Reid SJ, Jones AL, MacDonald ME, Faull RL, Snell RG. Related Articles, Li

Insoluble TATA-binding protein accumulation in Huntington's disease corte
Brain Res Mol Brain Res. 2002 Dec 30;109(1-2):1-10.
PMID: 12531510 [PubMed - indexed for MEDLINE]

25: Gomez-Isla T, Irizarry MC, Mariash A, Cheung B, Soto O, Schrump S, Sondel J, Kotilinek L, Day J, Schwarzschild MA, Cha JH, Newell K, Miller DW, Ueda K, Young AB, Hyman BT, Ashe KH. Related Articles, Li

Motor dysfunction and gliosis with preserved dopaminergic markers in huma alpha-synuclein A30P transgenic mice.
Neurobiol Aging. 2003 Mar-Apr;24(2):245-58.
PMID: 12498958 [PubMed - indexed for MEDLINE]

26: Loftus SK, Erickson RP, Walkley SU, Bryant MA, Incao A, Heidenreich RA, Pavan WJ. Related Articles, Li

Rescue of neurodegeneration in Niemann-Pick C mice by a prion-promoter-driven Npc1 cDNA transgene.
Hum Mol Genet. 2002 Nov 15;11(24):3107-14.
PMID: 12417532 [PubMed - indexed for MEDLINE]

27: Ceciliani F, Pergami P. Related Articles, Li

Infective proteins: the prion puzzle.
Curr Protein Pept Sci. 2001 Sep;2(3):191-204. Review.
PMID: 12369932 [PubMed - indexed for MEDLINE]

28: Kirkitadze MD, Bitan G, Teplow DB. Related Articles, Li

Paradigm shifts in Alzheimer's disease and other neurodegenerative disorder the emerging role of oligomeric assemblies.
J Neurosci Res. 2002 Sep 1;69(5):567-77. Review.
PMID: 12210822 [PubMed - indexed for MEDLINE]

29: O'Rourke KI, Duncan JV, Logan JR, Anderson AK, Norden DK, Williams ES, Combs BA, Stobart RH, Moss GE, Sutton DL. Related Articles, Li

Active surveillance for scrapie by third eyelid biopsy and genetic susceptibil testing of flocks of sheep in Wyoming.
Clin Diagn Lab Immunol. 2002 Sep;9(5):966-71.
PMID: 12204945 [PubMed - indexed for MEDLINE]

30: Zarranz JJ, Berenguer J, Saiz A, Ribalta MT. Related Articles, Li

[Rapidly progressive visual disorder and cognitive impairment in a 66-year-c woman]
Med Clin (Barc). 2002 Jun 29;119(4):149-57. Spanish. No abstract available.
PMID: 12106528 [PubMed - indexed for MEDLINE]

31: Yanagihara C, Yasuda M, Maeda K, Miyoshi K, Nishimura Y. Related Articles, Li

Rapidly progressive dementia syndrome associated with a novel four extra repeat mutation in the prion protein gene.
J Neurol Neurosurg Psychiatry. 2002 Jun;72(6):788-91.
PMID: 12023426 [PubMed - indexed for MEDLINE]

32: Croes EA, van Gool WA, Jansen GH, van Duijn CM. Related Articles, Li

[Creutzfeldt-Jakob disease: diagnosis, incidence, prevention and treatment]
Ned Tijdschr Geneeskd. 2002 Apr 20;146(16):750-4. Dutch.
PMID: 11998351 [PubMed - indexed for MEDLINE]

33: Mishra RS, Gu Y, Bose S, Verghese S, Kalepu S, Singh N. Related Articles, Li

Cell surface accumulation of a truncated transmembrane prion protein in Gerstmann-Straussler-Scheinker disease P102L.
J Biol Chem. 2002 Jul 5;277(27):24554-61. Epub 2002 Apr 19.
PMID: 11967261 [PubMed - indexed for MEDLINE]

34: Tuo W, O'Rourke KI, Zhuang D, Cheevers WP, Spraker TR, Knowles DP. Related Articles, Li

Pregnancy status and fetal prion genetics determine PrPSc accumulation in placentomes of scrapie-infected sheep.
Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6310-5. Epub 2002 Apr 16.
PMID: 11959902 [PubMed - indexed for MEDLINE]

35: Cervenakova L, Brown P, Hammond DJ, Lee CA, Saenko EL. Related Articles, Li

Factor VIII and transmissible spongiform encephalopathy: the case for safety
Haemophilia. 2002 Mar;8(2):63-75. Review.
PMID: 11952840 [PubMed - indexed for MEDLINE]

36: Cibula JE, Eisenschenk S, Gold M, Eskin TA, Gilmore RL, Heilman KM. Related Articles, Li

Progressive dementia and hypersomnolence with dream-enacting behavior: oneiric dementia.
Arch Neurol. 2002 Apr;59(4):630-4.
PMID: 11939899 [PubMed - indexed for MEDLINE]

37: Solvason HB, Harris B, Zeifert P, Flores BH, Hayward C. Related Articles, Li

Psychological versus biological clinical interpretation: a patient with prion disease.
Am J Psychiatry. 2002 Apr;159(4):528-37. No abstract available.
PMID: 11925288 [PubMed - indexed for MEDLINE]

38: Dupuis L, Mbebi C, Gonzalez de Aguilar JL, Rene F, Muller A, de Tapia M, Loeffler JP Related Articles, Li

Loss of prion protein in a transgenic model of amyotrophic lateral sclerosis.
Mol Cell Neurosci. 2002 Feb;19(2):216-24.
PMID: 11860274 [PubMed - indexed for MEDLINE]

39: Autret A, Lucas B, Mondon K, Hommet C, Corcia P, Saudeau D, de Toffol B. Related Articles, Li

Sleep and brain lesions: a critical review of the literature and additional new cases.
Neurophysiol Clin. 2001 Dec;31(6):356-75. Review.
PMID: 11810986 [PubMed - indexed for MEDLINE]

40: Lovestone S, McLoughlin DM. Related Articles, Li

Protein aggregates and dementia: is there a common toxicity?
J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):152-61. Review.
PMID: 11796764 [PubMed - indexed for MEDLINE]

41: Esteban JC, Atares B, Zarranz JJ, Velasco F, Lambarri I. Related Articles, Li

Dementia, amyotrophy, and periodic complexes on the electroencephalogran a diagnostic challenge.
Arch Neurol. 2001 Oct;58(10):1669-72.
PMID: 11594927 [PubMed - indexed for MEDLINE]

42: La Spada AR, Fu YH, Sopher BL, Libby RT, Wang X, Li LY, Einum DD, Huang J, Possin DE, Smith AC, Martinez RA, Koszdin KL, Treuting PM, Ware CB, Hurley JB, Ptacek LJ, Chen S. Related Articles, Li

Polyglutamine-expanded ataxin-7 antagonizes CRX function and induces co rod dystrophy in a mouse model of SCA7.
Neuron. 2001 Sep 27;31(6):913-27. Erratum in: Neuron 2001 Dec 6;32(5):957-8.
PMID: 11580893 [PubMed - indexed for MEDLINE]

43: Dervaux A, Vicart S, Lopes F, Le Borgne MH. Related Articles, Li

[Psychiatric manifestations of a new variant of Creutzfeldt-Jakob disease. Apropos of a case]
Encephale. 2001 Mar-Apr;27(2):194-7. French.
PMID: 11407273 [PubMed - indexed for MEDLINE]

44: Masters CL, Beyreuther K. Related Articles, Li

The Worster-Drought syndrome and other syndromes of dementia with spast paraparesis: the paradox of molecular pathology.
J Neuropathol Exp Neurol. 2001 Apr;60(4):317-9. Review. No abstract available.
PMID: 11305866 [PubMed - indexed for MEDLINE]

45: Chiesa R, Pestronk A, Schmidt RE, Tourtellotte WG, Ghetti B, Piccardo P, Harris DA. Related Articles, Li

Primary myopathy and accumulation of PrPSc-like molecules in peripheral tissues of transgenic mice expressing a prion protein insertional mutation.
Neurobiol Dis. 2001 Apr;8(2):279-88.
PMID: 11300723 [PubMed - indexed for MEDLINE]

46: Mercer JF. Related Articles, Li

The molecular basis of copper-transport diseases.
Trends Mol Med. 2001 Feb;7(2):64-9. Review.
PMID: 11286757 [PubMed - indexed for MEDLINE]

47: Tuo W, Zhuang D, Knowles DP, Cheevers WP, Sy MS, O'Rourke KI. Related Articles, Li

Prp-c and Prp-Sc at the fetal-maternal interface.
J Biol Chem. 2001 May 25;276(21):18229-34. Epub 2001 Mar 27.

PMID: 11274195 [PubMed - indexed for MEDLINE]

48: Sghirlanzoni A, Carella F. Related Articles, Li

The insomnia plague: a Gabriel Garcia Marquez story.
Neurol Sci. 2000 Aug;21(4):251-3.
PMID: 11214666 [PubMed - indexed for MEDLINE]

49: Oomkes C, van Knapen F. Related Articles, Li

Cows, cats, and FSE: death penalty justified?
Vet Q. 2001 Jan;23(1):51-2.
PMID: 11206004 [PubMed - indexed for MEDLINE]

50: Bowen J, Mitchell T, Pearce R, Quinn N. Related Articles, Li

Chorea in new variant Creutzfeldt-Jacob disease.
Mov Disord. 2000 Nov;15(6):1284-5. No abstract available.
PMID: 11104228 [PubMed - indexed for MEDLINE]

51: Lones MA, Kirov I, Said JW, Shintaku IP, Neudorf S. Related Articles, Li

Post-transplant lymphoproliferative disorder after autologous peripheral stem cell transplantation in a pediatric patient.
Bone Marrow Transplant. 2000 Nov;26(9):1021-4. Review.
PMID: 11100284 [PubMed - indexed for MEDLINE]

52: Tagliavini F, Lievens PM, Tranchant C, Warter JM, Mohr M, Giaccone G, Perini F, Rossi G, Salmona M, Piccardo P, Ghetti B, Beavis RC, Bugiani O, Frangione B, Prelli F. Related Articles, Li

A 7-kDa prion protein (PrP) fragment, an integral component of the PrP regi required for infectivity, is the major amyloid protein in Gerstmann-Straussle Scheinker disease A117V.
J Biol Chem. 2001 Feb 23;276(8):6009-15. Epub 2000 Nov 21.
PMID: 11087738 [PubMed - indexed for MEDLINE]

53: Scaravilli F, Cordery RJ, Kretzschmar H, Gambetti P, Brink B, Fritz V, Temlett J, Kaplan C, Fish D, An SF, Schulz-Schaeffer WJ, Rossor MN. Related Articles, Li

Sporadic fatal insomnia: a case study.
Ann Neurol. 2000 Oct;48(4):665-8.
PMID: 11026452 [PubMed - indexed for MEDLINE]

54: Wada R, Tifft CJ, Proia RL. Related Articles, Li

Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation.
Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10954-9.
PMID: 11005868 [PubMed - indexed for MEDLINE]

55: Kovari E, Leuba G, Savioz A, Saini K, Anastasiu R, Miklossy J, Bouras C. Related Articles, Li

Familial frontotemporal dementia with ubiquitin inclusion bodies and witho motor neuron disease.
Acta Neuropathol (Berl). 2000 Oct;100(4):421-6.
PMID: 10985702 [PubMed - indexed for MEDLINE]

56: Wong BS, Pan T, Liu T, Li R, Petersen RB, Jones IM, Gambetti P, Brown DR, Sy MS. Related Articles, Li

Prion disease: A loss of antioxidant function?
Biochem Biophys Res Commun. 2000 Aug 28;275(2):249-52. Review.
PMID: 10964653 [PubMed - indexed for MEDLINE]

57: de Pedro Cuesta J. Related Articles, Li

[The future and problems of vigilance in Creutzfeldt-Jakob disease]

Rev Neurol. 2000 Jul 16-31;31(2):167-70. Spanish.
PMID: 10951677 [PubMed - indexed for MEDLINE]

58: Merino-Ramirez MA, Escudero-Torrella M. Related Articles, Li

[Sleep disorders associated to prion diseases]
Rev Neurol. 2000 Jul 16-31;31(2):147-51. Spanish.
PMID: 10951672 [PubMed - indexed for MEDLINE]

59: Brun A, Castilla J, Torres JM. Related Articles, Li

[Transmissible spongiform encephalopathies in animals]
Rev Neurol. 2000 Jul 16-31;31(2):133-7. Spanish.
PMID: 10951669 [PubMed - indexed for MEDLINE]

60: Rossi G, Giaccone G, Giampaolo L, Iussich S, Puoti G, Frigo M, Cavaletti G, Frattola L, Bugiani O, Tagliavini F. Related Articles, Li

Creutzfeldt-Jakob disease with a novel four extra-repeat insertional mutation the PrP gene.
Neurology. 2000 Aug 8;55(3):405-10.
PMID: 10932276 [PubMed - indexed for MEDLINE]

61: Johnson WG. Related Articles, Li

Late-onset neurodegenerative diseases--the role of protein insolubility.
J Anat. 2000 May;196 (Pt 4):609-16. Review.
PMID: 10923991 [PubMed - indexed for MEDLINE]

62: Mitrova E, Belay G. Related Articles, Li

Creutzfeldt-Jakob disease risk in Slovak recipients of human pituitary growtl hormone.
Bratisl Lek Listy. 1999 Apr;100(4):187-91.
PMID: 10914140 [PubMed - indexed for MEDLINE]

63: Lopez Garcia F, Zahn R, Riek R, Wuthrich K. Related Articles, Li

NMR structure of the bovine prion protein.
Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8334-9.
PMID: 10899999 [PubMed - indexed for MEDLINE]

64: Wetterberg L. Related Articles, Li

[Mental disease a heritage. New genetic knowledge can reveal "public diseases" such as autism, dyslexia, alcoholism, anorexia, schizophrenia]
Lakartidningen. 2000 Feb 9;97(6):558-62, 565-7. Review. Swedish.
PMID: 10707480 [PubMed - indexed for MEDLINE]

65: Cabrera-Gomez JA, Lopez-Saura P. Related Articles, Li

[Recent advances in the treatment the nervous system disorders with interferon-alpha]
Rev Neurol. 1999 Dec 16-31;29(12):1225-35. Review. Spanish.
PMID: 10652752 [PubMed - indexed for MEDLINE]

66: Montagna P. Related Articles, Li

[Fatal familial insomnia: clinical, laboratory and pathological features]
Rev Neurol. 1999 Dec 1-15;29(11):1006-9. Spanish.
PMID: 10637858 [PubMed - indexed for MEDLINE]

67: Zahn R, Liu A, Luhrs T, Riek R, von Schroetter C, Lopez Garcia F, Billeter M, Calzolai L, Wider G, Wuthrich K. Related Articles, Li

NMR solution structure of the human prion protein.
Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):145-50.
PMID: 10618385 [PubMed - indexed for MEDLINE]

68: Boellaard JW, Brown P, Tateishi J. Related Articles, Li

Gerstmann-Straussler-Scheinker disease- the dilemma of molecular and clini correlations.
Clin Neuropathol. 1999 Nov-Dec;18(6):271-85. Review.
PMID: 10580553 [PubMed - indexed for MEDLINE]

69: [No authors listed] Related Articles, Li

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 28-1999. A 68-year-old woman with rapidly progressive dementia and a gait disorder.
N Engl J Med. 1999 Sep 16;341(12):901-8. No abstract available.
PMID: 10486423 [PubMed - indexed for MEDLINE]

70: Mohr M, Tranchant C, Steinmetz G, Floquet J, Grignon Y, Warter JM. Related Articles, Li

Gerstmann-Straussler-Scheinker disease and the French-Alsatian A117V variant.
Clin Exp Pathol. 1999;47(3-4):161-75.
PMID: 10472736 [PubMed - indexed for MEDLINE]

71: Keohane C. Related Articles, Li

The human prion diseases. A review with special emphasis on new variant C and comments on surveillance.
Clin Exp Pathol. 1999;47(3-4):125-32. Review.
PMID: 10472732 [PubMed - indexed for MEDLINE]

72: Farrer M, Gwinn-Hardy K, Hutton M, Hardy J. Related Articles, Li

The genetics of disorders with synuclein pathology and parkinsonism.
Hum Mol Genet. 1999;8(10):1901-5. Review.
PMID: 10469843 [PubMed - indexed for MEDLINE]

73: Dobson CM. Related Articles, Li

Protein misfolding, evolution and disease.
Trends Biochem Sci. 1999 Sep;24(9):329-32. Review. No abstract available.
PMID: 10470028 [PubMed - indexed for MEDLINE]

74: Jiang TT, Moses H, Gordon H, Obah E. Related Articles, Li

Sporadic Creutzfeldt-Jakob disease presenting as major depression.
South Med J. 1999 Aug;92(8):807-8.
PMID: 10456721 [PubMed - indexed for MEDLINE]

75: Zanusso G, Petersen RB, Jin T, Jing Y, Kanoush R, Ferrari S, Gambetti P, Singh N. Related Articles, Li

Proteasomal degradation and N-terminal protease resistance of the codon 14: mutant prion protein.
J Biol Chem. 1999 Aug 13;274(33):23396-404.
PMID: 10438517 [PubMed - indexed for MEDLINE]

76: Martin WJ, Anderson D. Related Articles, Li

Stealth virus epidemic in the Mohave Valley: severe vacuolating encephalopathy in a child presenting with a behavioral disorder.
Exp Mol Pathol. 1999 Apr;66(1):19-30.
PMID: 10331961 [PubMed - indexed for MEDLINE]

77: Scherzinger E, Sittler A, Schweiger K, Heiser V, Lurz R, Hasenbank R, Bates GP, Lehrach H, Wanker EE. Related Articles, Li

Self-assembly of polyglutamine-containing huntingtin fragments into amyloi like fibrils: implications for Huntington's disease pathology.
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4604-9.

PMID: 10200309 [PubMed - indexed for MEDLINE]

☐ **78:** Wetterberg L. Related Articles, Li

[Complex hereditary diseases with psychiatric symptoms]
Tidsskr Nor Laegeforen. 1999 Feb 28;119(6):839-45. Review. Norwegian.
PMID: 10101948 [PubMed - indexed for MEDLINE]

☐ **79:** Kropp S, Zerr I, Schulz-Schaeffer WJ, Riedemann C, Bodemer M, Laske C, Kretzschmar HA, Poser S. Related Articles, Li

Increase of neuron-specific enolase in patients with Creutzfeldt-Jakob diseas
Neurosci Lett. 1999 Feb 12;261(1-2):124-6.
PMID: 10081943 [PubMed - indexed for MEDLINE]

☐ **80:** Yamada M, Tomimitsu H, Yokota T, Tomi H, Sunohara N, Mukoyama M, Itoh Y, Suematsu N, Otomo E, Okeda R, Matsushita M, Mizusawa H. Related Articles, Li

Involvement of the spinal posterior horn in Gerstmann-Straussler-Scheinker disease (PrP P102L).
Neurology. 1999 Jan 15;52(2):260-5.
PMID: 9932941 [PubMed - indexed for MEDLINE]

☐ **81:** Marcotte EM, Eisenberg D. Related Articles, Li

Chicken prion tandem repeats form a stable, protease-resistant domain.
Biochemistry. 1999 Jan 12;38(2):667-76.
PMID: 9888807 [PubMed - indexed for MEDLINE]

☐ **82:** Arnold SE, Trojanowski JQ, Parchi P. Related Articles, Li

Protease resistant prion proteins are not present in sporadic "poor outcome" schizophrenia.
J Neurol Neurosurg Psychiatry. 1999 Jan;66(1):90-2.
PMID: 9886461 [PubMed - indexed for MEDLINE]

☐ **83:** Chiesa R, Piccardo P, Ghetti B, Harris DA. Related Articles, Li

Neurological illness in transgenic mice expressing a prion protein with an insertional mutation.
Neuron. 1998 Dec;21(6):1339-51.
PMID: 9883727 [PubMed - indexed for MEDLINE]

☐ **84:** Axelsson S. Related Articles, Li

Physical bioenergetics of degradation-resistant proteins in diseases and aging
Med Hypotheses. 1998 Jul;51(1):47-51. Review.
PMID: 9881836 [PubMed - indexed for MEDLINE]

☐ **85:** Zerr I, Giese A, Windl O, Kropp S, Schulz-Schaeffer W, Riedemann C, Skworc K, Bodemer M, Kretzschmar HA, Poser S. Related Articles, Li

Phenotypic variability in fatal familial insomnia (D178N-129M) genotype.
Neurology. 1998 Nov;51(5):1398-405.
PMID: 9818868 [PubMed - indexed for MEDLINE]

☐ **86:** Jimenez-Huete A, Lievens PM, Vidal R, Piccardo P, Ghetti B, Tagliavini F, Frangione B, Prelli F. Related Articles, Li

Endogenous proteolytic cleavage of normal and disease-associated isoforms the human prion protein in neural and non-neural tissues.
Am J Pathol. 1998 Nov;153(5):1561-72.
PMID: 9811348 [PubMed - indexed for MEDLINE]

☐ **87:** Hardy J, Gwinn-Hardy K. Related Articles, Li

Genetic classification of primary neurodegenerative disease.
Science. 1998 Nov 6;282(5391):1075-9. Review.
PMID: 9804538 [PubMed - indexed for MEDLINE]

88: Hauw JJ, Lazarini F, Sazdovitch V, Seilhean D, Suarez S, Colle MA, Boularand S, Delasnerie-Laupretre N, Duyckaerts C. Related Articles, Li

[Diseases transmitted by non-conventional agents ("prions"): nosology and diagnosis]
Rev Neurol (Paris). 1998 Feb;154(2):131-7. Review. French.
PMID: 9773033 [PubMed - indexed for MEDLINE]

89: Ironside JW. Related Articles, Li

Neuropathological findings in new variant CJD and experimental transmissic of BSE.
FEMS Immunol Med Microbiol. 1998 Jun;21(2):91-5. Review.
PMID: 9684997 [PubMed - indexed for MEDLINE]

90: Gambetti P, Lugaresi E. Related Articles, Li

Conclusions of the symposium.
Brain Pathol. 1998 Jul;8(3):571-5.
PMID: 9669714 [PubMed - indexed for MEDLINE]

91: Fisher E, Telling G, Collinge J. Related Articles, Li

Prions and the prion disorders.
Mamm Genome. 1998 Jul;9(7):497-502. Review.
PMID: 9657843 [PubMed - indexed for MEDLINE]

92: Parchi P, Chen SG, Brown P, Zou W, Capellari S, Budka H, Hainfellner J, Reyes PF, Golden GT, Hauw JJ, Gajdusek DC, Gambetti P. Related Articles, Li

Different patterns of truncated prion protein fragments correlate with distinct phenotypes in P102L Gerstmann-Straussler-Scheinker disease.
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8322-7.
PMID: 9653185 [PubMed - indexed for MEDLINE]

93: Stewart GE, Ironside JW. Related Articles, Li

New variant Creutzfeldt-Jakob disease.
Curr Opin Neurol. 1998 Jun;11(3):259-62. Review.
PMID: 9642546 [PubMed - indexed for MEDLINE]

94: Schwarz M, De Bleser R, Poeck K, Weis J. Related Articles, Li

A case of primary progressive aphasia. A 14-year follow-up study with neuropathological findings.
Brain. 1998 Jan;121 (Pt 1):115-26.
PMID: 9549492 [PubMed - indexed for MEDLINE]

95: Lowe J. Related Articles, Li

Establishing a pathological diagnosis in degenerative dementias.
Brain Pathol. 1998 Apr;8(2):403-6. Review.
PMID: 9546296 [PubMed - indexed for MEDLINE]

96: Morimoto RI, Kline MP, Bimston DN, Cotto JJ. Related Articles, Li

The heat-shock response: regulation and function of heat-shock proteins and molecular chaperones.
Essays Biochem. 1997;32:17-29. Review.
PMID: 9493008 [PubMed - indexed for MEDLINE]

97: Samaia HB, Mari JJ, Vallada HP, Moura RP, Simpson AJ, Brentani RR. Related Articles, Li

A prion-linked psychiatric disorder.
Nature. 1997 Nov 20;390(6657):241. No abstract available.
PMID: 9384372 [PubMed - indexed for MEDLINE]

98: Cohen DL, Hedera P, Premkumar DR, Friedland RP, Kalaria RN. Related Articles, Li

Amyloid-beta protein angiopathies masquerading as Alzheimer's disease?
Ann N Y Acad Sci. 1997 Sep 26;826:390-5.
PMID: 9329710 [PubMed - indexed for MEDLINE]

99: Muramoto T, DeArmond SJ, Scott M, Telling GC, Cohen FE, Prusiner SB. Related Articles, Li

Heritable disorder resembling neuronal storage disease in mice expressing prion protein with deletion of an alpha-helix.
Nat Med. 1997 Jul;3(7):750-5.
PMID: 9212101 [PubMed - indexed for MEDLINE]

100: Munk C, Lohler J, Prassolov V, Just U, Stockschlader M, Stocking C. Related Articles, Li

Amphotropic murine leukemia viruses induce spongiform encephalomyelopathy.
Proc Natl Acad Sci U S A. 1997 May 27;94(11):5837-42.
PMID: 9159161 [PubMed - indexed for MEDLINE]

101: Castellani RJ, Parchi P, Madoff L, Gambetti P, McKeever P. Related Articles, Li

Biopsy diagnosis of Creutzfeldt-Jakob disease by western blot: a case repor
Hum Pathol. 1997 May;28(5):623-6.
PMID: 9158712 [PubMed - indexed for MEDLINE]

102: Mori S. Related Articles, Li

[Kuru]
Nippon Rinsho. 1997 Apr;55(4):987-92. Review. Japanese.
PMID: 9103906 [PubMed - indexed for MEDLINE]

103: Kalman J, Jardanhazy T, Cserhati A, Szekeres G, Demeter I, Berek I, Dobranovics I, Csernay L, Janka Z. Related Articles, Li

[Prion dementias: nosology and diagnostic difficulties in the spectrum of Creutzfeld-Jakob encephalopathy]
Orv Hetil. 1997 Mar 23;138(12):731-7. Hungarian.
PMID: 9157343 [PubMed - indexed for MEDLINE]

104: Alezrah C, Monteil AL, Faillie X, Hatem O. Related Articles, Li

[Creutzfeldt-Jakob disease and psychiatry. Apropos of a case]
Encephale. 1997 Jan-Feb;23(1):72-5. French.
PMID: 9172971 [PubMed - indexed for MEDLINE]

105: Ardila A, Rosselli M, Arvizu L, Kuljis RO. Related Articles, Li

Alexia and agraphia in posterior cortical atrophy.
Neuropsychiatry Neuropsychol Behav Neurol. 1997 Jan;10(1):52-9.
PMID: 9118197 [PubMed - indexed for MEDLINE]

106: Schulz-Schaeffer WJ, Giese A, Windl O, Kretzschmar HA. Related Articles, Li

Polymorphism at codon 129 of the prion protein gene determines cerebellar pathology in Creutzfeldt-Jakob disease.
Clin Neuropathol. 1996 Nov-Dec;15(6):353-7.
PMID: 8937783 [PubMed - indexed for MEDLINE]

107: Ironside JW. Related Articles, Li

Review: Creutzfeldt-Jakob disease.
Brain Pathol. 1996 Oct;6(4):379-88. Review.
PMID: 8944311 [PubMed - indexed for MEDLINE]

108: Windl O, Dempster M, Estibeiro JP, Lathe R, de Silva R, Esmonde T, Will R, Springbett A, Campbell TA, Sidle KC, Palmer MS, Collinge J. Related Articles, Li

Genetic basis of Creutzfeldt-Jakob disease in the United Kingdom: a systematic analysis of predisposing mutations and allelic variation in the

PRNP gene.
Hum Genet. 1996 Sep;98(3):259-64.
PMID: 8707291 [PubMed - indexed for MEDLINE]

☐ **109:** Bons N, Mestre-Frances N, Charnay Y, Salmona M, Tagliavini F. Related Articles, Li

Spontaneous spongiform encephalopathy in a young adult rhesus monkey.
C R Acad Sci III. 1996 Aug;319(8):733-6.
PMID: 8949398 [PubMed - indexed for MEDLINE]

☐ **110:** Ghetti B, Piccardo P, Spillantini MG, Ichimiya Y, Porro M, Perini F, Kitamoto T, Tateishi J, Seiler C, Frangione B, Bugiani O, Giaccone G, Prelli F, Goedert M, Dlouhy SR, Tagliavini F. Related Articles, Li

Vascular variant of prion protein cerebral amyloidosis with tau-positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNP.
Proc Natl Acad Sci U S A. 1996 Jan 23;93(2):744-8.
PMID: 8570627 [PubMed - indexed for MEDLINE]

☐ **111:** Obermaier G, Kretzschmar HA, Hafner A, Heubeck D, Dahme E. Related Articles, Li

Spongiform central nervous system myelinopathy in African dwarf goats.
J Comp Pathol. 1995 Nov;113(4):357-72.
PMID: 8746958 [PubMed - indexed for MEDLINE]

☐ **112:** Piccardo P, Ghetti B, Dickson DW, Vinters HV, Giaccone G, Bugiani O, Tagliavini F, Young K, Dlouhy SR, Seiler C, et al. Related Articles, Li

Gerstmann-Straussler-Scheinker disease (PRNP P102L): amyloid deposits a best recognized by antibodies directed to epitopes in PrP region 90-165.
J Neuropathol Exp Neurol. 1995 Nov;54(6):790-801.
PMID: 7595652 [PubMed - indexed for MEDLINE]

☐ **113:** Spudich S, Mastrianni JA, Wrensch M, Gabizon R, Meiner Z, Kahana I, Rosenmann H, Kahana E, Prusiner SB. Related Articles, Li

Complete penetrance of Creutzfeldt-Jakob disease in Libyan Jews carrying the E200K mutation in the prion protein gene.
Mol Med. 1995 Sep;1(6):607-13.
PMID: 8529127 [PubMed - indexed for MEDLINE]

☐ **114:** Ragno M, Tournier-Lasserve E, Fiori MG, Manca A, Patrosso MC, Ferlini A, Sirocchi G, Trojano L, Chabriat H, Salvi F. Related Articles, Li

An Italian kindred with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).
Ann Neurol. 1995 Aug;38(2):231-6.
PMID: 7654071 [PubMed - indexed for MEDLINE]

☐ **115:** Perry RT, Go RC, Harrell LE, Acton RT. Related Articles, Li

SSCP analysis and sequencing of the human prion protein gene (PRNP) detects two different 24 bp deletions in an atypical Alzheimer's disease family.
Am J Med Genet. 1995 Feb 27;60(1):12-8.
PMID: 7485229 [PubMed - indexed for MEDLINE]

☐ **116:** Ghetti B, Dlouhy SR, Giaccone G, Bugiani O, Frangione B, Farlow MR, Tagliavini F. Related Articles, Li

Gerstmann-Straussler-Scheinker disease and the Indiana kindred.
Brain Pathol. 1995 Jan;5(1):61-75. Review.
PMID: 7767492 [PubMed - indexed for MEDLINE]

☐ **117:** Amouyel P, Vidal O, Launay JM, Laplanche JL. Related Articles, Li

The apolipoprotein E alleles as major susceptibility factors for Creutzfeldt-

Jakob disease. The French Research Group on Epidemiology of Human Spongiform Encephalopathies.
Lancet. 1994 Nov 12;344(8933):1315-8.
PMID: 7968026 [PubMed - indexed for MEDLINE]

☐ **118:** Salvatore M, Genuardi M, Petraroli R, Masullo C, D'Alessandro M, Pocchiari M. Related Articles, Li

Polymorphisms of the prion protein gene in Italian patients with Creutzfeld Jakob disease.
Hum Genet. 1994 Oct;94(4):375-9. Erratum in: Hum Genet 1995 May;95(5):605.
PMID: 7927332 [PubMed - indexed for MEDLINE]

☐ **119:** Steelman VM. Related Articles, Li

Creutzfeld-Jakob disease: recommendations for infection control.
Am J Infect Control. 1994 Oct;22(5):312-8.
PMID: 7847639 [PubMed - indexed for MEDLINE]

☐ **120:** Collinge J, Whittington MA, Sidle KC, Smith CJ, Palmer MS, Clarke AR, Jefferys JG. Related Articles, Li

Prion protein is necessary for normal synaptic function.
Nature. 1994 Jul 28;370(6487):295-7.
PMID: 8035877 [PubMed - indexed for MEDLINE]

☐ **121:** Kaaden OR, Truyen U, Groschup MH, Uysal A, Kaiser E, Kretzschmar H, Bogumil T, Pohlenz J, Diringer H, Steinhagen P, et al. Related Articles, Li

Bovine spongiform encephalopathy in Germany.
Zentralbl Veterinarmed B. 1994 Jun;41(4):294-304. Erratum in: Zentralbl Veterinarmed [E 1994 Nov;41(9):following 627.
PMID: 7839751 [PubMed - indexed for MEDLINE]

☐ **122:** DeArmond SJ, Yang SL, Cayetano-Canlas J, Groth D, Prusiner SB. Related Articles, Li

The neuropathological phenotype in transgenic mice expressing different prion protein constructs.
Philos Trans R Soc Lond B Biol Sci. 1994 Mar 29;343(1306):415-23. Review.
PMID: 7913760 [PubMed - indexed for MEDLINE]

☐ **123:** Gabizon R, Rosenman H, Meiner Z, Kahana I, Kahana E, Shugart Y, Ott J, Prusiner SB. Related Articles, Li

Mutation in codon 200 and polymorphism in codon 129 of the prion protein gene in Libyan Jews with Creutzfeldt-Jakob disease.
Philos Trans R Soc Lond B Biol Sci. 1994 Mar 29;343(1306):385-90.
PMID: 7913755 [PubMed - indexed for MEDLINE]

☐ **124:** Liberski PP. Related Articles, Li

Transmissible spongiform encephalopathies or prion disorders--current vie
Folia Neuropathol. 1994;32(2):65-73. Review.
PMID: 7922109 [PubMed - indexed for MEDLINE]

☐ **125:** Clinton J, Mann DM, Roberts GW. Related Articles, Li

Frontal lobe dementia is not a variant of prion disease.
Neurosci Lett. 1993 Dec 24;164(1-2):1-4.
PMID: 8152581 [PubMed - indexed for MEDLINE]

☐ **126:** DeArmond SJ. Related Articles, Li

Alzheimer's disease and Creutzfeldt-Jakob disease: overlap of pathogenic mechanisms.
Curr Opin Neurol. 1993 Dec;6(6):872-81. Review.
PMID: 7904883 [PubMed - indexed for MEDLINE]

☐ **127:** Chapman AH, Vieira e Silva D. Related Articles, Li

Creutzfeldt-Jakob disease. A case report, with special attention to the electroencephalogram in this disorder and to its possible relationships to ku scrapie and "mad cow disease".
Arq Neuropsiquiatr. 1993 Jun;51(2):258-66. Review.
PMID: 8274092 [PubMed - indexed for MEDLINE]

128: Guiroy DC, Williams ES, Song KJ, Yanagihara R, Gajdusek DC. Related Articles, Li

Fibrils in brain of Rocky Mountain elk with chronic wasting disease contai scrapie amyloid.
Acta Neuropathol (Berl). 1993;86(1):77-80.
PMID: 8372644 [PubMed - indexed for MEDLINE]

129: Ridley RM, Baker HF. Related Articles, Li

Genetics of human prion disease.
Dev Biol Stand. 1993;80:15-23. Review.
PMID: 7903647 [PubMed - indexed for MEDLINE]

130: Maciulis A, Hunter N, Wang S, Goldmann W, Hope J, Foote WC. Related Articles, Li

Polymorphisms of a scrapie-associated fibril protein (PrP) gene and their association with susceptibility to experimentally induced scrapie in Cheviot sheep in the United States.
Am J Vet Res. 1992 Oct;53(10):1957-60.
PMID: 1360777 [PubMed - indexed for MEDLINE]

131: Giaccone G, Verga L, Bugiani O, Frangione B, Serban D, Prusiner SB, Farlow MR, Ghetti B, Tagliavini F. Related Articles, Li

Prion protein preamyloid and amyloid deposits in Gerstmann-Straussler-Scheinker disease, Indiana kindred.
Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9349-53. Erratum in: Proc Natl Acad Sci U A 1993 Jan 1;90(1):302.
PMID: 1357663 [PubMed - indexed for MEDLINE]

132: Korczyn AD, Chapman J, Belmaker RH, Shimon H, Baron M. Related Articles, Li

Absence of prion protein mutation in bipolar manic-depressive patients.
Br J Psychiatry. 1992 Jul;161:132. No abstract available.
PMID: 1353393 [PubMed - indexed for MEDLINE]

133: Manetto V, Medori R, Cortelli P, Montagna P, Tinuper P, Baruzzi A, Rancurel G, Hauw JJ, Vanderhaeghen JJ, Mailleux P, et al. Related Articles, Li

Fatal familial insomnia: clinical and pathologic study of five new cases.
Neurology. 1992 Feb;42(2):312-9.
PMID: 1736158 [PubMed - indexed for MEDLINE]

134: Collinge J, Poulter M, Davis MB, Baraitser M, Owen F, Crow TJ, Harding AE. Related Articles, Li

Presymptomatic detection or exclusion of prion protein gene defects in families with inherited prion diseases.
Am J Hum Genet. 1991 Dec;49(6):1351-4.
PMID: 1684089 [PubMed - indexed for MEDLINE]

135: Goldfarb LG, Brown P, Mitrova E, Cervenakova L, Goldin L, Korczyn AD, Chapman J, Galvez S, Cartier L, Rubenstein R, et al. Related Articles, Li

Creutzfeldt-Jacob disease associated with the PRNP codon 200Lys mutatio an analysis of 45 families.
Eur J Epidemiol. 1991 Sep;7(5):477-86.
PMID: 1684755 [PubMed - indexed for MEDLINE]

136: Guiroy DC, Williams ES, Yanagihara R, Gajdusek DC. Related Articles, Li

Immunolocalization of scrapie amyloid (PrP27-30) in chronic wasting disea

of Rocky Mountain elk and hybrids of captive mule deer and white-tailed deer.
Neurosci Lett. 1991 May 27;126(2):195-8.
PMID: 1681473 [PubMed - indexed for MEDLINE]

137: Hsiao K, Meiner Z, Kahana E, Cass C, Kahana I, Avrahami D, Scarlato G, Abramsky O, Prusiner SB, Gabizon R. Related Articles, Li

Mutation of the prion protein in Libyan Jews with Creutzfeldt-Jakob diseas
N Engl J Med. 1991 Apr 18;324(16):1091-7.
PMID: 2008182 [PubMed - indexed for MEDLINE]

138: Tagliavini F, Prelli F, Ghiso J, Bugiani O, Serban D, Prusiner SB, Farlow MR, Ghetti B, Frangione B. Related Articles, Li

Amyloid protein of Gerstmann-Straussler-Scheinker disease (Indiana kindr is an 11 kd fragment of prion protein with an N-terminal glycine at codon 5
EMBO J. 1991 Mar;10(3):513-9.
PMID: 1672107 [PubMed - indexed for MEDLINE]

139: Jacob F, Ries F, Dicato M. Related Articles, Li

Prion diseases in man.
Biomed Pharmacother. 1991;45(9):379-82. Review.
PMID: 1786343 [PubMed - indexed for MEDLINE]

140: Brown J, Smith S, Brun A, Collinge J, Gydesen S, Hardy J, Mullan M, Goate A. Related Articles, Li

Genetic characterization of a novel familial dementia.
Ann N Y Acad Sci. 1991;640:181-3.
PMID: 1776737 [PubMed - indexed for MEDLINE]

141: Doh-ura K, Tateishi J, Kitamoto T, Sasaki H, Sakaki Y. Related Articles, Li

Creutzfeldt-Jakob disease patients with congophilic kuru plaques have the missense variant prion protein common to Gerstmann-Straussler syndrome.
Ann Neurol. 1990 Feb;27(2):121-6.
PMID: 2180366 [PubMed - indexed for MEDLINE]

142: Prusiner SB, DeArmond SJ. Related Articles, Li

Prion diseases of the central nervous system.
Monogr Pathol. 1990(32):86-122. Review.
PMID: 2192281 [PubMed - indexed for MEDLINE]

143: Ghetti B, Tagliavini F, Masters CL, Beyreuther K, Giaccone G, Verga L, Farlow MR, Conneally PM, Dlouhy SR, Azzarelli B, et al. Related Articles, Li

Gerstmann-Straussler-Scheinker disease. II. Neurofibrillary tangles and plaques with PrP-amyloid coexist in an affected family.
Neurology. 1989 Nov;39(11):1453-61.
PMID: 2573006 [PubMed - indexed for MEDLINE]

144: Rivera H, Zuffardi O, Maraschio P, Caiulo A, Anichini C, Scarinci R, Vivarelli R. Related Articles, Li

Alternate centromere inactivation in a pseudodicentric (15;20)(pter;pter) associated with a progressive neurological disorder.
J Med Genet. 1989 Oct;26(10):626-30.
PMID: 2685311 [PubMed - indexed for MEDLINE]

145: Westaway D, Carlson GA, Prusiner SB. Related Articles, Li

Unraveling prion diseases through molecular genetics.
Trends Neurosci. 1989 Jun;12(6):221-7. Review.
PMID: 2473558 [PubMed - indexed for MEDLINE]

146: Related Articles, Li

Rosenberg RN, Green JB, White CL 3rd, Sparkman DR, DeArmond

SJ, Kepes JJ.

Dominantly inherited dementia and parkinsonism, with non-Alzheimer amyloid plaques: a new neurogenetic disorder.
Ann Neurol. 1989 Feb;25(2):152-8.
PMID: 2645825 [PubMed - indexed for MEDLINE]

147: Hope J, Ritchie L, Farquhar C, Somerville R, Hunter N. Related Articles, Li

Bovine spongiform encephalopathy: a scrapie-like disease of British cattle.
Prog Clin Biol Res. 1989;317:659-67.
PMID: 2574875 [PubMed - indexed for MEDLINE]

148: Hope J, Reekie LJ, Hunter N, Multhaup G, Beyreuther K, White H, Scott AC, Stack MJ, Dawson M, Wells GA. Related Articles, Li

Fibrils from brains of cows with new cattle disease contain scrapie-associat protein.
Nature. 1988 Nov 24;336(6197):390-2.
PMID: 2904126 [PubMed - indexed for MEDLINE]

149: DeArmond SJ, Mobley WC, DeMott DL, Barry RA, Beckstead JH, Prusiner SB. Related Articles, Li

Changes in the localization of brain prion proteins during scrapie infection.
Neurology. 1987 Aug;37(8):1271-80. Erratum in: Neurology 1987 Nov;37(11):1770.
PMID: 3112607 [PubMed - indexed for MEDLINE]

150: Hogan RN, Baringer JR, Prusiner SB. Related Articles, Li

Scrapie infection diminishes spines and increases varicosities of dendrites i hamsters: a quantitative Golgi analysis.
J Neuropathol Exp Neurol. 1987 Jul;46(4):461-73.
PMID: 3598605 [PubMed - indexed for MEDLINE]

151: Kitamoto T, Tateishi J, Tashima T, Takeshita I, Barry RA, DeArmond SJ, Prusiner SB. Related Articles, Li

Amyloid plaques in Creutzfeldt-Jakob disease stain with prion protein antibodies.
Ann Neurol. 1986 Aug;20(2):204-8.
PMID: 3092727 [PubMed - indexed for MEDLINE]

152: Prusiner SB, Groth DF, Bolton DC, Kent SB, Hood LE. Related Articles, Li

Purification and structural studies of a major scrapie prion protein.
Cell. 1984 Aug;38(1):127-34.
PMID: 6432339 [PubMed - indexed for MEDLINE]

153: Baringer JR, Bowman KA, Prusiner SB. Related Articles, Li

Replication of the scrapie agent in hamster brain precedes neuronal vacuolation.
J Neuropathol Exp Neurol. 1983 Sep;42(5):539-47.
PMID: 6411868 [PubMed - indexed for MEDLINE]

154: Kingsbury DT, Kasper KC, Stites DP, Watson JD, Hogan RN, Prusiner SB. Related Articles, Li

Genetic control of scrapie and Creutzfeldt-Jakob disease in mice.
J Immunol. 1983 Jul;131(1):491-6.
PMID: 6408182 [PubMed - indexed for MEDLINE]

155: Prusiner SB, McKinley MP, Groth DF, Bowman KA, Mock NI, Cochran SP, Masiarz FR. Related Articles, Li

Scrapie agent contains a hydrophobic protein.
Proc Natl Acad Sci U S A. 1981 Nov;78(11):6675-9.
PMID: 6273882 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg

156: Gudnadottir M. Related Articles, Li

Slow viral infections of animals: experimental models for human disease.
Med Biol. 1981 Apr;59(2):77-84. Review.
PMID: 6273667 [PubMed - indexed for MEDLINE]

157: Marsh RF, Sipe JC, Morse SS, Hanson RP. Related Articles, Li

Transmissible mink encephalopathy. Reduced spongiform degeneration in aged mink of the Chediak-Higashi genotype.
Lab Invest. 1976 Apr;34(4):381-6.
PMID: 131218 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

h cb h g e e e fcg

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for passive immunization AND prion Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Items 1 - 5 of 5 One p

1: Koster T, Singh K, Zimmermann M, Gruys E. Related Articles, Li

Emerging therapeutic agents for transmissible spongiform encephalopathies: a review.
J Vet Pharmacol Ther. 2003 Oct;26(5):315-26. Review.
PMID: 14633183 [PubMed - indexed for MEDLINE]

2: White AR, Enever P, Tayebi M, Mushens R, Linehan J, Brandner S, Anstee D, Collinge J, Hawke S. Related Articles, Li

Monoclonal antibodies inhibit prion replication and delay the development of prion disease.
Nature. 2003 Mar 6;422(6927):80-3.
PMID: 12621436 [PubMed - indexed for MEDLINE]

3: Brown P. Related Articles, Li

Drug therapy in human and experimental transmissible spongiform encephalopathy.
Neurology. 2002 Jun 25;58(12):1720-5. Review.
PMID: 12088013 [PubMed - indexed for MEDLINE]

4: Aucouturier P, Geissmann F, Damotte D, Saborio GP, Meeker HC, Kascsak R, Kascsak R, Carp RI, Wisniewski T Related Articles, Li

Infected splenic dendritic cells are sufficient for prion transmission to the CNS in mouse scrapie.
J Clin Invest. 2001 Sep;108(5):703-8.
PMID: 11544275 [PubMed - indexed for MEDLINE]

5: Enari M, Flechsig E, Weissmann C. Related Articles, Li

Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody.
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9295-9. Epub 2001 Jul 24.
PMID: 11470893 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

h cb hg e e e fcg e ch b e

```
Connecting via Winsock to STN
Welcome to STN International!  Enter x:x
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *
* * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:45:05 ON 08 NOV 2004

=> File BIOSCIENCE
FILE 'ADISCTI' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 16:45:15 ON 08 NOV 2004

FILE 'ANABSTR' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUALINE' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 16:45:15 ON 08 NOV 2004
Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOENG' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 16:45:15 ON 08 NOV 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 16:45:15 ON 08 NOV 2004

FILE 'CAPLUS' ENTERED AT 16:45:15 ON 08 NOV 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 16:45:15 ON 08 NOV 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 16:45:15 ON 08 NOV 2004
```

COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'CROPU' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DDFB' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DRUGB' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DRUGMONOG2' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'EMBAL' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 16:45:15 ON 08 NOV 2004

FILE 'FOMAD' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 16:45:15 ON 08 NOV 2004

FILE 'HEALSAFE' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSDRUGNEWS' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSPRODUCT' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSRESEARCH' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 16:45:15 ON 08 NOV 2004

FILE 'NIOSHTIC' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 16:45:15 ON 08 NOV 2004
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 16:45:15 ON 08 NOV 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 16:45:15 ON 08 NOV 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 16:45:15 ON 08 NOV 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'PS' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 Thieme on STN

FILE 'RDISCLOSURE' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 16:45:15 ON 08 NOV 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'SYNTHLINE' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 16:45:15 ON 08 NOV 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:45:15 ON 08 NOV 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

```
FILE 'WPIFV' ENTERED AT 16:45:15 ON 08 NOV 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> S AScr OR prion
  46 FILES SEARCHED...
L1        72645 ASCR OR PRION

=> S L1 AND antibody
  25 FILES SEARCHED...
  63 FILES SEARCHED...
L2        10980 L1 AND ANTIBODY

=> S L2 AND passive immunization
  25 FILES SEARCHED...
  53 FILES SEARCHED...
L3          157 L2 AND PASSIVE IMMUNIZATION

=> DUP REM L3
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L3
L4          125 DUP REM L3 (32 DUPLICATES REMOVED)

=> D L4 1-125

L4   ANSWER 1 OF 125  USPATFULL on STN                    DUPLICATE 1
AN     2004:220874  USPATFULL
TI     PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
IN     Schenk, Dale B., Burlingame, CA, UNITED STATES
PA     Neuralab Limited, Smiths, BERMUDA (U.S. corporation)
PI     US 2004170641      A1   20040902
       US 6808712         B2   20041026
AI     US 2004-815353     A1   20040331 (10)
RLI    Continuation of Ser. No. US 2000-723927, filed on 28 Nov 2000, PENDING
       Division of Ser. No. US 1998-201430, filed on 30 Nov 1998, PENDING
PRAI   US 1998-80970P      19980407 (60)
       US 1997-67740P      19971202 (60)
DT     Utility
FS     APPLICATION
LN.CNT 2808
INCL   INCLM: 424/184.100
NCL    NCLM:  424/193.100
       NCLS:  424/185.100; 530/300.000; 530/327.000; 530/329.000; 530/330.000;
              530/350.000; 530/391.700; 530/403.000; 514/002.000; 514/004.000
IC     [7]
       ICM: A61K039-00
       ICS: A61K039-38; C12N001-20
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4   ANSWER 2 OF 125  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2004:490740  CAPLUS
DN   141:52857
TI     ***Prion***   inhibition with   ***antibody***
IN   Collinge, John; Hawke, Simon
PA   Medical Research Council, UK
SO   PCT Int. Appl., 52 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    -------------------     --------
PI   WO 2004050120        A2    20040617    WO 2003-GB5225          20031128
     WO 2004050120        A3    20040923
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
             NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM,
             AZ, BY, KG, KZ
```

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI GB 2002-27886 A 20021129

L4 ANSWER 3 OF 125 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:333821 CAPLUS
DN 140:337933
TI Use of monoclonal ***antibodies*** to distinguish protein conformational isoforms
IN Lingappa, Vishwanath R.; Korth, Carsten
PA Regents of the University of California, USA; Heinrich Heine University of Dusseldorf
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004033628	A2	20040422	WO 2003-US25994	20030818
WO 2004033628	A3	20040819		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-417886P P 20021010

L4 ANSWER 4 OF 125 USPATFULL on STN
AN 2004:279846 USPATFULL
TI Prevention and treatment of amyloidogenic disease
IN Schenk, Dale B., Burlingame, CA, UNITED STATES
PA Neuralab Limited, Flatts, Smiths, BERMUDA (U.S. corporation)
PI US 2004219146 A1 20041104
AI US 2004-828548 A1 20040419 (10)
RLI Continuation of Ser. No. US 1999-322289, filed on 28 May 1999, PENDING Continuation-in-part of Ser. No. US 1998-201430, filed on 30 Nov 1998, GRANTED, Pat. No. US 6787523
PRAI US 1998-80970P 19980407 (60)
US 1997-67740P 19971202 (60)
DT Utility
FS APPLICATION
LN.CNT 3871
INCL INCLM: 424/141.100
INCLS: 424/145.100
NCL NCLM: 424/141.100
NCLS: 424/145.100
IC [7]
ICM: A61K039-395

L4 ANSWER 5 OF 125 USPATFULL on STN
AN 2004:260604 USPATFULL
TI Brain-associated inhibitor of tissue-type plasminogen activator
IN Hastings, Gregg A., Westlake Village, CA, UNITED STATES
Coleman, Timothy A., Derwood, MD, UNITED STATES
Dillon, Patrick J., Carlsbad, CA, UNITED STATES
Lawrence, Daniel A., Derwood, MD, UNITED STATES
Sandkvist, Maria, Derwood, MD, UNITED STATES
Yepes, Manuel, Rockville, MD, UNITED STATES
Wong, Michael K. K., East Amhurst, NY, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)
The American Red Cross, Rockville, MD (U.S. corporation)
PI US 2004203101 A1 20041014
AI US 2004-752041 A1 20040107 (10)
RLI Continuation-in-part of Ser. No. US 2001-987021, filed on 13 Nov 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-957485, filed on 21 Sep 2001, ABANDONED Continuation of Ser. No. US 2000-521664, filed on 8 Mar 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-722292,

filed on 28 Nov 2000, GRANTED, Pat. No. US 6541452 Division of Ser. No. US 1999-348817, filed on 8 Jul 1999, GRANTED, Pat. No. US 6191260 Division of Ser. No. US 1997-948997, filed on 10 Oct 1997, GRANTED, Pat. No. US 6008020 Continuation-in-part of Ser. No. US 2003-355208, filed on 31 Jan 2003, PENDING Division of Ser. No. US 2001-957485, filed on 21 Sep 2001, ABANDONED Continuation of Ser. No. US 2000-521664, filed on 8 Mar 2000, ABANDONED
PRAI US 2000-247971P 20001114 (60)
US 1999-123704P 19990310 (60)
US 1996-28117P 19961011 (60)
US 1999-123704P 19990310 (60)
DT Utility
FS APPLICATION
LN.CNT 10699
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C07H021-04
ICS: C07K014-705

L4 ANSWER 6 OF 125 USPATFULL on STN
AN 2004:254305 USPATFULL
TI ANTI-AMYLOID PEPTIDE ***ANTIBODY*** BASED DIAGNOSIS AND TREATMENT OF A NEUROLOGICAL DISEASE OR DISORDER
IN Weksler, Marc E., Paris, FRANCE
Szabo, Paul, Linden, NJ, UNITED STATES
PA Cornell Research Foundation, Inc. (non-U.S. corporation)
PI US 2004197831 A1 20041007
AI US 2002-99880 A1 20020314 (10)
PRAI US 2001-276659P 20010316 (60)
DT Utility
FS APPLICATION
LN.CNT 817
INCL INCLM: 435/007.200
INCLS: 435/007.920
NCL NCLM: 435/007.200
NCLS: 435/007.920
IC [7]
ICM: G01N033-53
ICS: G01N033-567; G01N033-537; G01N033-543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 125 USPATFULL on STN
AN 2004:247988 USPATFULL
TI Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration
IN Eisenbach-Schwartz, Michal, Rehovot, ISRAEL
Hauben, Ehud, Rehovot, ISRAEL
PI US 2004192588 A1 20040930
AI US 2004-466220 A1 20040105 (10)
WO 2002-IL32 20020114
PRAI IL 2001-140888 20010114
DT Utility
FS APPLICATION
LN.CNT 1949
INCL INCLM: 514/008.000
INCLS: 514/012.000
NCL NCLM: 514/008.000
NCLS: 514/012.000
IC [7]
ICM: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 125 USPATFULL on STN
AN 2004:227009 USPATFULL
TI PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
IN Schenk, Dale B., Burlingame, CA, UNITED STATES
PA Neuralab Limited, Smiths, BERMUDA (U.S. corporation)
PI US 2004175394 A1 20040909
AI US 2004-815391 A1 20040331 (10)
RLI Continuation of Ser. No. US 1998-201430, filed on 30 Nov 1998, PENDING
PRAI US 1998-80970P 19980407 (60)
US 1997-67740P 19971202 (60)
DT Utility

FS APPLICATION
LN.CNT 2930
INCL INCLM: 424/185.100
NCL NCLM: 424/185.100
IC [7]
ICM: A61K039-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 125 USPATFULL on STN
AN 2004:222043 USPATFULL
TI Humanized ***antibodies*** that recognize beta amyloid peptide
IN Schenk, Dale B., Burlingame, CA, UNITED STATES
Basi, Guriq, Palo Alto, CA, UNITED STATES
PI US 2004171816 A1 20040902
AI US 2003-704070 A1 20031107 (10)
RLI Continuation of Ser. No. US 2003-388389, filed on 12 Mar 2003, PENDING
Continuation-in-part of Ser. No. US 2001-10942, filed on 6 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2000-580015, filed on 26 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-322289, filed on 28 May 1999, PENDING Continuation-in-part of Ser. No. US 1998-201430, filed on 30 Nov 1998, PENDING
PRAI US 2000-251892P 20001206 (60)
US 1998-80970P 19980407 (60)
DT Utility
FS APPLICATION
LN.CNT 5439
INCL INCLM: 530/388.150
NCL NCLM: 530/388.150
IC [7]
ICM: C07K016-44
ICS: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 125 USPATFULL on STN
AN 2004:222042 USPATFULL
TI Humanized ***antibodies*** that recognize beta amyloid peptide
IN Schenk, Dale B., Burlingame, CA, UNITED STATES
Yednock, Ted, Forest Knolls, CA, UNITED STATES
Basi, Guriq, Palo Alto, CA, UNITED STATES
PI US 2004171815 A1 20040902
AI US 2003-703713 A1 20031107 (10)
RLI Continuation of Ser. No. US 2003-388389, filed on 12 Mar 2003, PENDING
Continuation-in-part of Ser. No. US 2001-10942, filed on 6 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2000-580015, filed on 26 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-322289, filed on 28 May 1999, PENDING Continuation-in-part of Ser. No. US 1998-201430, filed on 30 Nov 1998, PENDING
PRAI US 2000-251892P 20001206 (60)
US 1998-80970P 19980407 (60)
DT Utility
FS APPLICATION
LN.CNT 5473
INCL INCLM: 530/388.150
NCL NCLM: 530/388.150
IC [7]
ICM: A61K039-395
ICS: C07K016-44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 125 USPATFULL on STN
AN 2004:215013 USPATFULL
TI Prevention and treatment of amyloidogenic disease
IN Schenk, Dale B., Burlingame, CA, UNITED STATES
PA Neuralab Limited, Smiths, BERMUDA, FL04 (U.S. corporation)
PI US 2004166119 A1 20040826
AI US 2004-816529 A1 20040331 (10)
RLI Continuation of Ser. No. US 1998-201430, filed on 30 Nov 1998, PENDING
PRAI US 1998-80970P 19980407 (60)
US 1997-67740P 19971202 (60)
DT Utility
FS APPLICATION
LN.CNT 2839
INCL INCLM: 424/185.100
NCL NCLM: 424/185.100
IC [7]
ICM: A61K039-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 125 USPATFULL on STN
AN 2004:203887 USPATFULL
TI Prevention and treatment of amyloidogenic disease
IN Schenk, Dale B., Burlingame, CA, UNITED STATES
PA Neuralab Limited, Smiths, BERMUDA, FL04 (U.S. corporation)
PI US 2004157779 A1 20040812
AI US 2004-816022 A1 20040331 (10)
RLI Continuation of Ser. No. US 1998-201430, filed on 30 Nov 1998, PENDING
PRAI US 1998-80970P 19980407 (60)
US 1997-67740P 19971202 (60)
DT Utility
FS APPLICATION
LN.CNT 2931
INCL INCLM: 514/012.000
NCL NCLM: 514/012.000
IC [7]
ICM: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 125 USPATFULL on STN
AN 2004:184986 USPATFULL
TI Treatment for central nervous system disorders
IN Poduslo, Joseph F., Rochester, MN, UNITED STATES
Curran, Geoffry L., Rochester, MN, UNITED STATES
PA Mayo Foundation for Medical Education and Research ,a MN corporation (U.S. corporation)
PI US 2004142872 A1 20040722
AI US 2004-796522 A1 20040309 (10)
RLI Continuation of Ser. No. US 2001-942253, filed on 29 Aug 2001, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 812
INCL INCLM: 514/012.000
INCLS: 536/023.500; 530/350.000; 800/012.000
NCL NCLM: 514/012.000
NCLS: 536/023.500; 530/350.000; 800/012.000
IC [7]
ICM: A01K067-00
ICS: C07H021-04; A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 125 USPATFULL on STN
AN 2004:164897 USPATFULL
TI ***Passive*** ***immunization*** against Clostridium difficile disease
IN Thomas, William D., JR., Somerville, MA, UNITED STATES
Giannasca, Paul J., Newton, MA, UNITED STATES
Zhang, Zhenxi, Cambridge, MA, UNITED STATES
Lei, Wende, Cambridge, MA, UNITED STATES
Monath, Thomas P., Harvard, MA, UNITED STATES
PI US 2004126383 A1 20040701
AI US 2003-737270 A1 20031216 (10)
RLI Continuation-in-part of Ser. No. US 2001-815452, filed on 22 Mar 2001, GRANTED, Pat. No. US 6680168 Continuation of Ser. No. US 1998-176076, filed on 20 Oct 1998, GRANTED, Pat. No. US 6214341
PRAI US 1997-62522P 19971020 (60)
DT Utility
FS APPLICATION
LN.CNT 1020
INCL INCLM: 424/184.100
NCL NCLM: 424/184.100
IC [7]
ICM: A61K039-00
ICS: A61K039-38
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 15 OF 125 USPATFULL on STN
AN 2004:138959 USPATFULL
TI Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells
IN Huang, Fei, Princeton, NJ, UNITED STATES
Han, Xia, Somerset, NJ, UNITED STATES
Reeves, Karen A., Ewing, NJ, UNITED STATES

Amler, Lukas C., Pennington, NJ, UNITED STATES
Fairchild, Craig R., Yardley, PA, UNITED STATES
Lee, Francis Y., Yardley, PA, UNITED STATES
Shaw, Peter, Yardley, PA, UNITED STATES
PI US 2004106132 A1 20040603
AI US 2003-648593 A1 20030826 (10)
PRAI US 2002-406385P 20020827 (60)
DT Utility
FS APPLICATION
LN.CNT 5402
INCL INCLM: 435/006.000
INCLS: 536/024.300
NCL NCLM: 435/006.000
NCLS: 536/024.300
IC [7]
ICM: C12Q001-68
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 16 OF 125 USPATFULL on STN
AN 2004:114931 USPATFULL
TI Humanized ***antibodies*** that recognize beta amyloid peptide
IN Basi, Guriq, Palo Alto, CA, UNITED STATES
Saldanha, Jose, Enfield, UNITED KINGDOM
Yednock, Ted, Forest Knolls, CA, UNITED STATES
PA Elan Pharmaceuticals, Inc., South San Francisco, CA (U.S. corporation)
PI US 2004087777 A1 20040506
AI US 2003-388389 A1 20030312 (10)
RLI Continuation-in-part of Ser. No. US 2001-10942, filed on 6 Dec 2001, PENDING
PRAI US 2000-251892P 20001206 (60)
DT Utility
FS APPLICATION
LN.CNT 6063
INCL INCLM: 530/387.300
INCLS: 530/388.150
NCL NCLM: 530/387.300
NCLS: 530/388.150
IC [7]
ICM: C07K016-44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 17 OF 125 USPATFULL on STN
AN 2004:108360 USPATFULL
TI Humanized ***antibodies*** that recognize beta amyloid peptide
IN Basi, Guriq, Palo Alto, CA, UNITED STATES
Saldanha, Jose, Enfield, UNITED KINGDOM
PA Elan Pharmaceuticals, Inc., South San Francisco, CA (U.S. corporation)
PI US 2004082762 A1 20040429
AI US 2003-388214 A1 20030312 (10)
PRAI US 2002-363751P 20020312 (60)
DT Utility
FS APPLICATION
LN.CNT 4345
INCL INCLM: 530/388.150
INCLS: 530/387.300
NCL NCLM: 530/388.150
NCLS: 530/387.300
IC [7]
ICM: C07K016-44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 18 OF 125 USPATFULL on STN
AN 2004:107258 USPATFULL
TI Prevention and treatment of amyloidogenic disease
IN Schenk, Dale B., Burlingame, CA, UNITED STATES
PA Neuralab Limited, Flatts, Smiths, BERMUDA (U.S. corporation)
Athena Neurosciences, Inc. (U.S. corporation)
PI US 2004081657 A1 20040429
AI US 2003-429216 A1 20030502 (10)
RLI Continuation of Ser. No. US 1998-201430, filed on 30 Nov 1998, PENDING
PRAI US 1997-67740P 19971202 (60)
US 1998-80970P 19980407 (60)
DT Utility
FS APPLICATION
LN.CNT 2951

INCL INCLM: 424/185.100
INCLS: 424/486.000; 514/054.000
NCL NCLM: 424/185.100
NCLS: 424/486.000; 514/054.000
IC [7]
ICM: A61K039-00
ICS: A61K009-14; A61K031-739
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 19 OF 125 USPATFULL on STN
AN 2004:100750 USPATFULL
TI Molecular antigen arrays
IN Bachmann, Martin F., Seuzach, SWITZERLAND
Tissot, Alain, Zurich, SWITZERLAND
Pumpens, Paul, Riga, LATVIA
Cielens, Indulis, Riga, LATVIA
Renhofa, Regina, Riga, LATVIA
PI US 2004076611 A1 20040422
AI US 2003-617876 A1 20030714 (10)
PRAI US 2002-396126P 20020717 (60)
DT Utility
FS APPLICATION
LN.CNT 5340
INCL INCLM: 424/093.200
INCLS: 424/204.100
NCL NCLM: 424/093.200
NCLS: 424/204.100
IC [7]
ICM: A61K048-00
ICS: A61K039-12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 20 OF 125 USPATFULL on STN
AN 2004:89782 USPATFULL
TI Transgenic ungulates capable of human ***antibody*** production
IN Robl, James M., Brandon, SD, UNITED STATES
Collas, Philippe, Oslo, NORWAY
Sullivan, Eddie, Manhattan, KS, UNITED STATES
Kasinathan, P., Manhattan, KS, UNITED STATES
Goldsby, Richard A., Leverett, MA, UNITED STATES
Kuroiwa, Yoshimi, Sionx Falls, JAPAN
Tomizuka, Kazuma, Takasaki, JAPAN
Ishida, Isao, Isehara, JAPAN
PI US 2004068760 A1 20040408
AI US 2003-441503 A1 20030519 (10)
RLI Continuation-in-part of Ser. No. US 2001-988115, filed on 16 Nov 2001, PENDING Continuation-in-part of Ser. No. US 2000-714185, filed on 17 Nov 2000, PENDING Continuation-in-part of Ser. No. US 2001-32191, filed on 21 Dec 2001, PENDING
PRAI US 2002-381531P 20020517 (60)
US 2002-425056P 20021108 (60)
US 2001-311625P 20010809 (60)
US 2000-256458P 20001220 (60)
US 1999-166410P 19991119 (60)
US 2000-258151P 20001222 (60)
DT Utility
FS APPLICATION
LN.CNT 8417
INCL INCLM: 800/006.000
INCLS: 800/014.000; 800/015.000; 800/016.000; 800/017.000
NCL NCLM: 800/006.000
NCLS: 800/014.000; 800/015.000; 800/016.000; 800/017.000
IC [7]
ICM: A01K067-027
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 21 OF 125 USPATFULL on STN
AN 2004:77315 USPATFULL
TI Hapten-carrier conjugates and uses thereof
IN Bachmann, Martin F., Seuzach, SWITZERLAND
Maurer, Patrik, Winterthur, SWITZERLAND
PI US 2004059094 A1 20040325
AI US 2003-622064 A1 20030718 (10)
PRAI US 2002-396575P 20020718 (60)
DT Utility
FS APPLICATION

LN.CNT 4790
INCL INCLM: 530/350.000
INCLS: 530/403.000
NCL NCLM: 530/350.000
NCLS: 530/403.000
IC [7]
ICM: C07K014-005
ICS: C07K014-195
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 22 OF 125 USPATFULL on STN
AN 2004:24734 USPATFULL
TI Production of functional ***antibodies*** in filamentous fungi
IN Power, Scott D., San Bruno, CA, UNITED STATES
Wang, Huaming, Fremont, CA, UNITED STATES
Ward, Michael, San Francisco, CA, UNITED STATES
PI US 2004018573 A1 20040129
AI US 2003-418836 A1 20030417 (10)
PRAI US 2002-373889P 20020418 (60)
US 2002-411540P 20020918 (60)
US 2002-411537P 20020918 (60)
US 2003-452134P 20030304 (60)
DT Utility
FS APPLICATION
LN.CNT 2677
INCL INCLM: 435/007.310
INCLS: 530/388.500; 435/188.500
NCL NCLM: 435/007.310
NCLS: 530/388.500; 435/188.500
IC [7]
ICM: G01N033-53
ICS: G01N033-569; C12N009-00; C07K016-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 23 OF 125 USPATFULL on STN
AN 2004:18378 USPATFULL
TI Neurotoxic oligomers
IN Bush, Ashley, Somerville, MA, UNITED STATES
Cherny, Robert, Victoria, AUSTRALIA
PI US 2004013680 A1 20040122
AI US 2003-312437 A1 20030616 (10)
WO 2001-AU786 20010628
DT Utility
FS APPLICATION
LN.CNT 1214
INCL INCLM: 424/185.100
INCLS: 530/400.000
NCL NCLM: 424/185.100
NCLS: 530/400.000
IC [7]
ICM: A61K039-00
ICS: C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 24 OF 125 USPATFULL on STN
AN 2004:223763 USPATFULL
TI Prevention and treatment of amyloidogenic disease
IN Schenk, Dale B., Burlingame, CA, United States
PA Neuralab Limited, BERMUDA (non-U.S. corporation)
PI US 6787523 B1 20040907
AI US 1998-201430 19981130 (9)
PRAI US 1997-67740P 19971202 (60)
US 1998-80970P 19980407 (60)
DT Utility
FS GRANTED
LN.CNT 3308
INCL INCLM: 514/021.000
INCLS: 514/002.000; 514/012.000; 530/324.000; 436/015.000; 436/086.000;
436/507.000; 424/001.570; 424/185.100; 424/009.100; 424/009.200
NCL NCLM: 514/021.000
NCLS: 514/002.000; 514/012.000; 530/324.000; 436/015.000; 436/086.000;
436/507.000; 424/001.570; 424/185.100; 424/009.100; 424/009.200
IC [7]
ICM: A61K038-00
ICS: A01N037-18
EXF 514/2; 514/12; 514/21; 424/1.57; 424/185.1; 424/9.1; 424/9.2; 436/15;

436/86; 436/507; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 25 OF 125 USPATFULL on STN
AN 2004:223663 USPATFULL
TI Prevention and treatment of amyloidogenic disease
IN Schenk, Dale B., Burlingame, CA, United States
PA Neuralab Limited, BELGIUM (non-U.S. corporation)
PI US 6787144 B1 20040907
AI US 2000-723762 20001128 (9)
RLI Division of Ser. No. US 1998-201430, filed on 30 Nov 1998
PRAI US 1997-67740P 19971202 (60)
US 1998-80970P 19980407 (60)
DT Utility
FS GRANTED
LN.CNT 3436
INCL INCLM: 424/197.110
INCLS: 424/009.200; 424/001.570; 424/185.100; 424/193.100; 424/236.110; 436/086.000; 514/002.000; 514/021.000; 530/324.000
NCL NCLM: 424/197.110
NCLS: 424/009.200; 424/001.570; 424/185.100; 424/193.100; 424/236.110; 436/086.000; 514/002.000; 514/021.000; 530/324.000
IC [7]
ICM: A61K039-00
ICS: A61K039-385; A61K039-39
EXF 536/23.5; 435/320.1; 435/69.1; 435/69.3; 424/185.1; 424/193.1; 424/1.57; 424/9.2; 424/197.11; 424/236.1; 436/86; 514/2; 514/12; 514/21; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 26 OF 125 USPATFULL on STN
AN 2004:223662 USPATFULL
TI Prevention and treatment of amyloidogenic disease
IN Schenk, Dale B., Burlingame, CA, United States
PA Neuralab Limited, BERMUDA (non-U.S. corporation)
PI US 6787143 B1 20040907
AI US 2000-724477 20001128 (9)
RLI Division of Ser. No. US 1998-201430, filed on 30 Nov 1998
PRAI US 1998-80970P 19980407 (60)
US 1997-67740P 19971202 (60)
DT Utility
FS GRANTED
LN.CNT 3337
INCL INCLM: 424/193.100
INCLS: 424/009.200; 424/185.100; 424/236.100; 424/197.110; 424/001.570; 436/086.000; 514/002.000; 514/012.000; 530/324.000
NCL NCLM: 424/193.100
NCLS: 424/009.200; 424/185.100; 424/236.100; 424/197.110; 424/001.570; 436/086.000; 514/002.000; 514/012.000; 530/324.000
IC [7]
ICM: A61K039-00
ICS: A61K039-385; A61K039-39
EXF 435/7.95; 435/70.21; 435/7.1; 435/7.92; 435/810; 436/548; 436/518; 436/811; 436/86; 424/1.57; 424/9.2; 424/185.1; 424/193.1; 424/236.1; 424/197.11; 514/2; 514/12; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 27 OF 125 USPATFULL on STN
AN 2004:223660 USPATFULL
TI Prevention and treatment of amyloidogenic disease
IN Schenk, Dale B., Burlingame, CA, United States
PA Neuralab Limited, BERMUDA (non-U.S. corporation)
PI US 6787140 B1 20040907
AI US 2000-724489 20001128 (9)
RLI Division of Ser. No. US 1998-201430, filed on 30 Nov 1998
PRAI US 1997-67740P 19971202 (60)
US 1998-80970P 19980407 (60)
DT Utility
FS GRANTED
LN.CNT 3489
INCL INCLM: 424/185.100
INCLS: 424/001.570; 424/009.100; 424/009.200; 436/015.000; 436/086.000; 436/507.000; 514/002.000; 514/012.000; 514/021.000; 530/324.000
NCL NCLM: 424/185.100
NCLS: 424/001.570; 424/009.100; 424/009.200; 436/015.000; 436/086.000; 436/507.000; 514/002.000; 514/012.000; 514/021.000; 530/324.000
IC [7]

ICM: A61K038-00
ICS: A01N037-18
EXF 514/2; 514/12; 514/21; 424/1.57; 424/185.1; 424/9.1; 424/9.2; 436/15; 436/86; 436/507; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 28 OF 125 USPATFULL on STN
AN 2004:223659 USPATFULL
TI Prevention and treatment of amyloidogenic disease
IN Schenk, Dale B., Burlingame, CA, United States
PA Neuralab Limited, BERMUDA (non-U.S. corporation)
PI US 6787139 B1 20040907
AI US 2000-724102 20001128 (9)
RLI Division of Ser. No. US 1998-201430, filed on 30 Nov 1998
PRAI US 1997-67740P 19971202 (60)
US 1998-80970P 19980407 (60)
DT Utility
FS GRANTED
LN.CNT 3535
INCL INCLM: 424/185.100
INCLS: 424/001.570; 424/009.200; 514/002.000; 514/021.000; 436/086.000
NCL NCLM: 424/185.100
NCLS: 424/001.570; 424/009.200; 514/002.000; 514/021.000; 436/086.000
IC [7]
ICM: A61K038-00
EXF 435/7.95; 435/70.21; 435/7.1; 435/7.92; 435/810; 436/548; 436/518; 436/811; 436/86; 514/2; 514/21; 424/1.57; 424/185.1; 424/9.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 29 OF 125 USPATFULL on STN
AN 2004:223658 USPATFULL
TI Prevention and treatment of amyloidogenic disease
IN Schenk, Dale B., Burlingame, CA, United States
PA Neuralab Limited, BERMUDA (non-U.S. corporation)
PI US 6787138 B1 20040907
AI US 2000-723927 20001128 (9)
RLI Division of Ser. No. US 1998-201430, filed on 30 Nov 1998
PRAI US 1998-80970P 19980407 (60)
US 1997-67740P 19971202 (60)
DT Utility
FS GRANTED
LN.CNT 3460
INCL INCLM: 424/185.100
INCLS: 424/001.570; 424/009.100; 424/009.200; 436/015.000; 436/086.000; 436/507.000; 514/002.000; 514/012.000; 514/021.000; 530/324.000
NCL NCLM: 424/185.100
NCLS: 424/001.570; 424/009.100; 424/009.200; 436/015.000; 436/086.000; 436/507.000; 514/002.000; 514/012.000; 514/021.000; 530/324.000
IC [7]
ICM: A61K038-00
ICS: A01N037-18
EXF 514/2; 514/12; 514/21; 424/1.57; 424/185.1; 424/9.1; 424/9.2; 436/15; 436/86; 436/507; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 30 OF 125 USPATFULL on STN
AN 2004:72673 USPATFULL
TI Transgenic mouse assay to determine the effect of A.beta. ***antibodies*** and A.beta. Fragments on alzheimer's disease characteristics
IN Schenk, Dale B., Burlingame, CA, United States
PA Neuralab Limited, BERMUDA (non-U.S. corporation)
PI US 6710226 B1 20040323
AI US 2000-723384 20001127 (9)
RLI Continuation of Ser. No. US 1999-322289, filed on 28 May 1999
Continuation-in-part of Ser. No. US 1998-201430, filed on 30 Nov 1998
PRAI US 1997-67740P 19971202 (60)
US 1998-80970P 19980407 (60)
DT Utility
FS GRANTED
LN.CNT 3945
INCL INCLM: 800/012.000
INCLS: 800/003.000; 800/018.000
NCL NCLM: 800/012.000
NCLS: 800/003.000; 800/018.000
IC [7]

ICM: A01K067-00
ICS: G01N033-00
EXF 800/8; 800/12; 800/13; 800/14; 800/18; 800/3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 31 OF 125 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 2003:719977 PROMT
TITLE: Neurodegenerative Disorders -- 21st & 22nd May 2003 The Hatton, London -- http://www.smi-online.co.uk/neuro6.asp.
SOURCE: M2 Presswire, (26 Mar 2003) .
PUBLISHER: M2 Communications Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 1607
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L4 ANSWER 32 OF 125 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 2
AN 10422134 IFIPAT;IFIUDB;IFICDB
TI SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID BETA, ***PRION*** PROTEIN, AMYLIN, ALPHA-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO
IN Frangione Blas; Sigurdsson Einar M; Wisniewski Thomas
PA New York University (59449)
PI US 2003166558 A1 20030904
AI US 2002-301488 20021121
PRAI US 2001-331801P 20011121 (Provisional)
FI US 2003166558 20030904
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 115
GI 15 Figure(s).

FIG. 1 shows the results of a thioflavin T fluorometric assay. Fibril formation of A beta 1-42, A beta 1-30-NH2, and K6A beta 1-30-NH2 (SEQ ID NO:6) was measured in vitro following incubation at 37 degrees C. K6A beta 1-30-NH2 was the only peptide that did not form fibrils at any of the time points.

FIGS. 2A and 2B show that A beta 40 and A beta 42 are toxic to human neuroblastoma cells (SK-N-SH) in culture as determined by the MTT assay, whereas K6A beta 30-NH2 has no effect at 2 days (FIG. 2A) and is slightly trophic at 6 days (FIG. 2B). *p lessthan 0.05; **p less-than 0.01; ***p less-than 0.001 compared to VEH group (one-way ANOVA).

FIGS. 3A-3D show coronal sections (X50; original magnification) stained with 6E10 against A beta, through the hippocampus and cortex in a Tg control-(FIG. 3A) and K6A beta 1-30-treated (FIG. 3B) Tg mouse. FIGS. 3C and 3D are adjacent sections (X100) double stained for interleukin-1 that recognizes microglia, and A beta . Note the reduction of amyloid burden in the immunized mouse (FIG. 3B), and the lack of ramified microglia (FIG. 3D) surrounding A beta plaque in the same mouse, compared to a control mouse (FIG. 3A, 3C). The bars in FIGS. 3A and 3C are 100 mu m. Abbreviations: hip=hippocampus; cx=cortex; cc=corpus callosum.

FIGS. 4A-4C show the reduction in cortical (FIG. 4A) and hippocampal (FIG. 4B) amyloid burden (6E10) following 7 months treatment with K6A beta 1-30-NH2. There is an 89% reduction in cortical amyloid burden (*p=0.0002; t-test; n=4 per group) and an 81% reduction in hippocampal amyloid burden (*p=0.0001). Soluble A beta 1-42 levels (FIG. 4C) are reduced by 57% within the brains of the vaccinated mice (*p=0.0019).

FIG. 5 shows the results of a thioflavin T fluorometric assay. Fibril formation of A beta 1-42, A beta 1-40, A beta 1-30-NH2, A beta 1-30K6, A beta 1-30-NH2 (EE18,19) and A beta 1-30-NH2 (DDL18,19) was measured in vitro following incubation at 37 degrees C. for 15 days. Within this period, no fibril formation of the A beta derivatives containing a polylysine segment or an amino acid substitution within the hydrophobic region was detected.

FIGS. 6A and 6B show the results of MTT cell toxicity assay. Neurotoxicity of A beta 1-42, A beta 1-40, A beta 1-30-NH2, K6A beta 1-30-NH2, A beta 1-30K6, A beta 1-30-NH2(EE,18,19) and A beta 1-30-NH2(DD,18,19) was determined following treatment of human neuroblastoma cells (SK-N-SH) for 2 (FIG. 6A) and 6 (FIG. 6B) days. *p less-than 0.05; **p less-than 0.01; ***p less-than 0.001 compared to VEH group (one-way ANOVA). In this*** assay, A beta 1-40 and A beta 1-42 were toxic to human neuroblastoma*** cells (SK-N-SH) in culture. Of the A beta derivatives, even at the*** highest concentration (100 mu M), only A beta 1-30K6 displayed a slight*** toxicity and only on day 2 of the test. Several of the peptides were***

*** neurotrophic following 6 days incubation. *p less-than 0.05; **p***
*** less-than 0.01; ***p lessthan 0.001 (One-way Anova; Neuman Keuls' posthoc***
*** test). ***
*** FIG. 7 shows the ***antibody*** titer determined by ELISA in mice 14 weeks after vaccination with mouse recPrP.

FIGS. 8A and 8B show that a higher anti-PrPC (ME7 FAS PrP) ***antibody*** titer in vaccinated mice, as presented in FIG. 7, correlates with a longer incubation time in both PrPSc inoculated mouse groups at lower dilution (FIG. 8A; r2=0.4389, p=0.0052) and at higher dilution (FIG. 8B; r2=0.6786, p lessthan 0.0001).

FIG. 9 is a graph showing the effect of recPrP vaccination on disease onset, with day 0 being the first day an animal scored positive for disease. Group 1 mice were controls inoculated with PrPSc at a 10 fold dilution, while group 2 was inoculated at the same dilution but also received recPrP vaccination. Group 3 mice were controls inoculated with PrPSc at a 1000 fold dilution, while Group 4 received the same dilution of PrPSc along with recPrP vaccination. The two control groups received adjuvant and vehicle injections. Two way ANOVA shows a significant effect for vaccination (p=0.0005) and PrPSc dilution (p less-than 0.000001). The Newman-Keuls post-hoc test showed vaccination to have a stronger effect in the 10 fold dilution group (Group 1 versus 2, p=0.001 two-tailed; Group 3 versus 4, p=0.036 one-tailed).

FIG. 10 shows an alignment of amino acid sequences of ***prion*** protein (PrP) from human (SEQ ID NO:21), gorilla (SEQ ID NO:22), chimpanzee (SEQ ID NO:23), mouse (SEQ ID NO:24), rat (SEQ ID NO:25), Syrian hamster (SEQ ID NO:26), mink (SEQ ID NO:27), sheep (SEQ ID NO:28), goat (SEQ ID NO:29), cow (SEQ ID NO:30), and greater kudu (SEQ ID NO:31). Amino acid residues that are identical and conserved among the ***prion*** proteins of the species presented in this figure are boxed.

FIGS. 11A-C show ELISA evaluation of sera from individual animals vaccinated with K6A beta 1-30-NH2 and alum adjuvant, testing for ***antibody*** titer against antigen (FIG. 11A), A beta 142 (FIG. 11B) and A beta 1-40 (FIG. 11C).

FIGS. 12A-C show ELISA evaluation of sera from individual animals immunized with A beta 1-42 and alum adjuvant, testing for ***antibody*** titer against antigen (FIG. 12A), K6AP1-30-NH2 (FIG. 12B) and A beta 1-40 (FIG. 12C).

FIGS. 13A and 13B depict a linear maze used to evaluate cognitive capabilities of animals vaccinated with A beta 1-30NH2 and K6A beta 1-30-NH2 together with alum adjuvants, as well as controls. FIG. 13A shows the maze design during the adaptation phase, and FIG. 13B during testing. Dotted lines indicate blocked alleys.

FIGS. 14A-C depict results obtained from behavioral studies of animals of about 3-4 months of age, after vaccination with A beta 1-30-NH2 and K6A beta 1-30-NH2 together with alum adjuvants, as well as controls. The studies included testing of locomotor activity (FIG. 14A), spontaneous avoidance (FIG. 14B), and passive avoidance (FIG. 14C). See Example 6.

FIGS. 15A-N depict results obtained from behavioral studies of animals of about 11 months of age, after vaccination with A beta 1-30-NH2 and K6A beta 1-30-NH2 together with alum adjuvants, as well as controls. The studies included testing of locomotor activity (FIG. 15A), and cognitive testing using traverse beam (FIGS. 15B and 15C), rotarod (FIG. 15D), radial arm maze (FIGS. 15E and 15F), straight alley channel (FIG. 15G), visible platform (FIGS. 15H and 15T), Morris water maze (FIGS. 15J and 15K), probe trial (FIGS. 15L and 15M), and linear maze (FIG. 15N). See Example 6.

L4 ANSWER 33 OF 125 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:434266 CAPLUS
DN 139:21013
TI Synthetic immunogenic/non-deposit-forming polypeptides and peptides homologous to amyloid .beta., ***prion*** protein, amylin, .alpha.-synuclein, or polyglutamine repeats for induction of an immune response
IN Frangione, Blas; Wisniewski, Thomas; Sigurdsson, Einar M.
PA New York University, USA
SO PCT Int. Appl., 265 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003045128	A2	20030605	WO 2002-US37634	20021121

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2003166558 A1 20030904 US 2002-301488 20021121
PRAI US 2001-331801P P 20011121

L4 ANSWER 34 OF 125 USPATFULL on STN
AN 2003:318682 USPATFULL
TI Human G-protein chemokine receptor HSATU68
IN Li, Yi, Sunnyvale, CA, UNITED STATES
PI US 2003224426 A1 20031204
AI US 2003-411284 A1 20030411 (10)
RLI Continuation-in-part of Ser. No. US 1998-101518, filed on 21 Dec 1998, PENDING A 371 of International Ser. No. WO 1996-US499, filed on 11 Jan 1996, PENDING
PRAI US 2002-371725P 20020412 (60)
DT Utility
FS APPLICATION
LN.CNT 16542
INCL INCLM: 435/006.000
INCLS: 435/007.100; 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/007.100; 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; C07H021-04; C07K014-715; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 35 OF 125 USPATFULL on STN
AN 2003:312136 USPATFULL
TI ***Antibody*** gene transfer and recombinant AAV therefor
IN Clark, Kelly Reed, Westerville, OH, UNITED STATES
Johnson, Philip R., JR., New Albany, OH, UNITED STATES
PI US 2003219733 A1 20031127
AI US 2003-409938 A1 20030409 (10)
PRAI US 2002-371501P 20020409 (60)
DT Utility
FS APPLICATION
LN.CNT 1656
INCL INCLM: 435/005.000
INCLS: 435/070.210; 536/023.720; 435/325.000
NCL NCLM: 435/005.000
NCLS: 435/070.210; 536/023.720; 435/325.000
IC [7]
ICM: C12Q001-70
ICS: C07H021-04; C12P021-04; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 36 OF 125 USPATFULL on STN
AN 2003:299889 USPATFULL
TI Pharmaceutical compositions and articles of manufacture useful in reversal of a clinical episode of an incurable disease and methods of use thereof
IN Shimoni, Zvi, Netanya, ISRAEL
Niven, Mark Jonathan, Bnei Brak, ISRAEL
Bulvik, Shlomo, Kfar Haroeh, ISRAEL
PA LANIADO KIRYAT SANZ HOSPITAL (non-U.S. corporation)
PI US 2003211110 A1 20031113
AI US 2003-414011 A1 20030416 (10)
PRAI US 2002-377953P 20020507 (60)
DT Utility
FS APPLICATION
LN.CNT 858
INCL INCLM: 424/159.100
INCLS: 424/160.100; 424/161.100
NCL NCLM: 424/159.100
NCLS: 424/160.100; 424/161.100
IC [7]
ICM: A61K039-42

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 37 OF 125 USPATFULL on STN
AN 2003:250925 USPATFULL
TI Molecular antigen array
IN Renner, Wolfgang A., Zurich, SWITZERLAND
Bachmann, Martin, Winterthur, SWITZERLAND
Tissot, Alain, Zurich, SWITZERLAND
Maurer, Patrick, Winterthur, SWITZERLAND
Lechner, Franziska, Zurich, SWITZERLAND
Sebbel, Peter, Zurich, SWITZERLAND
Piossek, Christine, Winterthur, SWITZERLAND
Ortmann, Rainer, Saint Louis, SWITZERLAND
Luond, Rainer, Therwil, SWITZERLAND
Staufenbiel, Matthias, Lorrach, GERMANY, FEDERAL REPUBLIC OF
Frey, Peter, Bern, SWITZERLAND
PA Cytos Biotechnology AG (non-U.S. corporation)
PI US 2003175711 A1 20030918
AI US 2002-50898 A1 20020118 (10)
PRAI US 2001-331045P 20011107 (60)
US 2001-326998P 20011005 (60)
US 2001-288549P 20010504 (60)
US 2001-262379P 20010119 (60)
DT Utility
FS APPLICATION
LN.CNT 14673
INCL INCLM: 435/006.000
INCLS: 424/201.100; 435/005.000; 435/007.320
NCL NCLM: 435/006.000
NCLS: 424/201.100; 435/005.000; 435/007.320
IC [7]
ICM: C12Q001-70
ICS: G01N033-554; G01N033-569; A61K039-295; C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 38 OF 125 USPATFULL on STN
AN 2003:250504 USPATFULL
TI Molecular antigen array
IN Renner, Wolfgang A., Zurich, SWITZERLAND
Bachmann, Martin, Winterthur, SWITZERLAND
Tissot, Alain, Zurich, SWITZERLAND
Maurer, Patrick, Winterthur, SWITZERLAND
Lechner, Franziska, Zurich, SWITZERLAND
Sebbel, Peter, Zurich, SWITZERLAND
Piossek, Christine, Winterthur, SWITZERLAND
PA Cytos Biotechnology AG (non-U.S. corporation)
PI US 2003175290 A1 20030918
AI US 2002-50902 A1 20020118 (10)
PRAI US 2001-331045P 20011107 (60)
US 2001-326998P 20011005 (60)
US 2001-288549P 20010504 (60)
US 2001-262379P 20010119 (60)
DT Utility
FS APPLICATION
LN.CNT 15306
INCL INCLM: 424/186.100
INCLS: 435/005.000; 435/007.900; 435/287.200; 435/006.000
NCL NCLM: 424/186.100
NCLS: 435/005.000; 435/007.900; 435/287.200; 435/006.000
IC [7]
ICM: A61K039-12
ICS: C12Q001-70; G01N033-53; G01N033-542; C12M001-34; C12Q001-68;
C12M003-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 39 OF 125 USPATFULL on STN
AN 2003:237867 USPATFULL
TI Human G-protein chemokine receptor (CCR5) HDGNR10
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Roschke, Viktor, Rockville, MD, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PA Human Genome Sciences, Inc. (U.S. corporation)
PI US 2003166024 A1 20030904
AI US 2002-135839 A1 20020501 (10)
RLI Continuation of Ser. No. US 2001-779879, filed on 9 Feb 2001, ABANDONED

PRAI US 2000-181258P 20000209 (60)
      US 2000-187999P 20000309 (60)
      US 2000-234336P 20000922 (60)
DT   Utility
FS   APPLICATION
LN.CNT 17941
INCL INCLM: 435/007.230
      INCLS: 435/069.100; 435/320.100; 530/388.220; 536/023.530; 435/334.000
NCL   NCLM: 435/007.230
      NCLS: 435/069.100; 435/320.100; 530/388.220; 536/023.530; 435/334.000
IC   [7]
      ICM: G01N033-574
      ICS: C07H021-04; C12P021-02; C07K016-30; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 40 OF 125 USPATFULL on STN
AN   2003:237339 USPATFULL
TI   Humanized ***antibodies*** that recognize beta amyloid peptide
IN   Basi, Guriq, Palo Alto, CA, UNITED STATES
      Saldanha, Jose, Enfield, UNITED KINGDOM
      Yednock, Ted, Forest Knolls, CA, UNITED STATES
PA   Elan Pharmaceuticals, Inc., San Francisco, CA (U.S. corporation)
PI   US 2003165496   A1   20030904
AI   US 2001-10942   A1   20011206 (10)
PRAI US 2000-251892P   20001206 (60)
DT   Utility
FS   APPLICATION
LN.CNT 5733
INCL INCLM: 424/141.100
      INCLS: 530/388.150; 435/328.000
NCL   NCLM: 424/141.100
      NCLS: 530/388.150; 435/328.000
IC   [7]
      ICM: A61K039-395
      ICS: C12N005-06; C07K016-44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 41 OF 125 USPATFULL on STN
AN   2003:231634 USPATFULL
TI   Methods and compositions for treating or preventing skin disorders using
      binding agents specific for prostate specific membrane antigen
IN   Bander, Neil, New York, NY, UNITED STATES
PI   US 2003161832   A1   20030828
AI   US 2002-160506   A1   20020530 (10)
PRAI US 2001-324100P   20010920 (60)
      US 2002-362612P   20020308 (60)
DT   Utility
FS   APPLICATION
LN.CNT 7532
INCL INCLM: 424/155.100
NCL   NCLM: 424/155.100
IC   [7]
      ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 42 OF 125 USPATFULL on STN
AN   2003:152330 USPATFULL
TI   Cell-based vaccine
IN   Eibl, Martha, Vienna, AUSTRIA
      Kreil, Thomas, Klosterneuburg, AUSTRIA
      Mannhalter, Josef, Vienna, AUSTRIA
      Eibl, Johann, Vienna, AUSTRIA
      Kerschbaum, Astrid, Vienna, AUSTRIA
      Bruhl, Peter, Vienna, AUSTRIA
PI   US 2003103996   A1   20030605
AI   US 2002-255423   A1   20020926 (10)
RLI   Continuation of Ser. No. US 1998-224807, filed on 31 Dec 1998, ABANDONED
      Continuation of Ser. No. WO 1997-EP3452, filed on 2 Jul 1997, UNKNOWN
PRAI DE 1996-19626614   19960702
DT   Utility
FS   APPLICATION
LN.CNT 980
INCL INCLM: 424/185.100
      INCLS: 424/204.100; 424/192.100; 424/186.100; 435/006.000
NCL   NCLM: 424/185.100
      NCLS: 424/204.100; 424/192.100; 424/186.100; 435/006.000

IC [7]
ICM: A61K039-12
ICS: A61K039-00; C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 43 OF 125 USPATFULL on STN
AN 2003:146312 USPATFULL
TI Human G-protein Chemokine Receptor (CCR5) HDGNR10
IN Roschke, Viktor, Rockville, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PA Human Genome Sciences, Inc. (U.S. corporation)
PI US 2003100058 A1 20030529
AI US 2002-67800 A1 20020208 (10)
RLI Continuation-in-part of Ser. No. WO 2001-US4153, filed on 9 Feb 2001, UNKNOWN Continuation-in-part of Ser. No. US 2001-779880, filed on 9 Feb 2001, PENDING
PRAI US 2001-297257P 20010612 (60)
US 2001-310458P 20010808 (60)
US 2001-328447P 20011012 (60)
US 2001-341725P 20011221 (60)
DT Utility
FS APPLICATION
LN.CNT 18955
INCL INCLM: 435/069.100
INCLS: 435/326.000; 435/320.100; 530/388.800; 536/023.530
NCL NCLM: 435/069.100
NCLS: 435/326.000; 435/320.100; 530/388.800; 536/023.530
IC [7]
ICM: C12P021-02
ICS: C07H021-04; C12N005-06; C07K016-30
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 44 OF 125 USPATFULL on STN
AN 2003:119706 USPATFULL
TI Treatment for central nervous system disorders
IN Poduslo, Joseph F., Rochester, MN, UNITED STATES
Curran, Geoffry L., Rochester, MN, UNITED STATES
PI US 2003082191 A1 20030501
AI US 2001-942253 A1 20010829 (9)
DT Utility
FS APPLICATION
LN.CNT 803
INCL INCLM: 424/178.100
INCLS: 435/188.500; 424/001.490
NCL NCLM: 424/178.100
NCLS: 435/188.500; 424/001.490
IC [7]
ICM: A61K039-395
ICS: A61K051-00; C12N009-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 45 OF 125 USPATFULL on STN
AN 2003:52386 USPATFULL
TI Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates
IN Robl, James M., Belchertown, MA, UNITED STATES
Goldsby, Richard A., Leverett, MA, UNITED STATES
Ferguson, Stacy E., Worcester, MA, UNITED STATES
Kuroiwa, Yoshimi, Takasaki, JAPAN
Tomizuka, Kazuma, Takasaki, JAPAN
Ishida, Isao, Isehara, JAPAN
PI US 2003037347 A1 20030220
AI US 2001-988115 A1 20011116 (9)
RLI Continuation-in-part of Ser. No. US 2000-714185, filed on 17 Nov 2000, PENDING
PRAI US 2001-311625P 20010809 (60)
US 2000-256458P 20001220 (60)
US 1999-166410P 19991119 (60)
DT Utility
FS APPLICATION
LN.CNT 3863
INCL INCLM: 800/006.000
INCLS: 800/015.000; 800/014.000; 800/016.000; 800/017.000; 435/326.000
NCL NCLM: 800/006.000
NCLS: 800/015.000; 800/014.000; 800/016.000; 800/017.000; 435/326.000

IC [7]
ICM: A01K067-027
ICS: C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 46 OF 125 USPATFULL on STN
AN 2003:29853 USPATFULL
TI Use of coiled-coil structural scaffold to generate structure-specific peptides
IN Houston, Michael E., Edmonton, CANADA
Hodges, Robert, Denver, CO, UNITED STATES
PI US 2003021795 A1 20030130
AI US 2001-882774 A1 20010614 (9)
PRAI US 2000-211892P 20000614 (60)
US 2000-213387P 20000623 (60)
DT Utility
FS APPLICATION
LN.CNT 1934
INCL INCLM: 424/185.100
INCLS: 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000
NCL NCLM: 424/185.100
NCLS: 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000
IC [7]
ICM: A61K039-00
ICS: C07K007-06; C07K007-08; C07K014-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 47 OF 125 USPATFULL on STN
AN 2003:4060 USPATFULL
TI The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
IN Eisenbach-schwartz, Michael, Rehovot, ISRAEL
Cohen, Irun R., Rehovot, ISRAEL
Sela, Michael, Rehovot, ISRAEL
Yoles, Eti, Nahal Sorek, ISRAEL
Kipnis, Jonathan, Modiin, ISRAEL
PI US 2003004099 A1 20030102
AI US 2001-765644 A1 20010122 (9)
RLI Continuation-in-part of Ser. No. US 2000-620216, filed on 20 Jul 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-487793, filed on 20 Jan 2000, ABANDONED
PRAI US 2000-209799P 20000607 (60)
DT Utility
FS APPLICATION
LN.CNT 2844
INCL INCLM: 514/012.000
INCLS: 424/093.700
NCL NCLM: 514/012.000
NCLS: 424/093.700
IC [7]
ICM: A61K045-00
ICS: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 48 OF 125 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
DUPLICATE
AN 2003:37221368 BIOTECHNO
TI Good and bad amyloid ***antibodies*** [3]
AU Mattson M.P.; Chan S.L.
CS M.P. Mattson, Laboratory of Neurosciences, National Institute on Aging, 5600 Nathan Shock Drive, Baltimore, MD 21224, United States.
E-mail: mattsonm@grc.nia.nih.gov
SO Science, (26 SEP 2003), 301/5641 (1847-1849), 12 reference(s)
CODEN: SCIEAS ISSN: 0036-8075
DT Journal; Letter
CY United States
LA English

L4 ANSWER 49 OF 125 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2003434375 EMBASE
TI Intravenous immune globulins: An update for clinicians.
AU Knezevic-Maramica I.; Kruskall M.S.
CS Dr. M.S. Kruskall, Div. of Lab. and Transfus. Medicine, Yamins 309, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, United States. mkruskal@bidmc.harvard.edu

SO Transfusion, (1 Oct 2003) 43/10 (1460-1480).
Refs: 248
ISSN: 0041-1132 CODEN: TRANAT
CY United States
DT Journal; General Review
FS 026 Immunology, Serology and Transplantation
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
039 Pharmacy
LA English

L4 ANSWER 50 OF 125 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 4
AN 2004:42025 BIOSIS
DN PREV200400043291
TI Emerging therapeutic agents for transmissible spongiform encephalopathies: A review.
AU Koster, T.; Singh, K. [Reprint Author]; Zimmermann, M.; Gruys, E.
CS Department of Veterinary Pathobiology, Oklahoma State University, Stillwater, OK, USA
skuldee@okstate.edu
SO Journal of Veterinary Pharmacology and Therapeutics, (October 2003) Vol. 26, No. 5, pp. 315-326. print.
CODEN: JVPTD9. ISSN: 0140-7783.
DT Article
General Review; (Literature Review)
LA English
ED Entered STN: 14 Jan 2004
Last Updated on STN: 14 Jan 2004

L4 ANSWER 51 OF 125 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:192522 BIOSIS
DN PREV200300192522
TI Immunization approaches for the treatment of ***prion*** disease.
AU Wisniewski, Thomas [Reprint Author]; Sy, Man-Sun; Sadowski, Marcin [Reprint Author]; Kascsak, Richard J.; Kascsak, Regina; Carp, Richard; Goni, Fernando [Reprint Author]; Sigurdsson, Einar [Reprint Author]
CS New York, NY, USA
SO Neurology, (March 11 2003) Vol. 60, No. 5 Supplement 1, pp. A250. print.
Meeting Info.: 55th Annual Meeting of the American Academy of Neurology. Honolulu, Hawaii, USA. March 29-April 05, 2003.
ISSN: 0028-3878 (ISSN print).
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 16 Apr 2003
Last Updated on STN: 16 Apr 2003

L4 ANSWER 52 OF 125 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN DUPLICATE 5
AN 2003017512 EMBASE
TI Anti- ***prion*** ***antibodies*** for prophylaxis following ***prion*** exposure in mice.
AU Sigurdsson E.M.; Sy M.-S.; Li R.; Scholtzova H.; Kascsak R.J.; Kascsak R.; Carp R.; Meeker H.C.; Frangione B.; Wisniewski T.
CS T. Wisniewski, Department of Psychiatry, New York University Sch. of Medicine, Millhauser Laboratory, 550 First Avenue, New York, NY 10016, United States. thomas.wisniewski@med.nyu.edu
SO Neuroscience Letters, (23 Jan 2003) 336/3 (185-187).
Refs: 13
ISSN: 0304-3940 CODEN: NELED5
CY Ireland
DT Journal; Article
FS 008 Neurology and Neurosurgery
026 Immunology, Serology and Transplantation
030 Pharmacology
037 Drug Literature Index
LA English
SL English

L4 ANSWER 53 OF 125 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:389280 CAPLUS
DN 138:400002
TI Immunological therapeutic and imaging approaches for ***prion***

disease
AU Sadowski, Marcin; Wisniewski, Thomas
CS Department of Neurology, New York University School of Medicine, New York, NY, 10016, USA
SO Current Medicinal Chemistry: Immunology, Endocrine & Metabolic Agents (2003), 3(2), 113-118
CODEN: CMCIC8; ISSN: 1568-0134
PB Bentham Science Publishers Ltd.
DT Journal; General Review
LA English
RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 54 OF 125 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN DUPLICATE 6
AN 2003-12655 DRUGU M
TI Monoclonal ***antibodies*** inhibit ***prion*** replication and delay the development of ***prion*** disease.
AU White A R; Enever P; Tayebi M; Mushens R; Linehan J; Brandner S; Anstee D; Collinge J; Hawke S
CS Univ.London
LO London; Bristol, U.K.
SO Nature (422, No. 6927, 80-83, 2003) 3 Fig. 1 Tab. 30 Ref.
CODEN: NATUAS ISSN: 0028-0836
AV CNS Infection and Immunity group, Division of Neurosciences and Psychological Medicine, Faculty of Medicine, Imperial College, Norfolk Place, London, W2 1PG, England. (S.H.). s.hawke@imperial.ac.uk).
LA English
DT Journal
FA AB; LA; CT
FS Literature

L4 ANSWER 55 OF 125 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:629675 CAPLUS
TI ***Prion*** disease diagnostic and immune-based therapeutic approaches
AU Kascsak, Richard J.; Spinner, Daryl; Kascsak, Regina B.; Wolf, David E.
CS Immunological Neurovirology, New York State Institute for Basic Research, Staten Island, NY, 10314, USA
SO Abstracts of Papers, 226th ACS National Meeting, New York, NY, United States, September 7-11, 2003 (2003), ANYL-013 Publisher: American Chemical Society, Washington, D. C.
CODEN: 69EKY9
DT Conference; Meeting Abstract
LA English

L4 ANSWER 56 OF 125 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:10296 CAPLUS
DN 136:68700
TI Tyrosine cross-linked oligomers of amyloid peptide: Pathology and immunotherapy
IN Bush, Ashley; Cherny, Robert
PA Prana Biotechnology Limited, Australia; The General Hospital Corporation
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002000245	A1	20020103	WO 2001-AU786	20010628
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1296705	A1	20030402	EP 2001-947033	20010628
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004501204	T2	20040115	JP 2002-505026	20010628
	US 2004013680	A1	20040122	US 2003-312437	20030616
PRAI	US 2000-214779P	P	20000628		
	US 2000-242177P	P	20001023		

WO 2001-AU786 W 20010628
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 57 OF 125 USPATFULL on STN
AN 2002:343899 USPATFULL
TI Identification of microbial polynucleotides expressed during infection of a host
IN Hillman, Jeffrey Daniel, Gainesville, FL, UNITED STATES
PA iviGene Corporation (U.S. corporation)
PI US 2002197625 A1 20021226
AI US 2002-92243 A1 20020306 (10)
RLI Continuation-in-part of Ser. No. US 980845, PENDING A 371 of International Ser. No. WO 2000-US21340, filed on 4 Aug 2000, UNKNOWN
PRAI US 1999-147551P 19990806 (60)
DT Utility
FS APPLICATION
LN.CNT 1989
INCL INCLM: 435/006.000
INCLS: 435/005.000; 435/007.320
NCL NCLM: 435/006.000
NCLS: 435/005.000; 435/007.320
IC [7]
ICM: C12Q001-70
ICS: C12Q001-68; G01N033-554; G01N033-569
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 58 OF 125 USPATFULL on STN
AN 2002:343535 USPATFULL
TI Compositions and methods for preventing protein aggregation in neurodegenerative diseases
IN Ghanbari, Hossein A., Potomac, MD, UNITED STATES
Ghanbari, Kasra, Potomac, MD, UNITED STATES
PI US 2002197258 A1 20021226
AI US 2002-177604 A1 20020624 (10)
PRAI US 2001-300190P 20010622 (60)
DT Utility
FS APPLICATION
LN.CNT 386
INCL INCLM: 424/146.100
NCL NCLM: 424/146.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 59 OF 125 USPATFULL on STN
AN 2002:300834 USPATFULL
TI ***Prion*** protein dimers useful for vaccination
IN Schaetzl, Hermann, Olching, GERMANY, FEDERAL REPUBLIC OF
PI US 2002168377 A1 20021114
AI US 2002-115984 A1 20020405 (10)
PRAI EP 2001-109707 20010419
DT Utility
FS APPLICATION
LN.CNT 754
INCL INCLM: 424/185.100
INCLS: 514/002.000; 514/019.000; 424/184.100; 424/186.100
NCL NCLM: 424/185.100
NCLS: 514/002.000; 514/019.000; 424/184.100; 424/186.100
IC [7]
ICM: A61K038-00
ICS: A01N037-18; A61K039-00; A61K039-38; A61K039-12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 60 OF 125 USPATFULL on STN
AN 2002:295102 USPATFULL
TI Brain-associated inhibitor of tissue-type plasminogen activator
IN Yepes, Manuel, Alexandria, VA, UNITED STATES
Lawrence, Daniel A., Derwood, MD, UNITED STATES
Coleman, Timothy A., Gaithersburg, MD, UNITED STATES
PI US 2002165147 A1 20021107
AI US 2001-987021 A1 20011113 (9)
RLI Continuation-in-part of Ser. No. US 2001-957485, filed on 21 Sep 2001, PENDING Continuation of Ser. No. US 2000-521664, filed on 8 Mar 2000, ABANDONED Continuation of Ser. No. US 2000-722292, filed on 28 Nov 2000, PENDING Division of Ser. No. US 1999-348817, filed on 8 Jul 1999,

GRANTED, Pat. No. US 6191260 Division of Ser. No. US 1997-948997, filed on 10 Oct 1997, GRANTED, Pat. No. US 6008020
PRAI US 2000-247971P 20001114 (60)
US 1999-123704P 19990310 (60)
US 1996-28117P 19961011 (60)
DT Utility
FS APPLICATION
LN.CNT 9975
INCL INCLM: 514/012.000
INCLS: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/325.000
NCL NCLM: 514/012.000
NCLS: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/325.000
IC [7]
ICM: A61K038-17
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-435
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 61 OF 125 USPATFULL on STN
AN 2002:289248 USPATFULL
TI Prevention and treatment of alzheimer's disease
IN Lannfelt, Lars, Stockholm, SWEDEN
Nilsberth, Camilla, Norrkoping, SWEDEN
Westlind-Danielsson, Anita, Hollviken, SWEDEN
Naslund, Jan, Stockholm, SWEDEN
PI US 2002162129 A1 20021031
AI US 2001-899815 A1 20010709 (9)
PRAI EP 2000-202387 20000707
US 2000-217098P 20000710 (60)
DT Utility
FS APPLICATION
LN.CNT 741
INCL INCLM: 800/012.000
INCLS: 424/185.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 800/012.000
NCLS: 424/185.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: A01K067-027
ICS: C07H021-04; A61K039-00; C12N009-64; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 62 OF 125 USPATFULL on STN
AN 2002:221784 USPATFULL
TI Inhibitors of IAPP fibril formation and uses thereof
IN Fraser, Paul, Toronto, CANADA
PI US 2002119926 A1 20020829
AI US 2001-956625 A1 20010919 (9)
PRAI US 2000-233482P 20000919 (60)
DT Utility
FS APPLICATION
LN.CNT 1753
INCL INCLM: 514/012.000
INCLS: 435/184.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000
NCL NCLM: 514/012.000
NCLS: 435/184.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000
IC [7]
ICM: A61K038-17
ICS: A61K038-10; A61K038-08; C12N009-99
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 63 OF 125 USPATFULL on STN
AN 2002:178549 USPATFULL
TI Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
IN Chalifour, Robert, Ile Bizard, CANADA
Hebert, Lise, Brossard, CANADA
Kong, Xianqi, Dollard-des-Oremaux, CANADA
Gervais, Francine, Ile Bizard, CANADA
PI US 2002094335 A1 20020718
AI US 2001-867847 A1 20010529 (9)
RLI Continuation-in-part of Ser. No. US 2000-724842, filed on 28 Nov 2000, PENDING
PRAI US 1999-168594P 19991129 (60)
DT Utility
FS APPLICATION
LN.CNT 1946
INCL INCLM: 424/185.100

NCL NCLM: 424/185.100
IC [7]
ICM: A61K039-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 64 OF 125 USPATFULL on STN
AN 2002:119846 USPATFULL
TI Human G-protein Chemokine receptor (CCR5) HDGNR10
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Roschke, Viktor, Rockville, MD, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PI US 2002061834 A1 20020523
AI US 2001-779880 A1 20010209 (9)
PRAI US 2000-181258P 20000209 (60)
US 2000-187999P 20000309 (60)
US 2000-234336P 20000922 (60)
DT Utility
FS APPLICATION
LN.CNT 18667
INCL INCLM: 514/001.000
INCLS: 530/350.000; 536/023.500; 435/325.000; 435/320.100; 435/069.100
NCL NCLM: 514/001.000
NCLS: 530/350.000; 536/023.500; 435/325.000; 435/320.100; 435/069.100
IC [7]
ICM: A61K031-00
ICS: C07H021-04; C07K014-705; C12N005-06; C12P021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 65 OF 125 USPATFULL on STN
AN 2002:92268 USPATFULL
TI Human G-protein Chemokine Receptor HDGNR10
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Roschke, Viktor, Rockville, MD, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PI US 2002048786 A1 20020425
AI US 2001-779879 A1 20010209 (9)
PRAI US 2000-181258P 20000209 (60)
US 2000-187999P 20000309 (60)
US 2000-234336P 20000922 (60)
DT Utility
FS APPLICATION
LN.CNT 17969
INCL INCLM: 435/069.100
INCLS: 536/023.500; 424/130.100; 514/012.000; 435/007.200; 435/325.000
NCL NCLM: 435/069.100
NCLS: 536/023.500; 424/130.100; 514/012.000; 435/007.200; 435/325.000
IC [7]
ICM: G01N033-53
ICS: G01N033-567; A61K038-00; C07H021-04; C12P021-06; A61K039-395;
C12N005-02; C12N005-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 66 OF 125 USPATFULL on STN
AN 2002:67195 USPATFULL
TI Use of copolymer 1 and related peptides and polypeptides and T cells
treated therewith for neuroprotective therapy
IN Eisenbach-Schwartz, Michal, Rehovot, ISRAEL
Yoles, Eti, Rehovot, ISRAEL
Kipnis, Jonathan, Modiin, ISRAEL
PI US 2002037848 A1 20020328
AI US 2001-765301 A1 20010122 (9)
RLI Continuation-in-part of Ser. No. US 2000-620216, filed on 20 Jul 2000,
PENDING
PRAI US 2000-209799P 20000607 (60)
DT Utility
FS APPLICATION
LN.CNT 2839
INCL INCLM: 514/012.000
NCL NCLM: 514/012.000
IC [7]
ICM: A61K038-16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 67 OF 125 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on

STN DUPLICATE 7
AN 2002:404097 BIOSIS
DN PREV200200404097
TI Drug therapy in human and experimental transmissible spongiform encephalopathy.
AU Brown, Paul [Reprint author]
CS National Institutes of Health, Building 36, Room 4A-19 (MSC-4123), Bethesda, MD, 20892-4122, USA
brownp@ninds.nih.gov
SO Neurology, (June 25, 2002) Vol. 58, No. 12, pp. 1720-1725. print.
CODEN: NEURAI. ISSN: 0028-3878.
DT Article
General Review; (Literature Review)
LA English
ED Entered STN: 24 Jul 2002
Last Updated on STN: 24 Jul 2002

L4 ANSWER 68 OF 125 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2003037295 EMBASE
TI Grand ideas floating freely. Conference on the new ***prion*** biology: Basic science, diagnosis and therapy.
AU Chesebro B.
CS B. Chesebro, Rocky Mountain Laboratories, Nat'l Inst. of Allergy/Infect. Dis., National Institute of Health, Hamilton, MT 59840, United States.
bchesebro@nih.gov
SO EMBO Reports, (1 Dec 2002) 3/12 (1123-1126).
Refs: 17
ISSN: 1469-221X CODEN: ERMEAX
CY United Kingdom
DT Journal; Conference Article
FS 005 General Pathology and Pathological Anatomy
008 Neurology and Neurosurgery
037 Drug Literature Index
LA English

L4 ANSWER 69 OF 125 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN DUPLICATE 8
AN 2002439085 EMBASE
TI ***Prions*** - Immunological enigma?.
AU Ganchevska P.; Sarafian V.
CS V. Sarafian, Department of Biology, Medical University - Plovdiv, Plovdiv, Bulgaria
SO Clinical Application of Immunology, (2002) 1/2 (71-75).
Refs: 39
ISSN: 1312-0832 CODEN: CAILBU
CY Bulgaria
DT Journal; General Review
FS 004 Microbiology
026 Immunology, Serology and Transplantation
LA English
SL English

L4 ANSWER 70 OF 125 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:325687 BIOSIS
DN PREV200300325687
TI ***PASSIVE*** ***IMMUNIZATION*** WITH ANTI - PrP ***ANTIBODIES*** PROLONGS ***PRION*** INCUBATION PERIOD.
AU Wisniewski, T. [Reprint Author]; Sy, M. S.; Li, R.; Scholtzova, H. [Reprint Author]; Kascsak, R. J.; Kascsak, R.; Carp, R.; Meeker, H. C.; Frangione, B.; Sigurdsson, E. M.
CS Dept Neurology, Dept.Pathology, Dept. Psychiatry, New York Univ, Sch Med, New York, NY, USA
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002) Vol. 2002, pp. Abstract No. 692.16. http://sfn.scholarone.com. cd-rom.
Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience. Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
DT Conference; (Meeting)
Conference; (Meeting Poster)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 16 Jul 2003
Last Updated on STN: 16 Jul 2003

L4 ANSWER 71 OF 125 USPATFULL on STN DUPLICATE 9

AN 2001:229204 USPATFULL
TI ***Passive*** ***immunization*** against clostridium difficile disease
IN Thomas, William D., JR., Somerville, MA, United States
Giannasca, Paul J., Newton, MA, United States
Zhang, Zhenxi, Cambridge, MA, United States
Lei, Wende, Cambridge, MA, United States
Monath, Thomas P., Harvard, MA, United States
PI US 2001051153 A1 20011213
US 6680168 B2 20040120
AI US 2001-815452 A1 20010322 (9)
RLI Continuation of Ser. No. US 1998-176076, filed on 20 Oct 1998, GRANTED, Pat. No. US 6214341
PRAI US 1997-62522P 19971020 (60)
DT Utility
FS APPLICATION
LN.CNT 979
INCL INCLM: 424/130.100
INCLS: 435/007.320; 424/167.100
NCL° NCLM: 435/004.000
NCLS: 424/130.100; 424/150.100; 424/164.100; 424/167.100; 424/234.100; 424/236.100; 435/326.000; 435/340.000; 530/389.100; 530/389.500
IC [7]
ICM: G01N033-554
ICS: A61K039-40; G01N033-569; A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 72 OF 125 USPATFULL on STN
AN 2001:152492 USPATFULL
TI Proteinase K resistant surface protein of neisseria meningitidis
IN Brodeur, Bernard R., Sillery, Canada
Martin, Denis, St-Augustin-de-Des Maures, Canada
Hamel, Josee, Sillery, Canada
Rioux, Clement, Ville-de-Cap-Rouge, Canada
PA BioChem Pharma Inc., Quebec, Canada (non-U.S. corporation)
PI US 6287574 B1 20010911
AI US 1997-913362 19971113 (8)
RLI Continuation of Ser. No. US 1995-406362, filed on 17 Mar 1995, now abandoned
PRAI US 1995-1983P 19950804 (60)
DT Utility
FS GRANTED
LN.CNT 2034
INCL INCLM: 424/250.100
INCLS: 424/249.100; 424/184.100; 424/185.100; 424/190.100; 530/300.000; 530/350.000; 536/023.700
NCL NCLM: 424/250.100
NCLS: 424/184.100; 424/185.100; 424/190.100; 424/249.100; 530/300.000; 530/350.000; 536/023.700
IC [7]
ICM: A61K039-095
EXF 530/350; 530/412; 530/418; 530/300; 424/249.1; 424/250.1; 424/184.1; 424/185.1; 424/190.1; 536/23.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 73 OF 125 USPATFULL on STN
AN 2001:51565 USPATFULL
TI ***Passive*** ***immunization*** against Clostridium difficile disease
IN Thomas, Jr., William D., Somerville, MA, United States
Giannasca, Paul J., Newton, MA, United States
Zhang, Zhenxi, Cambridge, MA, United States
Lei, Wende, Cambridge, MA, United States
Monath, Thomas P., Harvard, MA, United States
PA OraVax, Cambridge, MA, United States (U.S. corporation)
PI US 6214341 B1 20010410
AI US 1998-176076 19981020 (9)
DT Utility
FS Granted
LN.CNT 947
INCL INCLM: 424/130.100
INCLS: 424/150.100; 424/164.100; 424/167.100; 530/389.100; 530/389.500
NCL NCLM: 424/130.100
NCLS: 424/150.100; 424/164.100; 424/167.100; 530/389.100; 530/389.500
IC [7]
ICM: A61K039-395

ICS: A61K039-40; C07K016-00
EXF 424/130.1; 424/150.1; 424/164.1; 424/167.1; 530/389.1; 530/389.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 74 OF 125 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 10
AN 2001:422385 BIOSIS
DN PREV200100422385
TI Scrapie ***prion*** protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a ***prion*** protein ***antibody*** .
AU Enari, Masato; Flechsig, Eckhard; Weissmann, Charles [Reprint author]
CS Medical Research Council Prion Unit, Neurogenetics, Imperial College School of Medicine at St. Mary's, London, W2 1PG, UK
c.weissmann@ic.ac.uk
SO Proceedings of the National Academy of Sciences of the United States of America, (July 31, 2001) Vol. 98, No. 16, pp. 9295-9299. print.
CODEN: PNASA6. ISSN: 0027-8424.
DT Article
LA English
ED Entered STN: 5 Sep 2001
Last Updated on STN: 22 Feb 2002

L4 ANSWER 75 OF 125 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:861516 CAPLUS
DN 134:28431
TI Prevention and treatment of amyloidogenic disease
IN Schenk, Dale B.
PA Neuralab Limited, Bermuda
SO PCT Int. Appl., 140 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000072876	A2	20001207	WO 2000-US15239	20000601
	WO 2000072876	A3	20010503		
	W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2375104	AA	20001207	CA 2000-2375104	20000601
	EP 1185296	A2	20020313	EP 2000-938075	20000601
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000011103	A	20020319	BR 2000-11103	20000601
	TR 200103469	T2	20020521	TR 2001-200103469	20000601
	EE 200100645	A	20030217	EE 2001-645	20000601
	JP 2003516929	T2	20030520	JP 2001-511318	20000601
	BG 106140	A	20020830	BG 2001-106140	20011123
	ZA 2001009662	A	20030523	ZA 2001-9662	20011123
	NO 2001005758	A	20020130	NO 2001-5758	20011126
	HR 2001000893	A1	20030430	HR 2001-893	20011130
PRAI	US 1999-137010P	P	19990601		
	WO 2000-US15239	W	20000601		

L4 ANSWER 76 OF 125 USPATFULL on STN
AN 2000:53899 USPATFULL
TI Process for producing GM2 specific ***antibodies***
IN Ritter, Gerd, New York, NY, United States
Old, Lloyd J., New York, NY, United States
PA Ludwig Institute For Cancer Research, New York, NY, United States (U.S. corporation)
PI US 6057115 20000502
AI US 1995-491310 19950616 (8)
DT Utility
FS Granted
LN.CNT 459
INCL INCLM: 435/007.230

INCLS: 435/007.320; 436/543.000; 436/547.000
NCL NCLM: 435/007.230
NCLS: 435/007.320; 436/543.000; 436/547.000
IC [7]
ICM: G01N033-574
ICS: G01N033-53
EXF 435/7.23; 435/7.32; 436/547; 436/543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 77 OF 125 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2000:363287 SCISEARCH
GA The Genuine Article (R) Number: 311MP
TI ***Antibodies*** in human infectious disease
AU Parren P W H I; Poignard P; Ditzel H J; Williamson R A; Burton D R (Reprint)
CS SCRIPPS CLIN & RES INST, DEPT IMMUNOL, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 (Reprint); SCRIPPS CLIN & RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037
CYA USA
SO IMMUNOLOGIC RESEARCH, (MAR 2000) Vol. 21, No. 2-3, pp. 265-278.
Publisher: HUMANA PRESS INC, 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512.
ISSN: 0257-277X.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 62
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 78 OF 125 USPATFULL on STN
AN 1999:150656 USPATFULL
TI Expression library immunization
IN Johnston, Stephen A., Dallas, TX, United States
Barry, Michael A., Carrollton, TX, United States
Lai, Wayne C., Richardson, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 5989553 19991123
AI US 1997-1157 19971230 (9)
RLI Division of Ser. No. US 1995-421155, filed on 7 Apr 1995, now patented, Pat. No. US 5703057
DT Utility
FS Granted
LN.CNT 2162
INCL INCLM: 424/190.100
INCLS: 424/184.100; 424/185.100; 424/188.100; 424/201.100; 424/207.100; 424/208.100; 424/234.100; 424/263.100; 424/264.100; 424/248.100; 435/325.000; 435/440.000; 435/455.000; 435/489.000; 530/403.000; 530/806.000; 530/825.000; 530/826.000; 530/868.000; 514/002.000
NCL NCLM: 424/190.100
NCLS: 424/184.100; 424/185.100; 424/188.100; 424/201.100; 424/207.100; 424/208.100; 424/234.100; 424/248.100; 424/263.100; 424/264.100; 435/325.000; 435/440.000; 435/455.000; 435/489.000; 514/002.000; 530/403.000; 530/806.000; 530/825.000; 530/826.000; 530/868.000
IC [6]
ICM: A61K039-00
ICS: A61K039-21
EXF 424/184.1; 424/185.1; 424/188.1; 424/190.1; 424/201.1; 424/207.1; 424/208.1; 424/234.1; 424/263.1; 424/264.1; 424/248.1; 435/325; 435/440; 435/455; 435/489; 530/403; 530/806; 530/825; 530/826; 530/868; 514/2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 79 OF 125 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1999-288172 [24] WPIDS
DNC C1999-085203
TI Treatment or prevention of Clostridium difficile infection.
DC B04 D16
IN GIANNASCA, P; LEI, W; MONATH, T P; THOMAS, W D; ZHANG, Z; GIANNASCA, P J
PA (ORAV-N) ORAVAX INC; (ACAM-N) ACAMBIS INC; (GIAN-I) GIANNASCA P J; (LEIW-I) LEI W; (MONA-I) MONATH T P; (THOM-I) THOMAS W D; (ZHAN-I) ZHANG Z; (ORAV-N) ORAVAX
CYC 83
PI WO 9920304 A1 19990429 (199924)* EN 43 A61K039-02
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE
GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG
MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG
UZ VN YU ZW

AU 9911082 A 19990510 (199938)
EP 1024826 A1 20000809 (200039) EN A61K039-02
R: CH DE FR GB LI SE
US 6214341 B1 20010410 (200122) A61K039-395
US 2001051153 A1 20011213 (200204) G01N033-554
AU 754270 B 20021107 (200302) A61K039-02
US 6680168 B2 20040120 (200407) C12Q001-00
US 2004126383 A1 20040701 (200444) A61K039-00

ADT WO 9920304 A1 WO 1998-US22216 19981020; AU 9911082 A AU 1999-11082 19981020; EP 1024826 A1 EP 1998-953806 19981020, WO 1998-US22216 19981020; US 6214341 B1 Provisional US 1997-62522P 19971020, US 1998-176076 19981020; US 2001051153 A1 Provisional US 1997-62522P 19971020, Cont of US 1998-176076 19981020, US 2001-815452 20010322; AU 754270 B AU 1999-11082 19981020; US 6680168 B2 Provisional US 1997-62522P 19971020, Cont of US 1998-176076 19981020, US 2001-815452 20010322; US 2004126383 A1 Provisional US 1997-62522P 19971020, Cont of US 1998-176076 19981020, CIP of US 2001-815452 20010322, US 2003-737270 20031216

FDT AU 9911082 A Based on WO 9920304; EP 1024826 A1 Based on WO 9920304; US 2001051153 A1 Cont of US 6214341; AU 754270 B Previous Publ. AU 9911082, Based on WO 9920304; US 6680168 B2 Cont of US 6214341; US 2004126383 A1 Cont of US 6214341, CIP of US 6680168

PRAI US 1997-62522P 19971020; US 1998-176076 19981020;
US 2001-815452 20010322; US 2003-737270 20031216

IC ICM A61K039-00; A61K039-02; A61K039-395; C12Q001-00; G01N033-554
ICS A61K039-08; A61K039-38; A61K039-40; C07K001-00; C07K016-00; C12N005-06; G01N033-569

L4 ANSWER 80 OF 125 USPATFULL on STN
AN 1998:162279 USPATFULL
TI Process for producing GM1 specific ***antibodies***
IN Ritter, Gerd, New York, NY, United States
Old, Lloyd J., New York, NY, United States
PA Ludwig Institute For Cancer Research, New York, NY, United States (U.S. corporation)
PI US 5854007 19981229
AI US 1997-847369 19970424 (8)
RLI Division of Ser. No. US 1995-491310, filed on 16 Jun 1995, now abandoned
DT Utility
FS Granted
LN.CNT 439
INCL INCLM: 435/007.230
INCLS: 436/547.000; 530/387.700; 530/388.400; 530/388.800; 530/389.500
NCL NCLM: 435/007.230
NCLS: 436/547.000; 530/387.700; 530/388.400; 530/388.800; 530/389.500
IC [6]
ICM: G01N033-574
ICS: G01N033-53
EXF 435/7.23; 436/547; 530/387.7; 530/388.4; 530/388.8; 530/389.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 81 OF 125 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:300268 CAPLUS
DN 129:93597
TI BSE viewed dynamically: a possible early cure based on ***passive*** ***immunization*** against PrPSc
AU Rossler, Otto E.; Hudson, John L.; Rossler, Reimara; Parisi, Jurgen
CS Division of Theoretical Chemistry, University of Tubingen, Tubingen, D-72076, Germany
SO Lecture Notes in Physics (1998), 503(Perspective Look at Nonlinear Media), 192-196
CODEN: LNPHA4; ISSN: 0075-8450
PB Springer-Verlag
DT Journal; General Review
LA English
RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 82 OF 125 USPATFULL on STN
AN 97:123194 USPATFULL
TI Expression library immunization
IN Johnston, Stephen A., Dallas, TX, United States
Barry, Michael A., Carrollton, TX, United States

Lai, Wayne C., Richardson, TX, United States
PA Board of Regents The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 5703057 19971230
AI US 1995-421155 19950407 (8)
DT Utility
FS Granted
LN.CNT 2243
INCL INCLM: 514/044.000
INCLS: 536/022.100; 536/023.100; 536/023.200; 536/023.400; 536/023.500; 536/023.510; 536/023.720; 536/023.740; 536/023.700; 435/325.000; 435/320.100; 435/172.300; 435/172.100; 435/006.000; 435/007.100; 424/422.000; 424/423.000; 424/009.200
NCL NCLM: 514/044.000
NCLS: 424/009.200; 424/422.000; 424/423.000; 435/006.000; 435/007.100; 435/320.100; 435/325.000; 536/022.100; 536/023.100; 536/023.200; 536/023.400; 536/023.500; 536/023.510; 536/023.700; 536/023.720; 536/023.740
IC [6]
ICM: A01N043-04
EXF 536/22.1; 536/23.1; 536/23.2; 536/23.4; 536/23.5; 536/23.51; 536/23.7; 536/23.72; 536/23.74; 514/44; 435/240.2; 435/320.1; 435/172.1; 435/172.3; 435/975; 435/6; 435/7.1; 435/325; 424/422; 424/423; 424/9.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 83 OF 125 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
AN 1994:24126323 BIOTECHNO
TI Panel discussion
SO Annals of Hematology, (1994), 68/SUPPL. 3 (S39-S43)
CODEN: ANHEE8 ISSN: 0939-5555
DT Journal; Conference Article
CY Germany, Federal Republic of
LA English

L4 ANSWER 84 OF 125 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 94136719 EMBASE
DN 1994136719
TI Panel discussion.
SO Annals of Hematology, (1994) 68/SUPPL. 3 (S39-S43).
ISSN: 0939-5555 CODEN: ANHEE8
CY Germany
DT Journal; Conference Article
FS 004 Microbiology
007 Pediatrics and Pediatric Surgery
022 Human Genetics
025 Hematology
026 Immunology, Serology and Transplantation
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English

L4 ANSWER 85 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42813 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Bovine ***prion*** protein homologous polypeptide, useful as immunogen.

L4 ANSWER 86 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42812 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -

IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Bovine ***prion*** protein homologous polypeptide, useful as immunogen.

L4 ANSWER 87 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42811 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Bovine ***prion*** protein homologous polypeptide, useful as immunogen.

L4 ANSWER 88 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42810 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Bovine ***prion*** protein homologous polypeptide, useful as immunogen.

L4 ANSWER 89 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42809 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Bovine ***prion*** protein homologous polypeptide, useful as immunogen.

L4 ANSWER 90 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42808 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]

DESC Bovine ***prion*** protein homologous polypeptide, useful as immunogen.

L4 ANSWER 91 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42807 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Human ***prion*** protein homologous polypeptide, useful as immunogen.

L4 ANSWER 92 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42806 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Human ***prion*** protein homologous polypeptide, useful as immunogen.

L4 ANSWER 93 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42805 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Human ***prion*** protein homologous polypeptide, useful as immunogen.

L4 ANSWER 94 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42804 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Human ***prion*** protein homologous polypeptide, useful as immunogen.

L4 ANSWER 95 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42803 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or

Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Human ***prion*** protein homologous polypeptide, useful as immunogen.

L4 ANSWER 96 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42802 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Human ***prion*** protein homologous polypeptide, useful as immunogen.

L4 ANSWER 97 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42801 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Cattle ***prion*** protein homologous polypeptide, useful as immunogen.

L4 ANSWER 98 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42800 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Human ***prion*** protein homologous polypeptide, useful as immunogen.

L4 ANSWER 99 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42799 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English

OS 2003-505145 [47]
DESC Greater kudu ***prion*** protein.

L4 ANSWER 100 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42798 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Bovine ***prion*** protein.

L4 ANSWER 101 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42797 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Goat ***prion*** protein.

L4 ANSWER 102 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42796 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Sheep ***prion*** protein.

L4 ANSWER 103 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42795 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Mink ***prion*** protein.

L4 ANSWER 104 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42794 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p

AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Syrian hamster ***prion*** protein.

L4 ANSWER 105 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42793 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Rat ***prion*** protein.

L4 ANSWER 106 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42792 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Mouse ***prion*** protein.

L4 ANSWER 107 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42791 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Chimpanzee ***prion*** protein.

L4 ANSWER 108 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42790 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Gorilla ***prion*** protein.

L4 ANSWER 109 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42789 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or

Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Human ***prion*** protein.

L4 ANSWER 110 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42788 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Amyloid beta-derived immunogenic polypeptide.

L4 ANSWER 111 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42787 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Amyloid beta-derived immunogenic polypeptide.

L4 ANSWER 112 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42786 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Amyloid beta-derived immunogenic polypeptide.

L4 ANSWER 113 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42785 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Amyloid beta-derived immunogenic polypeptide.

L4 ANSWER 114 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN

AN ABR42784 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Amyloid beta-derived immunogenic polypeptide.

L4 ANSWER 115 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42783 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Amyloid beta-derived immunogenic polypeptide.

L4 ANSWER 116 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42778 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Amyloid beta-derived immunogenic polypeptide.

L4 ANSWER 117 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42777 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Amyloid beta-derived immunogenic polypeptide.

L4 ANSWER 118 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42776 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English

OS 2003-505145 [47]
DESC Amyloid beta-derived immunogenic polypeptide.

L4 ANSWER 119 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42775 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Amyloid beta-derived immunogenic polypeptide.

L4 ANSWER 120 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42773 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Amyloid beta-derived immunogenic polypeptide.

L4 ANSWER 121 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42772 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Amyloid beta-derived immunogenic polypeptide.

L4 ANSWER 122 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42771 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Amyloid beta-derived immunogenic polypeptide.

L4 ANSWER 123 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42770 Protein DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p

AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Amyloid beta-derived immunogenic polypeptide.

L4 ANSWER 124 OF 125 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABR42769 Peptide DGENE
TI New synthetic immunogenic but non-deposit forming peptides, useful for inducing an immune response to ***prions*** , amyloids, amylin or amylin fibrils, particularly for treating e.g. Alzheimer's, scrapie or Creutzfeldt-Jacob disease -
IN Frangione B; Wisniewski T; Sigurdsson E M
PA (UYNY) UNIV NEW YORK STATE.
PI WO 2003045128 A2 20030605 265p
AI WO 2002-US37634 20021121
PRAI US 2001-331801P 20011121
DT Patent
LA English
OS 2003-505145 [47]
DESC Human amyloid beta(1-42) amino acid residues 1-30.

L4 ANSWER 125 OF 125 FEDRIP COPYRIGHT 2004 NTIS on STN
AN 2004:214263 FEDRIP
NR CRISP 1F31NS045510-01A1
TI Immuno-based Therapy for ***Prion*** Disease
SF Principal Investigator: WUERTZER, CHARLES A; CHARLES_WURTZER@URMC.ROCHESTER.EDU, UNIVERSITY OF ROCHESTER, 601 ELMWOOD AVE, BOX 645, ROCHESTER, NY 14642
CSP UNIVERSITY OF ROCHESTER, ROCHESTER, NEW YORK
CSS Supported By: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
DB 2008 (/01/03)
FYR 2003
FU New Award (Type 1)
FS National Institutes of Health
STN INTERNATIONAL LOGOFF AT 16:48:08 ON 08 NOV 2004